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INTRODUCTION AND OVERVIEW OF THIS THESIS 
 
Cardiovascular disease is a major health burden and associated with a high morbidity and 
mortality in middle-aged and older adults in most developed European countries.1,2 At the 
same time, significant progress has been made in prevention, detection, diagnosis and 
treatment of cardiovascular diseases. In this rapidly evolving field, the European Society of 
Cardiology (ESC) continuously develops and improves guidelines in order to assist 
cardiologists in every-day clinical decision making. These guidelines summarise and combine 
pathophysiological insight, the evolution of clinical experience as judged by panels of experts, 
and scientific evidence, which is mainly provided by randomized controlled clinical trials 
(RCTs).3,4 Although cardiologists and other health care professionals are encouraged to apply 
these guidelines in their practice, numerous factors will influence the physician in treating 
individual patients, including lack of awareness of specific guidelines, lack of agreement with 
the guidelines, the lack of facilities, or waiting lists. Furthermore, it is appreciated that the 
management of individual patients often is more complex than simply following the 
guidelines.  
 To implement guidelines, the ESC, and national societies develop guideline-based 
educational programmes. Furthermore, physicians are informed about clinical practice, based 
on disparities that were observed in the treatment and outcome of patients among different 
countries and geographic regions in Europe.5,6 In addition, the ESC initiated the Euro Heart 
Survey (EHS) programme in order to evaluate the application of recommended procedures 
management of cardiovascular disease in Europe. The Netherlands Heart Foundation (NHF) 
recognized the importance of the EHS programme, and supported this initiative through the 
NHF-Health Care programme (2000T101). Collecting information on patient management as 
seen in daily clinical practice is essential in identifying barriers in the application of evidence-
based medicine, and improving the quality of care. All together, three activities (i.e. guidelines, 
education, and surveys) became part of an overall programme to improve the quality of care. 
In this overall programme, the development of guidelines is followed by specific education, 
and evaluated by means of surveys (Figure 1). The results of the EHS programme, therefore, 
can be used for further development of the guidelines and educational programmes.  
 In the Netherlands, a combined EHS and NHF-Health Care programme was 
conducted. In addition to the initial EHS programme, the support of the NHF resulted in the 
extension of the survey programme in the Netherlands with two extra topics, the 
incorporation of care aspects, prolonged follow up, and a larger number of participating 
hospitals in the Netherlands. The outline of the survey programme, which consists of a series 
of consecutive cardiovascular surveys, was developed to (i) evaluate to which extend clinical 
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Education
Guidelines
Surveys
Research
Figure 1. Closing the loop in which evidence-based 
guidelines are followed by educational programmes, and 
evaluated by means of surveys. Verification of guidelines 
implementation can result in further improvement of 
guidelines, education, and clinical practice. 
practice corresponds with existing 
guidelines, (ii) evaluate the 
applicability of guideline-based 
medicine in every day clinical practice, 
and (iii) to evaluate the outcome of 
different disease management 
strategies.  
 Between 1999 and 2005 survey 
participation evolved from 47 
hospitals in 15 countries to 182 
hospitals in 35 ESC member 
countries. Participating hospitals were 
asked to enrol at least 25 consecutive 
patients. The Netherlands actively 
participated in the survey programme, 
as 21 hospitals in the Netherlands 
were involved (range 2 to 14 hospitals per survey) and 101 to 972 patients were enrolled per 
survey (approximately 12-13% of the total number of included patients in the survey 
programme).  
 Per survey, a scientific expert committee developed a protocol and Case Report Form 
(CRF) based on European and other guidelines. In the Netherlands, for each of the surveys a 
scientific expert committee was convened in order to assess applicability and feasibility of the 
protocol and Case Report Forms (CRF) in the Netherlands. Data collection was done by Data 
Collecting Officers (e.g. trained research nurses) on electronic CRF and sent to a central 
database. In addition to collecting data at baseline, follow up was systematically performed at 
1-year. In the Netherlands, the follow up period was extended to 2- or 4-years for part of the 
surveys. 
 Since the start of the survey programme in 1999, 13 surveys have been conducted, and 
over 67.000 patients enrolled this programme. These surveys addressed secondary prevention 
(EuroAspire-II, n=5556), Heart Failure-I (n=10.701), Valvular Heart Disease (n=5001), Acute 
Coronary Syndromes-I (n=10.484), Coronary Revascularisation (n=5619), Stable Angina 
Pectoris (n=3779), Diabetes (n=4961), Adult Congenital Heart Disease (n=4110), Atrial 
Fibrillation (n=5333), Acute Coronary Syndromes-II (n=6554), Heart Failure-II (n=3647). 
The two extra topics that were added to the EHS programme in the Netherlands only were: 
Stroke (n=972) and Peripheral Arterial Disease (n=711).   
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I had the privilege to participate in the survey programme, conduct analyses and prepare a 
number of key papers on several of the above mentioned surveys:  Heart Failure-I, Coronary 
Revascularisation, and Diabetes and the heart.  
 This thesis is closely related to the first two aims of the EHS programme: to evaluate 
to which extend every day clinical practice corresponds with evidence-based guidelines, and to 
identify patient groups which are under- or not represented in clinical trials which may effect 
the generalisability of evidence-based treatment.  
 In part 1 (chapters 2-4) of this thesis, we investigated the management of patients as 
observed in daily clinical practice. In addition, we also evaluated to what extend patients in 
clinical practice were comparable to those who participated in RCTs. In chapters 2 and 3 the 
focus is on patients with coronary artery disease, whereas chapter 4 focuses on patients with 
heart failure.  
 In part 2 (chapters 5-7) we evaluated the management of patients who were under-
represented in clinical trials, and consequently in evidence-based guidelines. In this context, 
the management of patients with heart failure and a preserved left ventricular function, 
women with heart failure, and patients with established coronary artery disease who were 
ineligible for revascularization are discussed.  
 In part 3 (chapters 8-9), the impact of health status and glucometabolic status on 1-
year mortality is evaluated. The value of self-perceived health status in predicting mortality is 
discussed in chapter 8, while chapter 9 focuses on the impact of diabetes on adverse 
outcomes.  
 
Finally, a general discussion is presented, including conclusions and recommendations for 
future research and clinical practice. 
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ABSTRACT 
 
Aims: The purpose of the Euro Heart Survey Programme of the European Society of 
Cardiology is to evaluate to which extent clinical practice endorses existing guidelines as well 
as to identify differences in population profiles, patient management and outcome across 
Europe. The current Survey focuses on the invasive diagnosis and treatment of patients with 
established coronary artery disease.  
 
Method: Between November 2001 and March 2002, 7769 consecutive patients undergoing 
invasive evaluation at 130 hospitals (31 countries) were screened for the presence of one or 
more coronary stenosis > 50% in diameter. Patient demographics and co-morbidity, clinical 
presentation, invasive parameters, treatment options and procedural technique were 
prospectively entered in an electronic database (550 variables + 29 per diseased coronary 
segment). Major Adverse Cardiac Events were evaluated at 30 days and 1 year.  
 
Results: Out of 5619 patients with angiographically proven coronary stenosis (72% of 
screened population), 53% presented with stable angina while STEMI was the indication for 
coronary angiography in 16% and NSTEMI/UA in 30%. Medical therapy only was continued 
in 21% while mechanical revascularisation was performed in the remainder (PCI in 58% and 
CABG in 21%). Patients referred for PCI were younger, more active, had a lower risk profile 
and less co-morbid conditions. CABG was performed mostly in patients with left main (21%), 
double (25%) or triple (67%) vessel disease with 4.1 diseased segments, on average. Single 
vessel PCI was performed in 82% of patients with either one (45%), double (33%) or triple 
(21%) vessel disease. Stents were used in 75% of attempted lesions, with a large variation 
between sites. Direct PCI for STEMI was performed in 410 cases, representing 7% of the 
entire workload in the participating catheterisation laboratories. Time delay was within 90 
minutes in 76% of direct PCI cases. In keeping with the recommendations of Practice 
Guidelines, the survey identified under-use of adjunctive medication (IIb/IIIa receptor 
blockers, statins and ACE inhibitors). Mortality rates at 30 days and 1 year were low in all 
subgroups. MACE primarily consisted of repeat PCI (12%).  
 
Conclusion: The current Euro Heart Survey on Coronary Revascularisation was performed in 
the era of bare metal stenting and provides a global European picture of the invasive approach 
to patients with CAD. These data will serve as a benchmark for the future evaluation of the 
impact of drug-eluting stents on the practice of interventional cardiology and bypass surgery.  
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INTRODUCTION 
The management of patients with coronary artery disease (CAD) is complex. Better 
understanding of the pathophysiology of the disease and the introduction of novel diagnostic 
techniques in conjunction with novel or more powerful pharmacologic and revascularisation 
therapies mandates continuous reassessment and evaluation of medical practice.1-6 
 Practice Guidelines for diagnostic procedures and patient management are established 
to help cardiologists in every day clinical decision making. The scientific foundation for these 
guidelines is provided by randomised clinical trials, although non-randomised trials, 
retrospective studies or consensus opinion of experts are also used. 7-9 
 The European Society of Cardiology (ESC) is dedicated to improve health by reducing 
the impact of cardiovascular disease, by various means. The Euro Heart Survey programme is 
meant to evaluate to which extent clinical practice endorses existing guidelines as well as to 
identify differences in population profiles, patient management and outcome across 
Europe.1010 
The current survey focuses on patients with at least one >50% diameter stenosis, 
visualised during coronary angiography, who are potential candidates for coronary 
revascularisation.  
 
METHODS  
The Euro Heart Survey on Coronary Revascularisation was conducted in 130 voluntary 
participating hospitals from 31 ESC member countries with the objective to evaluate clinical 
practice, adherence to guidelines, differences in the management and outcome of patients and 
to assess to what extent the patients of daily practice are represented in randomised clinical 
trials. Participating hospitals represent both academic (40%) and non-academic (60%) 
institutions with (83%) and without (17%) cardiac surgery and/or interventional cardiology 
facilities. These centers were asked to enrol blocks of 40 consecutive patients. The present 
survey was designed to screen all consecutive patients undergoing invasive diagnostic or 
therapeutic catheterisation, of which all patients with >50% diameter stenoses in at least one 
major epicardial vessel were asked to participate. In each hospital, data (550 patient variables 
and 29 variables per treated coronary segment) were collected by data collecting officers on 
computers, using the MacroTM software (InferMed, UK) and sent by Internet connection to a 
central database located at the European Heart House. The used software implemented 
internal edit checks for missing or contradictory entries or for values out of the normal range. 
The data management staff of the European Heart House performed additional edit checks. 
Canadian Class Society functional class (CCS) and Risk stratification were evaluated 
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prospectively in patients with stable angina.11,12 The EuroSCORE and TIMI risk score were 
calculated from the available variables.13,14 
 The survey on coronary revascularisation was conducted between November 2001 and 
March 2002. One year follow-up was made by personal or telephone contact and available in 
4770 patients (83%). Fourteen hospitals (11%) were not able to provide follow-up 
information. Median (quartiles) follow-up period was 12 month (11-13 month). Statistical 
analyses were carried out with SPSS statistical software (version 12.0 for Windows), using 
mostly descriptive statistics between subsets of patients defined by treatment preference. 
Results are presented as mean and median with corresponding values (standard deviation and 
inter quartiles, respectively), and percentages. Given the large sample size, P-value of ≤ 0.001 
was considered statistically significant.  
 
RESULTS 
A total of 7769 patients undergoing coronary angiography were screened of whom 5767 
fulfilled the inclusion criteria. Patients with either insufficient or invalid data (n=148) were 
excluded from further analysis. Therefore, the total population of the present report numbers 
5619. The baseline characteristics are summarised in Table 1. Stable angina was the most 
frequent indication to perform angiography (53%), followed by non-ST segment elevation 
myocardial infarction or unstable angina (NSTEMI/UA) (30%) and ST elevation myocardial 
infarction (STEMI) (16%). In 2002 of the screened patients (24%), no CAD or stenosis < 
50% was found. Absence of significant CAD differed between patients with acute coronary 
syndrome (16%) and stable ischemic heart disease (35%) but was most prevalent when CAD 
was not the primary reason for performing angiography (48%).  
 Mechanical revascularisation (PCI: 58%, CABG: 21%) was often performed or 
planned while a substantial number of patients were continued on medical treatment (21%). 
PCI was predominantly performed in patients admitted with acute coronary syndromes (ACS) 
with or without ST-segment elevation or unstable angina (53%) while CABG and medical 
treatment were applied mostly in patients with stable angina (64% and 61%, respectively). 
Patients who underwent PCI were in general younger, more active and with fewer co-morbid 
conditions. Patients who received medical therapy had a higher prevalence of previous bypass 
surgery and myocardial infarction (Table 1). 
 Of all diseased segments at coronary angiography (15,856), 51% was considered 
suitable for PCI and 69% for CABG, while 24% of the lesions (1597 patients) were judged as 
only suitable for CABG, not for PCI. Most of these lesions, unsuitable for PCI were totally 
occluded (70%) or located in the left main (20%). PCI was predominantly performed in 
patients with single vessel disease and preserved ventricular function (Table 2). Nonetheless, 
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Table 1. Clinical characteristics of total cohort and patients in different treatment groups 
(proportions are given per column) 
Total 
(n=5619) 
PCI 
(n=3254) 
CABG 
(n=1188) 
Medical 
(n=1177) 
 
       
Age (mean, SD)  63.2 ± 10.8 62.4 ±11.2 64.5 ±10.0 64.3 ±10.6 * 
Male gender, n (%)  4268 (76)  2448 (75) 933 (79) 887 (75)  
Smoking, n (%):       
 Current  1411 (25) 912 (28) 262 (22) 237 (20)  
 Past 1924 (34) 1045 (32) 434 (37) 445 (38) * 
 Never 2084 (37) 1170 (36) 452 (38) 462 (39)  
Diabetes mellitus, n (%):       
 type 1 208 (4) 121 (4) 38 (3) 49 (4)  
 type 2 1130 (20) 603 (19) 261 (22) 266 (23)  
       
Hypercholesterolemia, n (%)  3591 (65) 2130 (67) 737 (64) 724 (64)  
Hypertension, n (%)  3315 (60) 1851 (57) 714 (61) 750 (64) * 
Sedentary lifestyle, n (%)  1601(40) 869 (37) 357 (43) 375 (45) * 
Congestive heart failure, n (%)  1026 (18) 457 (14) 279 (24) 290 (25) * 
Chronic lung disease, n (%)  492 (9) 273 (8) 106 (9) 113 (10)  
Chronic renal failure, n (%)  226 (4) 137 (4) 33 (3) 56 (5)  
Peripheral vascular disease, n (%)  657 (12) 330 (10) 169 (14) 158 (14) * 
Cerebro-vascular disease, n (%)  427 (8) 205 (6) 116 (10) 106 (9) * 
Comorbidity per patient# (mean, SD)  0.5 ±0.8 0.4 ±0.7 0.6 ±0.8 0.6 ±0.8 * 
Risk factors per patient≠ (mean, SD)  2.1 ±1.0 2.1 ±0.9 2.1 ±1.0 2.1 ±1.0  
Prior CABG, n (%)  601 (11) 307 (10) 41 (4) 253 (22) * 
Prior PCI, n (%)  1140 (20) 738 (23) 130 (11) 272 (23) * 
Prior myocardial infarction, n (%)  2258 (39) 1168 (36) 448 (38) 542 (47) * 
Diagnosis at admission, n (%):       
 Stable angina 2936 (53) 1503 (47) 743 (64) 690 (61)  
 Non-ST elevation ACS/ UA 1672 (30) 1014 (31) 331 (28) 327 (29) * 
 ST elevation MI 906 (16) 710 (22) 88 (8) 108 (10)  
Hospitalisation in days (median, IQR)† 5 (3-11) 4 (3-8) 12 (7-22) 4 (2-10) * 
≠ risk factors included, smoking (ever), diabetes, hypercholesterolemia and hypertension 
# comorbidity included, congestive heart failure, chronic lung disease, renal failure, peripheral vascular disease 
and cerebro-vascular disease 
† Data known in 5291 cases (3142 PCI, 1102 CABG, 1047 Medical) 
* p ≤ 0.001 
two and three vessel disease was present in 33% and 21%, respectively, suggesting incomplete 
revascularisation by anatomy. Single vessel PCI was performed in 82% of all cases and the 
attempted lesions were of type A in 15%, B in 50% and C in 12%. Bypass surgery was mainly 
performed in patients with three vessel disease (67%), left main stem stenosis (21%) or 
extensive disease as reflected by the mean number of diseased segments (4.1). The LAD was 
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diseased in 90% of all patients undergoing CABG and extracorporeal circulation was used in 
81% of all operations. 
 
Patients who received medical therapy only, had a higher prevalence of advanced 
disease in comparison to PCI patients (61 vs 54% multivessel disease, 2.9 vs 2.3 diseased 
segments). Angiographic profile was worst in those who underwent CABG (92% multivessel 
disease, 4.1 diseased segments). Noteworthy, patients treated medically had the highest 
prevalence of poor ventricular function. Although the reason for choosing medical treatment 
was largely related to the clinical presentation and the severity and extent of CAD, we also 
observed large differences in treatment options between participating hospitals (Figure 1). 
Apart from contra-indications for mechanical revascularisation (i.e. vessels not suitable: 34%, 
Table 2. Angiographic results based on chosen treatment option 
(proportions are given per column) 
Total 
(5619) 
PCI 
(n=3254) 
CABG 
(n=1188) 
Medical 
(n=1177) 
     
Severity of coronary artery disease, n (%)#:     
 Single-vessel disease 2010 (36) 1469 (45) 87 (7) 454 (39) 
 Two-vessel disease 1701 (30) 1086 (33) 298 (25) 317 (27) *
 Three-vessel disease 1882 (34) 687 (21) 797 (67) 398 (34) 
 Left main lesions 476 (9) 126 (4) 251 (21) 99 (8) *
     
 Mean no.  diseased segments, SD 2.8 ±1.9 2.3 ±1.7 4.1 ±1.9 2.9 ±2.1 *
 Diseased  % valued as suitable for PCI  51 69 37 32 *
segments: % valued as suitable for CABG 69 63 91 52 *
      
Left ventricular function known, n (%): 4854 (86) 2732 (84) 1096 (92) 1026 (87) 
 Ejection fraction >50% 2904 (60) 1726 (63) 633 (58) 545 (53) 
 Ejection fraction 40 – 50% 1281 (26) 710 (26) 295 (27) 276 (27) *
 Ejection fraction <40 669 (14) 296 (11) 168 (15) 205 (20) 
      
Intervention within 30 days after CAG, n (%) 3339 2744 (84) 595 (50) - 
Total no. attempted / diseased segments‡ 5426 3564/ 6477 (55) 1862 / 2483 (75) - / 3404 (0)
Attempted segments per patient, mean ‡ - 1.30  3.13 - 
Successfully dilated/bypassed segments (%)‡ - 95 96 - 
      
Procedural technique: Stenting (%)‡ - 2050 (75) - - 
 ≥1Arterial Graft (%)‡ - - 531 (89) - 
# due to missing data (>1%) not counting up to total number of patients 
‡ Based on number (%) of patients who underwent the intervention within 30 days after angiography 
* p ≤ 0.001 
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high risk procedure: 17%), 13% of the medically treated patients had refused mechanical 
revascularisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In conjunction with the differences in baseline characteristics, the total and average 
number of attempted segments differed between PCI and CABG treated patients (Table 2). 
The large majority of patients undergoing PCI (84%) were treated within 30 days, whereas 
50% of CABG patients were treated within this period. The majority of patients undergoing 
PCI (59%), underwent the procedure within 24 hours after diagnostic angiography. There was 
a striking high use of stents (applied in 72% of all attempted segments and 75% of PCI 
patients) while at least one arterial graft was implanted in 89% of the surgical procedures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of patients with coronary artery stenosis >50%
0%
20%
40%
60%
80%
100%
PCI CABG non-invasive
Figure 1.  
 
The percentage of 
invasive (PCI and 
CABG) and medically 
treated patients in 
hospitals participating 
in the EHS-CR. 
 
Hospitals are ordered 
on the basis of patients 
referred for PCI. 
 
Figure 2.  
 
The variation in use of 
stents per hospital in 
patients who underwent PCI 
within 30 days after 
diagnostic angiography. 
  
It should be noted that the 
ordering of hospitals differs 
between the three figures 
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The variation in the use of stents in participating hospitals was huge as illustrated in 
figure 2. The assessment of procedure-related myocardial injury from serial sampling of 
necrosis markers was only performed in 61% of PCI and 31% of CABG cases. In accordance 
with Guidelines, consensus statements and data from clinical trials, PCI patients at increased 
risk (diabetes, ACS) should receive peri-procedural GP IIb/IIIa receptor blockers. GP 
IIb/IIIa receptor blockers were used only in 27% of all PCI procedures. 
Almost half (46%) of all STEMI patients undergoing primary PCI (n=393), were 
treated with GP IIb/IIIa receptor blockers. In NSTEMI/UA patients undergoing PCI within 
30 days after angiography, 32% received GP IIb/IIIa receptor blockers, mostly because of 
high risk features (60%). Among PCI patients with stable angina, 14% received GP IIb/IIIa 
receptor blockers and 23% were on  thienopyridine treatment prior to the intervention. No 
difference in GP IIb/IIIa blocker use was observed between patients with or without diabetes 
mellitus. Furthermore, we observed large differences in the use of GP IIb/IIIa receptor 
blockers between the participating hospitals (Figure 3).  
 
In most patients with stable angina Canadian Class Society functional class (CCS) was 
known (96%). Almost two-third of these patients were in CCS class 1 or 2 (Table 3). Patients 
in CCS 3 or 4 were more likely to be classified as high-risk patients as compared to patients in 
CCS 1 or 2 (23% versus 13%). Comparison of this risk stratification with the EuroSCORE, 
revealed a mean score of 3.3 in low-risk, 3.7 in intermediate, and 4.4 in high-risk patients. 
When calculating the EuroSCORE per treatment-group in patients with stable angina and 
NSTEMI/UA, we observed a lower risk in PCI patients, as compared to CABG and medically 
treated patients (Table 4). In NSTEMI/UA patients, the TIMI score was similar amongst the 
three treatment options (mean score 3.1 ±1.1). Despite proven CAD, a normal ECG was 
present in 23% of all NSTEMI/UA cases.  
GPIIb/IIIa inhibitors in PCI patients 
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 Figure 3.  
 
The variation in the use of 
GP IIb/IIIa receptor 
blockers per hospital in 
patients who underwent 
PCI within 30 days after 
diagnostic angiography. 
  
It should be noted that 
the ordering of hospitals 
differs between the three 
figures 
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Table 3. Risk assessment and outcome in patients with stable angina 
  Total 
 
 
2936 (53)
1 yr 
mortality
1 yr 
mortality / 
non-fatal MI 
1 yr mortality / 
non-fatal MI / 
rehosp for 
cardiac reason 
      
Canadian Class CCS 1 or 2 1795 (63)    
 Unknown 203 (11) 5 (3) 9 (4) 51 (25) 
Estimated   Low (<1% annual mortality) 536 (30) 14 (3) 22 (4) 108 (20) 
risk Intermediate (1-3% annual mortality) 818 (46) 16 (2) 27 (3) 156 (19) 
 High (>3% annual mortality) 238 (13) 10 (4) 13 (6) 59 (25) 
     
 CCS 3 or 4 1037 (37)    
 Unknown 144 (14) 7 (5) 10 (7) 35 (24) 
Estimated Low (<1% annual mortality) 158 (15) 8 (5) 10 (6) 42 (27) 
risk Intermediate (1-3% annual mortality) 496 (48) 18 (4) 26 (5) 120 (24) 
 High (>3% annual mortality) 239 (23) 18 (8) 20 (8) 69 (29) 
     
 
High-risk features or recurrent/persistent angina in NSTEMI/UA patients, and 
recurrent ischemia or complications in STEMI patients were the most frequent indications for 
angiography (62% and 42%, respectively). Cardiogenic shock was registered in 8% of STEMI 
patients. The rate of reperfusion therapy including fibrinolytic treatment and primary PCI in 
this selected group of STEMI patients who reached the catheterisation laboratory was 64% of 
which 68% underwent primary PCI. The median time from admission to the intervention was 
45 minutes (interquartiles: 15-90 minutes) and the procedure started within 90 minutes after 
admission in 76 %, indicating that the majority of patients was treated within the advocated 
timeframe of 90 minutes. It should be noted, however, that no information on in-hospital 
time delay was available in 28% of patients. Delayed angiography was performed on a 
systematic basis in 44% of the 513 STEMI patients who did not undergo primary PCI.  
Of the 5619 participating patients, 1.9% (104 patients) died within 30 days. The overall 
1 year mortality was 4.7% (263 patients). The mortality differed between diagnosis and 
treatment groups (Table 4). One-year mortality was lowest in patients with stable angina who 
underwent PCI (1.9%), and highest in STEMI patients not undergoing mechanical 
revascularisation (8.4%). However, significantly reduced one-year mortality between the three 
treatment groups was observed only in patients with stable angina, reflecting the large 
proportion of low-risk patients undergoing PCI.  
After one year, 13% of the PCI patients required repeat revascularisation (10% at least 
one repeat PCI, 3% were operated), whereas only 1% of patients initially treated with CABG 
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 Table 4. Risk assessment and outcome in three different diagnosis groups, based on treatment option 
 
 
Total 
 
PCI 
  
CABG 
 
Medical 
 
 
      
Stable angina, n  2936 1503 743 690  
 Hospitalisation in days (median, IQR) 3 (2-9) 3 (2-5) 10 (5-18) 3 (2-6) * 
 EuroSCORE (mean, SD) 3.8 ±2.7 3.3 ±2.4 4.4 ±3.0 4.2 ±2.6 * 
 30 day mortality, n (%): 25 (1) 5 (0) 17 (2) 3 (0) * 
      Total mortality at 1 year  101 (3) 28 (2) 41 (6) 32 (5) * 
      Non-fatal MI‡ 41 (2) 24 (2) 8 (1) 9 (2)  
      Rehospitalisation for cardiac reason‡  559 (24) 354 (29) 80 (14) 125 (23) * 
      (Repeat) revascularisation‡ 183 (7) 150 (12) 6 (1) 27 (5) * 
       
NSTEMI/UA, n  1672 1014 331 327  
 Hospitalisation in days (median, IQR) 7 (3-12) 5 (3-10) 16 (9-25) 7 (3-12) * 
 EuroSCORE (mean, SD) 5.8 ±2.8 5.4 ±2.6 6.1 ±3.2 6.5 ±2.8 * 
 30 day mortality, n (%): 35 (2) 19 (2) 8 (2) 8 (2)  
 Total mortality at 1 year  82 (5) 41 (4) 17 (5) 24 (7)  
 Non-fatal MI Ŧ 43 (3) 30 (4) 11 (4) 2 (1)  
 Rehospitalisation for cardiac reason Ŧ  376 (29) 249 (31) 48 (19) 78 (31) * 
 (Repeat) revascularization Ŧ 133 (10) 119 (14) 5 (2) 9 (3) * 
       
STEMI, n (%) 906 710 88 108  
 Hospitalisation in days (median, IQR) 7 (4-12) 7 (4-11) 13 (9-27) 9 (4-18) * 
 30 day mortality, n (%): 42 (5) 30 (4) 7 (8) 5 (5)  
 Total mortality at 1 year  67 (7) 51 (7) 7 (8) 9 (8)  
 Non-fatal MI† 18 (3) 13 (3) 2 (3) 3 (4)  
 Rehospitalisation for cardiac reason†  148 (23) 122 (24) 7 (11) 19 (24)  
 (Repeat) revascularisation† 63 (9) 58 (11) 0 5 (6)  
       
‡ Data known in 2472 patients (84%) of patients with stable angina (1279 PCI, 608 CABG, 585 Medical).  
Ŧ Data known in 1403 patients (84%) of patients with NonSTEMI/UA (862 PCI, 267 CABG, 274 Medical). 
† Data known in 704 patients (78%) of patients with STEMI (550 PCI, 66 CABG, 88 Medical). 
* p ≤ 0.001 
needed repeat revascularisation. A small proportion of patients, who were initially treated 
medically, eventually underwent mechanical revascularisation (4%). Re-hospitalisation for 
cardiac reasons was more frequent in PCI and medical patients (28% and 25%, respectively), 
as compared to those undergoing CABG (15%).  
 
At discharge, most patients (>90%) were prescribed at least one anti-thrombotic drug 
(either aspirin, thienopyridine or anticoagulants), irrespective of treatment allocation (Table 5). 
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When coronary stenting was performed, 94% were discharged on clopidogrel or ticlopidine. 
Other prophylactic drug classes, like beta-blockers, ACE-inhibitors and statins were used less 
frequently. Except for beta-blockers, comparison between the three treatment groups revealed 
significant differences in prescription profile. At one year follow-up, pharmacological 
treatment remained unchanged and below the target. Only the use of statins increased from 
discharge (54%) to one year in patients undergoing CABG (69%), but remained below the 
target.  
 
 
DISCUSSION 
Acute presentations of CAD represented the primary indication for diagnostic angiography in 
46% of all cases while in patients with stable angina, the selection of patients to undergo 
diagnostic angiography was based on symptomatic status and/or risk evaluation. In line with 
previous reports, we observed a global normalcy rate of 24%.10,15 This proportion was higher 
when the primary diagnosis leading to the angiography was stable angina rather than acute 
CAD. An indication for mechanical revascularization followed the diagnostic angiogram in 
57% of all cases screened and in 79% of those with at least one significant stenosis, indicating 
appropriate use of this invasive and expensive diagnostic procedure. This survey of current 
practice in Europe shows a clear preference for PCI over CABG (ratio 3:1), possibly 
suggesting under-use of the more invasive bypass operation.16 
 In accordance with Guidelines, patients selected for CABG were sicker and had more 
extensive CAD; however, a sizable proportion of patients with multivessel or left main 
disease, impaired left ventricular function or diabetes did not undergo bypass surgery. 
 Patient and/or physician preference as well as the shorter time delay between 
angiography and PCI (versus between angiography and CABG) may have contributed to this 
choice. In patients with multivessel disease, recent meta-analyses show no difference in the 
Table 5.  Pharmacological treatment at discharge 
 Total 
(5619) 
PCI 
(n=3254) 
CABG 
(n=1188) 
Medical 
(n=1177) 
 
      
Aspirin, n (%) 4857 (86) 2972 (91) 922 (78) 963 (82) * 
Any anti-thrombotic drug, n (%)† 5356 (95) 3179 (98) 1087 (92) 1090 (93) * 
Bèta-blocker, n (%) 4133 (74) 2442 (75) 833 (70) 858 (73)  
ACE-inhibitor, n (%) 3190 (57) 1845 (57) 590 (50) 755 (64) * 
Statin, n (%) 3740 (67) 2301 (71) 643 (54) 796 (68) * 
      
†  any anti-thrombotic drug includes anti-platelet drugs and coumadin  
* p ≤ 0.001 
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rate of major irreversible adverse events between PCI and CABG.17,18 However, after one year 
follow-up, repeat PCI was performed in 10 % and 3% eventually required CABG, indicative 
of the lower durability of the result after PCI. Coronary stenting using bare metal devices was 
applied in 72% of all segments and PCI was limited to a single vessel in 82% of cases. Use of 
stents varied widely from 0% in 2 hospitals to 100% in 17 hospitals, a wide range that 
probably relates to differences in local reimbursement policies. It should be remembered that 
all data from the current survey have been acquired prior to the clinical availability of drug-
eluting stents. Increased availability of these more durable devices will likely increase the 
confidence of interventional cardiologists in treating more complex patient and/or lesion 
subsets by means of PCI.19 
 Another proportion of patients who were at high-risk did not undergo 
revascularisation. This probably results from the limitations of currently available mechanical 
revascularization procedures in treating diffuse disease, or from the poor general condition of 
some patients unable to undergo an invasive treatment, or from estimated unacceptably high 
procedural risks.  
Despite their proven beneficial effects in high-risk patients (e.g. diabetes) and/or 
procedures,20,21 overall a sizable proportion of patients fulfilling these criteria did not receive 
GP IIb/IIIa receptor blockers. In addition, major variations across European hospitals in the 
use of GP IIb/IIIa receptor blockers were observed. Most surprising was the low use of these 
drugs in diabetic patients undergoing PCI for stable angina (15%). Also of concern was the 
failure to measure post-procedural necrosis markers in 39% of all PCI procedures. Increased 
levels of cardiac enzymes are indeed an independent predictor of cardiac mortality and 
subsequent myocardial infarction.22,23 Similarly, in patients undergoing CABG, necrosis 
markers were measured in only one-third, most likely reflecting the disputable value of these 
markers following surgery.24 
As to the treatment of STEMI, this survey concurs with previous studies in showing 
that reperfusion treatment remains underused,25 even in this selected subgroup of patients 
referred for angiography. By design, we cannot analyze the factors that contribute to this 
sobering observation. In accordance with the Guidelines, primary PCI is the preferred 
treatment for STEMI, provided this procedure can be performed by an experienced team 
within 90 minutes after first medical contact.9 It was encouraging to observe that the majority 
of patients undergoing primary PCI were treated within the advocated timeframe of 90 
minutes. However, due to missing admission or procedure times, the in-hospital delay was 
unknown in a sizeable proportion of patients. The current prospective survey clearly shows 
that in clinical practice, reporting of all relevant time intervals was not optimal. This failure 
stresses the importance of a thorough registration as well as the need for implementing in 
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each institution appropriate procedures and pathways that will permit to select the optimal 
treatment for an individual patient.26,27 
The overall mortality figures were low (1.9% at 30 days and 4.7% at 1 year) in all 
patient groups and treatment modalities, even after risk-adjustment using for instance the 
EuroSCORE. As expected, one year mortality rate was larger in STEMI (7%) and in 
NSTEMI/UA (5%) compared to stable angina patients (3%).  
Patients with established CAD enrolled in this survey should benefit from secondary 
prevention measures.28 Changing the patient risk behaviour (unhealthy diet, smoking, 
sedentary lifestyle) and prescribing drugs with proven prophylactic effects are essential aspects 
of current treatment, even after mechanical revascularisation.29-33 Furthermore, effective 
secondary prevention in clinical practice, using evidence-based treatment, has been proven 
effective in reducing the composite of death, myocardial infarction and stroke.34,35 Although 
the majority of patients used anti-thrombotics and beta-blockers, as recommended, ACE-
inhibitors were underused in all subgroups and statins were particularly underused after 
CABG. Overall, prescription of these prophylactic drugs was increased as compared to 
EuroAspire II,36 indicating that time is required before Guidelines are progressively endorsed. 
In any case, the moment that patients are admitted in the hospital to undergo an invasive 
procedure should be taken as an opportunity to further optimise their pharmacological 
treatment.  
The limitations of this study are those inherent to observational surveys involving 
voluntarily participating hospitals. Although we have attempted to include a wide spectrum of 
hospitals in different countries, almost certainly the results are biased towards better than 
average practices. The sample size only represents a small fraction of all patients admitted in 
catheterisation laboratories throughout Europe during the study period. Nevertheless, because 
patient inclusion was consecutive at the participating sites, we trust that the Survey depicts the 
ongoing clinical practice. Data on the one year follow-up were not obtainable in 14 hospitals 
(from 10 countries) due to management problems unrelated to individual patient 
characteristics. Presumably this did not introduce significant selection bias. Data quality was 
checked through queries for missing or contradictory entries. However, no site visits or source 
data verification were performed. However, since many participating sites are part of other 
Euro Heart Surveys, their performance is regularly evaluated.  
To summarize, the current Euro Heart Survey on Coronary Revascularisation provides 
a global European picture of the invasive approach to patients with CAD, as they present with 
either stable angina, STEMI or NSTEMI/UA. While the recommendations of Guidelines are 
mostly endorsed, the main area for improvement pertains to the under-use of adjunctive 
pharmacology (GP IIb/IIIa inhibitors, statins and ACE inhibitors). These data on the 
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indications for revascularisation, the choice between PCI or CABG and their outcome in the 
era of bare metal stenting will serve as a benchmark for the future evaluation of the impact of 
drug-eluting stents on the practice of coronary revascularisation.  
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ABSTRACT 
 
Aims: Revascularization in patients with coronary artery disease changed over the last two 
decades, favouring the number of patients treated by means of percutaneous coronary 
interventions (PCI) as compared to coronary artery bypass grafting (CABG). Many 
randomised controlled trials (RCTs) have been performed to compare these two competing 
revascularization techniques. Due to the strict enrolment criteria of RCTs in which highly 
selected patients are recruited, the applicability of the results may be limited in clinical practice. 
The current study evaluates to what extent patients in clinical practice were similar to those 
who participated in RCTs comparing PCI with CABG. 
 
Methods and Results: Clinical characteristics and 1-year outcome of 4,713 patients enrolled 
in the Euro Heart Survey on Coronary Revascularization were compared with 8,647 patients 
who participated in 14 major RCTs, comparing PCI with CABG. In addition, we analysed 
which proportion of survey patients would have disqualified for trial participation (n=3033, 
64%), aiming at identifying differences between trial-eligible and trial-ineligible survey patients. 
In general, important differences were observed between trial participants and survey patients. 
Patients in clinical practice were older, more often had comorbid conditions, single vessel 
disease, and left main stem stenosis as compared to trial participants. Almost identical 
differences were observed between trial-eligible and trial-ineligible survey patients. In clinical 
practice, PCI was the treatment of choice, even in patients who were trial-ineligible (46% PCI, 
26% CABG, and 28% medical). PCI remained the preferred treatment option in patients with 
multivessel disease (57% in trial-eligible and 40% in trial-ineligible patients, respectively, 
p<.001); yet, the risk profile of patients treated by PCI was better than for patients treated 
either by CABG or medical therapy. In the RCTs, there was no mortality difference between 
PCI and CABG. In clinical practice, however, we observed one-year unadjusted survival 
benefit for PCI vs. CABG (2.9 vs. 5.4%, p <0.001).  Survival benefit was only observed in 
trial-ineligible patients (3.3 vs. 6.2%, p <0.001).  
 
Conclusion: Many patients in clinical practice were not represented in RCTs. Moreover, only 
36% of these patients were considered eligible for participating in a trial comparing PCI with 
CABG.  We demonstrated that RCTs included younger patients with a better cardiovascular 
risk profile as compared to patients in every day clinical practice. This study highlights the 
disparity between patients in clinical practice and patients in whom the studies that provide 
the evidence for treatment guidelines are performed. 
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INTRODUCTION 
Cardiovascular diseases are the major cause of mortality in the western world, and it is 
expected that this will remain so during the foreseeable future.1-3 Treatment of patients with 
coronary artery disease (CAD) includes risk factor management, drug therapy and 
revascularization techniques. The last decades, changes in revascularization techniques were 
observed, favouring the number of patients treated by means of percutaneous coronary 
interventions (PCI) as compared to the more invasive coronary artery bypass grafting 
(CABG). As these competitive techniques are both feasible in many patients, randomized 
controlled clinical trials (RCTs) have been performed in order to compare the two procedures. 
Based on these RCTs, the results of registries and consensus of experts, international societies 
developed guidelines in order to support physicians in clinical decision making.4-7 In these 
guidelines, RCTs are valued as the highest level of evidence in the ranking order. It should be 
noted however, that RCTs have strict enrolment criteria. Consequently, patients who 
participate in trials may represent a selected group of patients that is poorly representative of 
the majority of patients treated in routine clinical practice.8 This may complicate the 
applicability of the results of clinical trials in everyday practice and limit the generalisability of 
recommendations.9 
 In the current study, we aimed to evaluate to what extent patients in clinical practice 
were similar to those who participated in randomized clinical trials comparing CABG with 
PCI. Patient outcome was compared as well between the selected treatment options.  
 
METHODS 
We performed a comparison between participants in RCTs and patients enrolled in the Euro 
Heart Survey on Coronary Revascularization (EHS-CR). Details of the survey were published 
previously.10 Briefly, between September 2001 and March 2002, a total of 5.619 patients from 
130 hospitals throughout 31 countries belonging to the ESC were included in this survey. All 
consecutive patients entering the catheterization laboratory were screened, and patients with 
>50% diameter stenosis in at least one major epicardial vessel were asked to participate. Data 
were collected on medical history, demography, clinical, hemodynamic and angiographic 
status, and sent by Internet connection to a central database located at the European Heart 
House. A follow up was performed at 1-year (median 11-13 months). Follow up information, 
including vital status, was available in 83%, as 14 hospitals (11%) were not able to provide 
follow up information. The survey was approved by the relevant national authorities.   
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Selection of Trials  
We intended to identify all major randomised phase III clinical trials of CABG versus PCI 
which were published in the English language during 1980-2005, using the Medical Subject 
Heading terms “angioplasty, transluminal, percutaneous coronary”, “coronary artery bypass”, 
“randomized controlled trial”, and “comparative study”, as was used in a recent meta-analysis 
by Hoffman et al.11 We identified 15 major trials comparing initial strategies of PCI and 
CABG. Since the AWESOME trial12 included patients that would have been excluded in the 
other trials (i.e. patients with severe heart failure or very recent myocardial infarction), this trial 
was excluded from the analysis. Table 1 shows the characteristics of 14 trials with a total of 
8647 patients that were selected for this analysis. In 10 of these trials, only patients with 
multivessel coronary disease were included while in one trial patients with single or multivessel 
disease could be enrolled.8,13-22 In the remaining three trials, only patients with single vessel 
disease were included.23-25 Medical therapy alone was added to the two invasive treatment 
options in one trial.22,24 The tabulated patient characteristics, as presented in the main 
publication article of the separate clinical trials were compiled in an electronic database and 
the data were pooled. In case of a discrepancy between the text of the manuscript and a table, 
we used the values as shown in the tables. 
 
Selection of Patients 
Patients enrolled in the EHS-CR were considered eligible for the comparison between trial 
participants and clinical practice unless the primary diagnosis was ST-elevation myocardial 
infarction (n=4713), as these patients were excluded from all trials comparing CABG with 
PCI. In addition, we analysed which proportion of survey patients would have been 
disqualified for participation in a coronary intervention trial, aiming at separating trial-eligible 
from trial-ineligible patients in our clinical practice population. Since all patients in this survey 
had at least one >50% diameter stenosis in a major epicardial vessel, we considered patients as 
trial-eligible if no major exclusion criteria were observed. As Table 2 clearly reveals, we only 
selected the most important exclusion criteria. If we would use the enrolment criteria of the 
individual trials that we were able to identify in our database, approximately 11-25% of the 
survey patients would be eligible for participation in the individual trials. However, by using 
only major exclusion criteria, we aimed at comparing an average of patients as seen in clinical 
practice with RCT participants, decreasing the risk of identifying a highly selective group of 
survey patients. It should be noted, however, this selection is, by necessity, crude. We also 
would like to state that defining patients from clinical practice as trial-eligible or trial-ineligible 
was done in retrospect.  
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Statistical analyses 
Differences in baseline characteristics between survey patients and pooled intervention trials 
were analysed by chi-square tests, using EpiInfo (version 5.0). To analyse continuous variables 
we used the highest standard deviation presented in the selected coronary intervention trials. 
Comparison between trial-eligible and trial-ineligible survey patients was analysed by chi-
square tests, Fisher’s exact tests or t-tests as appropriate, using SPSS for Windows (version 
12.0). Data are presented as percentage and 95% confidence interval (95%, C.I.), unless 
indicated otherwise. A p-value of <.001 was considered significant (two-sided).  
 As we acknowledged the fact that patients, who were treated medically, differ 
considerable from those who were intended to undergo revascularization we repeated all 
analyses excluding medically treated patients. As the results of these analyses were highly 
consistent, we report our original choice on the basis of all three treatment groups (i.e. PCI, 
CABG, and medical). 
 
RESULTS 
In total 8647 patients enrolled the identified RCTs that compared CABG with PCI. The 
duration of follow-up varied between 1 and 5.4 years. As table 1 visualizes, the competitive 
procedures differed hardly in survival rates and non-fatal myocardial infarction. The need for 
repeat revascularization, however, differed largely between the two revascularization 
techniques, favouring CABG.  
 Based on the selection of major exclusion criteria, we estimated that almost two-third 
(n=3033, 64%) of the 4713 EHS-CR patients would have disqualified for trial participation 
(Table 2). Most frequently observed obstacles for trial participation were prior 
Table 2. Major exclusion criteria, used in RCTs8,13-25 applied to patients included in this study. 
  RCTs EHS-CR  
 Exclusion criteria Number of trials Number of patients (%) 
    
A Age ≥ 80 years 2 195 (4) 
B Prior PCI 13 1054 (22) 
C Prior CABG 13 566 (12) 
D Ejection fraction ≤ 35% 5 294 (6) 
E Left main disease 8 427 (9) 
F Valvular heart disease 8 319 (7) 
G CABG or PCI not suitable  14 1757 (37) 
    
  Three of the above (B,C,G) 14 2585 (55) 
  Five of the above     (B,C,D,E,G) 14 2841 (60) 
  Any of the above   (A – G) 14 3033 (64) 
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revascularization and non suitability of the diseased vessels for CABG and/or PCI. The 
remaining 36% (n=1680) was considered trial-eligible. 
 There were important differences in clinical and angiographical characteristics between 
participants of the identified RCTs and patients as seen in clinical practice (Table 3). In 
general, patients in clinical practice were older and more often had comorbid conditions as 
compared to trial participants. Interestingly, unstable angina was more frequent in trial 
populations as well as in trial-eligible patients. As most RCTs included only patients with 
Table 3. Characteristics of patients enrolled in randomised trials as compared to EHS-CR patients*. 
Characteristics 
 
Pooled 
trials 
Number 
of trials
EHS-CR
      P1 
EHS-CR
 mvd‡       P2
    
Patients (n) 8647 [14] 4713 3081
  
Mean age, yr (sd)  60 ±12 [12] 63 ±11 < .01 64 ±10 <.01
Male gender (%, 95%CI) 77 (76-78) [14] 76 (75-77) .29 77 (76-79) .40
History (%, 95%CI)  
Hyperlipidemia  56 (54-57) [8] 67 (66-69) <.001 68 (67-71) <.001
Hypertension  47 (46-48) [12] 62 (60-63) <.001 63 (62-66) <.001
Diabetes  20 (19-20) [13] 24 (22-26) <.001 27 (25-28) <.001
Peripheral vascular disease  8 (7-9) [5] 13 (12-14) <.001 14 (13-16) <.001
Renal failure n.a. [14] 4 (4-5) -- 6 (5-7) --
Prior myocardial infarction  44 (43-45) [13] 41 (39-42) <.001 44 (42-46) .91
Congestive heart failure n.a. [14] 17 (16-19) -- 20 (19-21) --
Cerebro-vascular disease  4 (4-5) [4] 8 (7-9) <.001 9 (8-10) <.001
Presentation(%, 95%CI)  
Unstable angina 42 (41-43) [8] 35 (34-37) <.001 35 (33-37) <.001
Stable angina n.a. [15] 62 (61-64) -- 63 (61-65) --
                CCS 3-4 (%) 42 (41-43) [7] 35 (34-37) <.001 39 (37-41) .006
Chronic medication (%, 95%CI)  
Antiplatelet agents  83 (81-84) [4] 85 (84-86) .02 86 (84-87) .006
ACE-i/ Angiotensin-II blockers 23 (20-26) [2] 50 (49-51) <.001 52 (50-53) <.001
Bèta-blocker  68 (66-69) [6] 69 (67-70) .35 70 (68-71) .12
Calcium-antagonist  65 (63-66) [6] 28 (26-29) <.001 28 (27-30) <.001
Nitrates  61 (59-63) [6] 56 (54-57) <.001 59 (57-61) .30
Statins n.a.  52 (51-54) -- 52 (50-54) --
Coronary angiogram (%, 95%CI)  
Diseased left anterior descending 73 (72-75) [11] 74 (72-75) .73 86 (84-87) <.001
Diseased right coronary artery 68 (66-69) [4] 62 (60-63) <.001 78 (78-81) <.001
Diseased left circumflex 69 (67-71) [4] 59 (57-60) <.001 79 (77-80) <.001
Diseased left main stem  2 (1-3) [2] 9 (8-10) <.001 14 (13-15) <.001
Number of diseased vessels  <.001 --
    1  11 (10-12) [14] 35 (33-36) 0
    2   53 (52-55) [14] 31 (29-32) 47 (45-49)
    3   35 (34-36) [14] 34 (33-36) 53 (51-54)
 Treatment (preference/option) (%)  -- --
 PCI 49  54 46 (44-47)
 CABG 48  23 33 (31-35)
 Medical only 3  23 21 (20-23)
      
* Patients, admitted with ST-elevation infarction were excluded 
‡ MVD= multi vessel disease 
P1 pooled trials versus EHS-CR population     
P2 pooled trials versus EHS-CR population with MVD 
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multivessel disease, we identified survey patients with multivessel disease and compared this 
major subgroup (65%) with those who participated in RCTs. On top of the observed 
differences between survey patients and trial participants, patients enrolled in the EHS-CR 
with multivessel disease were more likely to have three-vessel disease as compared to trial 
participants.  
 
 
Table 4. Comparison between trial-eligible and trial-ineligible EHS-CR patients. 
Patient characteristics 
 
Trial-eligible  
EHS-CR patients 
 Trial-ineligible  
EHS-CR patients 
P 
     
     
Patients (n) 1680  3033  
Mean age, yr (±sd)  62 ±10  64 ±11 <.001 
Male gender (%, 95%CI) 74 (72-76)  77 (75-78) .052 
History  (%, 95%CI)     
Hyperlipidemia  66 (64-69)  68 (67-70) .23 
Hypertension  59 (57-61)  63 (61-65) .006 
Diabetes  21 (19-23)  26 (25-28) <.001 
Peripheral vascular disease  10 (8-11)  14 (13-15) <.001 
Renal failure 3 (2-4)  5 (4-6) <.001 
Prior myocardial infarction  32 (30-35)  46 (43-47) <.001 
Congestive heart failure 12 (11-14)  20 (19-22) <.001 
Cerebrovascular disease  7 (6-9)  8 (7-9) .31 
Presentation  (%, 95%CI)     
Unstable angina 41 (39-44)  32 (30-34) <.001 
   Stable angina 57 (55-59)  65 (64-67) <.001 
        CCS class 3-4 (%) 35 (31-37)  36 (34-38) .21 
Chronic medication  (%, 95%CI)     
Antiplatelet agents  85 (83-86)  85 (84-86) .76 
ACE-inhibitors/ Angiotensin-II blockers 45 (42-47)  53 (51-55) <.001 
Bèta-blocker  68 (66-71)  69 (67-70) .69 
Calcium-antagonist  25 (23-27)  29 (28-31) .003 
Nitrates  54 (52-56)  56 (55-58) .11 
Statines 46 (44-49)  55 (44-49) <.001 
Coronary angiogram   (%, 95%CI)     
Diseased left anterior descending 73 (71-76)  74 (72-75) .78 
Diseased right coronary artery 58 (56-61)  64 (62-65) <.001 
Diseased left circumflex 54 (52-57)  61 (59-63) <.001 
Diseased left main stem  0  14 (13-15) <.001 
Number of diseased vessels    <.001 
                   1  40 (37-42)  32 (30-33)  
                   2   34 (31-36)  29 (27-31)  
                   3   26 (24-28)  39 (37-41)  
 RISK SCORE (mean, ±sd)     
EuroSCORE* 3.6 ±2.3  5.0 ±3.0 <.001 
 Treatment (preference/option) (%)    <.001 
PCI 69  46  
CABG 19  26  
Medical only 13  28  
*) EuroSCORE was calculated from the available variables 31 
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 PCI was clearly the preferred treatment in clinical practice, whereas CABG and 
medical treatment was evenly distributed in RCTs, the choice of treatment being dictated by 
randomisation. In contrast to the observed differences, it is important to note that the under-
representation of women as seen in RCTs was also observed in clinical practice.      
 Within the study population, a comparison between trial-eligible and trial-ineligible 
patients was made, and revealed that patients who would be excluded from trial participation 
had a worse clinical profile as compared to trial-eligible patients (Table 4). Trial-ineligible 
patients were older, more likely to have a comorbid condition, and had a higher proportion of 
diseased coronary arteries including left main stenosis. By means of the EuroSCORE, trial-
ineligible patients would have a higher estimated peri-procedural risk. These trial-ineligible 
patients were treated more often surgically or medically as compared to trial-eligible patients, 
though PCI remained the treatment of choice. When excluding patients with single vessel 
disease from the analyses, PCI remained the preferred treatment option in 57% of trial-
eligible, and 40% of trial-ineligible patients (p<.001). CABG did not differ between patients 
with multivessel disease in the two subgroups (31 vs. 34%, respectively). The majority of 
patients with left main disease (n=427) was treated by means of CABG (n=239), whereas 96 
patients were treated 
percutaneously and 92 
did not undergo 
revascularization. Of the 
96 patients undergoing 
PCI, the left main was 
not protected by means 
of a prior CABG in 45 
patients (47%).  
 Identical to the 
outcomes in RCTs, the 
most important 
difference between PCI 
and CABG was 
observed in the lower 
need for repeat 
revascularizations in 
CABG patients (Figure 
1). In contrast to the 
trials, the overall 
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Figure 1. Outcome at 1 year 
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unadjusted one-year survival differed between PCI and CABG (2.9 versus 5.4%, p <0.001). As 
figure 1 clearly reveals, this survival benefit in PCI patients was only observed in those who 
would be excluded from trial participation (3.3 versus 6.2%, p <0.001). In trial-eligible patients 
neither treatment had a clear advantage over the other for preventing death.  
 
DISCUSSION 
This study revealed that participants of RCTs are not representative of patients treated in daily 
clinical practice. Moreover, only a minority of patients in clinical practice (36%) were 
potentially eligible for participation in one of the RCTs. These trial-eligible patients had a 
different clinical profile as compared to RCT participants. 
 The importance of this finding is related to the fact that RCTs are valued as highest in 
the hierarchy of evidence that is used in the guidelines and for the formulation of 
recommendations. That patients enrolled in these trials may not be representative for the 
general clinical practice26, obviously depends on the in- and exclusion criteria. As the result of 
this and other factors such as physician preference, 58-96% of the screened patients and 84-
98% of the eligible patients are eventually not enrolled.8,13,15-17,23,27 As a result, many RCTs are 
known to have a limited generalisability.9,28  
 These observations highlight the difficulties experts have in writing guidelines, as well 
as for clinicians who have to choose the most appropriate treatment for individual patients. In 
addition to this, observational studies can be useful adjuncts to RCTs, as they are more likely 
to reflect clinical practice, and consequently can provide information on subpopulations that 
were disregarded in trials, as well as on the effectiveness of evidence-based treatments in 
routine practice.  
 Regarding the observed differences between RCT participants and patients enrolled in 
the EHS-CR, we would like to address the under-representation of women (25%) in both 
groups (i.e. pooled RCTs and the EHS-CR). This observation erroneously suggests that men 
are more likely to have CAD. In fact, approximately 50% of all patients with CAD are known 
to be women, though women are approximately 10 years older.29 Apparently, and in line with 
previous findings, women are less likely to undergo invasive investigations and consequently 
revascularization.30,31  
 As most trials included only patients with multivessel disease, it was no surprise to 
observe that patients with two-vessel disease dominated in the RCTs. In clinical practice, the 
number of diseased coronary vessels was more evenly distributed. Although this suggests a 
more extensive coronary artery disease in RCT participants, it should be noted that left main 
disease was seen more often in clinical practice. Regarding demographics, risk factors and co-
morbid conditions, patients in clinical practice were somewhat older and had a worse clinical 
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profile as compared to the trial patients. In addition to this, a high proportion of patients had 
a history of heart failure. Though no numbers were given regarding heart failure patients in 
the selected trials, it is unlikely that they approximate to the observed proportion as seen in 
the EHS-CR. This study therefore provides a valuable perspective on the disparity between 
patients in clinical practice and patients in whom the studies that provide the evidence for 
treatment guidelines are performed. It should be noted, however, that the AWESOME trial, 
which was excluded from the selection of trials, has specifically addressed the impact of PCI 
or CABG in patients with high-risk clinical characteristics and thus trying to overcome the gap 
between clinical practice and RCTs. In AWESOME, as in the other selected RCTs, mortality 
rates were similar between the two treatment groups.12 
 In clinical practice, treatment preference was unmistakable in favour of PCI (54%), 
whereas surgically and medically treated patients were comparable. Though PCI seemed to be 
the treatment of choice, we observed a shift toward fewer percutaneous interventions in those 
who did not qualify for trial participation. In contrast to RCTs, the choice of treatment in 
clinical practice is not dictated by randomization, but influenced by the weight clinicians and 
patients gave to a variety of factors. In this respect, the major advantages of PCI as compared 
to CABG (e.g. relative ease of use, no need for general anaesthesia, thoracotomy, and 
extracorporeal circulation) seemed superior to the disadvantages (e.g. higher risk of early 
restenosis, and lower ability to achieve complete revascularization). 
 Not surprisingly, as observed in the selected trials 8,12-21,32, the need for repeat 
revascularisation in clinical practice was considerably higher in the PCI group as compared to 
CABG. However, with respect to irreversible adverse events such as death, myocardial 
infarction and cerebro-vascular events, this study only partly supports the conclusion of most 
RCTs, that PCI and CABG patients have similar outcome. Indeed, trial-ineligible patients 
undergoing CABG had a worse survival as compared to trial-ineligible patients undergoing 
PCI. This difference is only partly explained by the fact that patients with unprotected left 
main stenosis were treated by CABG rather than by PCI 10 in line with the guidelines, 
advocating CABG in high-risk patients 5,7.  Previous real life studies likewise showed that 
patients selected for CABG have more extensive disease, more comorbidities, higher 
procedural risk, and therefore unadjusted event rates tend to be worse with CABG than with 
PCI. However, propensity analysis showed that under those circumstances, CABG actually 
improves outcome.33,34 The implications are that trial results are indeed confirmed in real life, 
but only in trial-eligible patients. Clearly, this does not appear to be the case in trial-ineligible 
patients.  
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Limitations.  
The limitations of this study are those inherent to observational surveys involving voluntarily 
participating hospitals. Although we have attempted to include a wide spectrum of hospitals in 
different countries, almost certainly the results are biased towards better than average 
practices. The sample size only represents a small fraction of all patients admitted in 
catheterisation laboratories throughout Europe during the study period. Patient inclusion was 
consecutive in all participating sites, therefore reflecting the ongoing clinical practice. 
Although we have attempted to include a wide spectrum of hospitals in different countries, 
almost certainly the results are biased towards better than average practices. Consequently, 
even though the results of this survey reflect the real world better than RCTs it should be 
noted that this may still be too far away from daily practice. Regarding the selection of trial-
ineligible patients, we focussed on the major exclusion criteria of the pooled trials. Obviously, 
in retrospect, we could not trace the complete decision making process leading to trial-
(in)eligibility of patients enrolled in this Survey.  
 
Conclusions.  
The present study revealed that only a minority of patients, enrolled in the Euro Heart Survey 
on Revascularization would have qualified for participation in a RCT comparing PCI and 
CABG. Furthermore, we demonstrated that trial participants had a better clinical profile as 
compared to patients in every day clinical practice. Nevertheless, the less invasive approach 
with percutaneous intervention was the preferred treatment over surgical and medical 
treatment. 
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ABSTRACT 
 
Background: Surveys on heart failure management suggest under-utilization of life-saving 
evidence-based treatment. Evidence-based medicine and clinical guidelines are based on the 
results of Randomized Controlled Trials. Therefore, we investigated how patients who 
fulfilled the enrolment criteria of randomized trials were treated in “real-life”. 
 
Methods: We selected three large placebo-controlled trials of patients with chronic heart 
failure in which ACE-inhibitors, β-blockers, and spironolactone proved to be safe and 
effective. The trials’ major enrolment criteria were identified and applied to patients enrolled 
in the Euro Heart Survey on Heart Failure to identify the proportion of patients eligible for 
treatment and also treated appropriately. 
 
Results: Of the 10,701 patients who were enrolled in the Euro Heart Survey on Heart Failure, 
only a small percentage (13%) would have qualified for participation in at least one of the 
selected trials. Patients who fulfilled enrolment criteria of the identified trials were more likely 
to be treated with ACE-inhibitors (83% of SOLVD-eligible patients), β-blockers (54% of 
MERIT-HF-eligible patients), and aldosterone antagonists (43% of RALES-eligible patients) 
than trial-ineligible patients. Almost half of SOLVD-eligible patients who were treated with 
ACE-inhibitors received the target dose as recommended in the guidelines, but less than 10% 
of MERIT-HF eligible patients who were treated with β-blockers received the target dose.   
 
Conclusions: ACE-inhibitors are widely utilized but given in lower doses than proven 
effective in clinical trials. β-blockers are underused and given in lower doses to patients who 
fulfil the enrolment criteria of relevant landmark trials. 
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INTRODUCTION 
Chronic heart failure is a major health problem with a high morbidity and mortality.1,2 Over 
the last two decades, major advances have occurred in the treatment of heart failure patients.  
Randomized clinical trials (RCTs) showed that ACE-inhibitors,3-5 β-blockers,6-8 and 
aldosterone antagonists9,10 could reduce morbidity and mortality in patients with heart failure.  
Guidelines have been established to support physicians in clinical decision making in this 
rapidly evolving field.11-14 In these guidelines, RCTs are accorded the highest level of evidence. 
However, although physicians are increasingly encouraged to apply these guidelines in their 
practice, it is repeatedly observed that a considerable proportion of heart failure patients do 
not receive evidence-based treatment.15-20 
Several factors may explain the reported under-utilization of evidence-based treatment 
such as lack of knowledge, lack of expertise in the use of such drugs, lack of time, and 
economic restraints. Another issue that is often brought forward is the limited generalisability 
(external validity) of RCTs and it is emphasized that these trials usually enrol highly selected 
patients.21-27 In reality, clinicians may be right to withhold treatment in patients who do not 
fulfil the inclusion and exclusion criteria used to select patients for RCTs. Information is 
scarce on whether evidence-based treatment is offered more often to patients who match the 
profile of patients who were enrolled in RCTs as compared to those who were not.  
Therefore, we investigated what proportion of patients with suspected or known heart 
failure who enrolled the Euro Heart Survey on Heart Failure,19 were eligible for participation 
in the largest placebo controlled trials of ACE-inhibitors, β-blockers, and aldosterone 
antagonists that demonstrated the effectiveness and safety of these agents. We then analyzed 
what proportion of patients met or did not meet these criteria, and were treated according to 
the guidelines.  
 
METHODS 
Euro Heart Survey on Heart Failure 
Between March 2000 and May 2001, 46,788 patients from 115 hospitals in 24 ESC member 
countries were screened for enrolment in the Euro Heart Survey on Heart Failure.19,20,28 
Briefly, all consecutive discharges and deaths from general medical, cardiology or cardiac 
surgery wards were screened over a 6-week period. Patients who fulfilled one or more of the 
following four criteria were enrolled: 1) a clinical diagnosis of heart failure during the 
admission; 2) a diagnosis of heart failure recorded at any time in the last three years; 3) 
administration of a loop diuretic for any reason other than renal failure in the 24h before 
death or discharge; and/or 4) pharmacological treatment for heart failure or ventricular 
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dysfunction in the 24h before death or discharge. Information on patient characteristics, 
diagnosis, and treatment on 10,701 enrolled patients was collected.19,20   
 
Trial selection 
To compare patients in the RCTs with those enrolled in the Euro Heart Survey, we selected 
the largest placebo-controlled trials in which ACE-inhibitors, β-blockers, and aldosterone 
antagonists had been shown to reduce mortality in patients with chronic heart failure. These 
were SOLVD (ACE-inhibitor), MERIT-HF (β-blocker), and RALES (aldosterone 
antagonist).4,6,9 In addition, we compiled the tabulated patient characteristics, as presented in 
the main results papers of these trials (“pooled RCTs”). Data were pooled if the certain 
characteristics were available in at least two trials, either by reports of the actual counts or by 
percentages. 
 The major enrolment criteria for these trials were extracted from the main articles and 
summarized in Table 1. The most important inclusion criterion in these trials was the left 
ventricular ejection fraction (LVEF).  Important exclusion criteria were renal failure, 
respiratory disease (including asthma and chronic obstructive respiratory disease during the 
index admission), obstructive valvular heart disease, acute coronary syndrome during the index 
admission, and limited life-expectancy by other diseases. We furthermore identified, 
pacemakers, ventricular assist devices, planned heart transplantation, congenital heart disease, 
laboratory values (i.e. creatinine and potassium), and administered cardiovascular drugs (i.e. 
calcium antagonists and amiodarone), as exclusion criteria in some of these trials.  
Table 1.  Major in- and exclusion criteria of selected trials 
 SOLVD MERIT-HF RALES 
 1991 1999 1999 
    
Drug comparison enalapril metoprolol spironolactone 
Number of participants 2569 3991 1663 
    
Major enrolment  criteria    
  Age ≤ 80 40-80 - 
  NYHA - II-IV III-IV 
  LVEF ≤ 0.35 ≤ 0.40 ≤ 0.35 
    
  Renal failure (creatinine level) exclude (>2.0 mg/dl) - exclude (>2.5 mg/dl) 
  Severe pulmonary disease exclude exclude - 
  Severe valve disease exclude - exclude 
  (recent) ACS exclude exclude exclude 
  Limited life -expectancy exclude exclude exclude 
    
  ACE-inhibitor therapy exclude mandatory mandatory 
  β-blocker therapy - exclude - 
  Calcium antagonists - exclude - 
  Diuretics  mandatory mandatory* 
  Amiodarone - exclude - 
NYHA= New York Heart Association; LVEF= left ventricular ejection fraction; ACS= acute coronary 
syndrome. 
* potassium-sparing diuretics excluded 
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Identifying trial-eligible survey patients 
Based on the above mentioned criteria, survey patients with identifiable contra-indications (i.e. 
age, co-morbidity, etc) or a higher LVEF than allowed in the RCTs were classified as trial-
ineligible patients. Trial-eligible patients were those, who had no contra-indications and 
fulfilled the LVEF criterion, while the remaining patients were classified as “other survey 
patients”. In these patients no quantitative measurement of the LVEF was available, while no 
contra-indications were observed. It should be noted, however, that defining patients from 
clinical practice as trial-eligible or trial-ineligible is, by necessity, crude. 
 Within the subgroups of SOLVD, MERIT-HF and RALES-eligible patients, we 
analysed the administered dose of ACE-inhibitors and β-blockers on the day of discharge or 
the day prior to death as compared to the target dose. We defined the target dose as the 
minimum recommended maintenance dose or higher approved for the treatment of heart 
failure in Europe.13 For ACE-inhibitors this is 75mg for captopril, 20mg for enalapril, 5mg for 
ramipril, 5mg for lisinopril, and 4mg for perindopril. For β-blockers these dosages were 
150mg for metoprolol, 50mg for atenolol, 50mg for carvedilol, and 10mg for bisoprolol.  
 
Statistical analysis 
Descriptive statistics included percentages for dichotomous variables, and medians with 
corresponding 25th and 75th percentiles for continues variables. Differences between trial-
eligible and trial-ineligible patients were analyzed by Chi-square, and Mann-Whitney or 
Kruskal-Wallis test as appropriate. For all tests a p value of 0.05 or less (two-sided) was 
consistent statistically significant. All analyses were performed with SPSS (version 12.0). 
 We acknowledge the fact that patients’, who died during the initial hospitalisation, 
could have a worse clinical profile, and as a result influence the results. Therefore, we repeated 
the analyses excluding patients who did not survive to hospital discharge. Since the results of 
the analyses with and without patients who died during the initial hospitalisation were highly 
consistent, we report our original choice, based on the total survey population.   
 
RESULTS 
As shown in figure 1, only small proportions of patients enrolled in the Euro Heart Survey on 
Heart Failure would have qualified for participating in the SOLVD (9%), MERIT-HF (5%), 
and RALES (7%) trials. Exclusion criteria like age and identified contra-indications were the 
most important reasons for not classifying patients as trial-eligible.  In addition to this, we 
were unable to classify a considerable proportion of patients as trial-eligible due to the absence 
of a LVEF measurement. Similarly, patients were only considered MERIT-HF eligible if they 
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were treated with a diuretic and ACE-inhibitor (or angiotensin-II-antagonist), and RALES-
eligible when treated with an ACE-inhibitor and loop diuretic. 
 Overall, 1346 patients (13%) would have qualified for participating in at least one of 
the selected trials (Table 2). Within this pooled trial-eligible population, 256 patients would 
have qualified for all three trials, while 692 patients would have qualified for at least 2 trials. 
 These trial-eligible patients show considerable differences as compared to those who 
did not qualify for trial participation. Consistent with the results of clinical trials, the majority 
of trial-eligible patients were men (75%). It should be noted however, that almost half (47%) 
of the survey participants were women, whereas they represented only 27% of those with a 
LVEF ≤ 0.40. Ischemic heart disease was observed less frequently in patients without 
exclusion criteria but unknown LVEF (other survey patients) as compared to trial-eligible and 
trial-ineligible patients. Limited life-expectancy was defined as any known malignancy, and 
observed in 16% of the trial-ineligible patients. 
 Most patients who fulfilled trial-criteria were treated with ACE-inhibitors (83% to 
100%) (Table 3). Almost two-third of all trial-eligible patients were treated with at least half of 
the target dose, and 40% to 50% received the minimum regulatory recommended dose.13 As 
the recommended maintenance doses of ACE-inhibitors in the guidelines are given as dose 
ranges, we also repeated the analysis using the maximum regulatory recommended doses. This 
corresponded to 50% of SOLVD, and 57% of MERIT-HF and RALES eligible patients who 
were treated with at least half of this higher target dose. With regard to β-blockers, 54% of 
MERIT-eligible patients received a β-blocker, of whom in 20% at least half of the target dose 
was given, while only 6% received the target dose. Aldosterone antagonists were given to a 
large minority (43%) of heart failure patients, fulfilling the enrolment criteria of the RALES-
trial. Of all survey patients, 3658 (34% of all patients or 54% of those who underwent 
imaging) had evidence of a left ventricular systolic dysfunction (LVSD), defined as a LVEF ≤ 
0.40 or a report of moderate or severe LVSD on echocardiography. Of these patients, 78% 
was treated with an ACE-inhibitor, 46% with a β-blocker, and 29% with an aldosterone 
antagonist. In the absence of renal failure and asthma (n=2762, 26%), slightly more patients 
were given ACE-inhibitors (80%) and β-blocker (48%), while treatment with aldosterone 
antagonists remained 29%.   
 The incidence of all-cause mortality during the 12-week follow-up period of hospital 
survivors was lower in patients who received at least 50% of the target dose of ACE-inhibitors 
or β-blockers in respectively SOLVD (4.0% vs. 8.7%) and MERIT-HF (2.9% vs. 8.8%) 
eligible patients (Table 4). This beneficial effect of treating patients with 50% or more of the 
target dose was also observed in patients who did not fulfil the study criteria of the selected 
trials.
Chapter 4
53
Pg
. 5
3 *) n
um
be
r o
f c
on
tra
-in
di
ca
tio
ns
, u
se
d 
in
 th
e a
na
lys
is
‡ ) 
pe
rc
en
ta
ge
 is
 b
as
ed
 o
n 
to
ta
l s
ur
ve
y 
po
pu
lat
io
n
SO
LV
D
 e
nr
ol
lm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
�
80
 y
rs
N
o
n=
24
89
Ye
s
n=
82
12
Co
nt
ra
-in
di
ca
tio
ns
 (5
)*
Ye
s
n=
35
94
N
o
n=
46
18
LV
E
F 
in
clu
sio
n
LV
E
F 
>
0.
35
n=
15
14
 (1
4%
)‡
LV
E
F 
�
0.
35
n
=
10
05
(9
%
)‡
LV
E
F 
un
kn
ow
n
n=
20
99
 (2
0%
)‡
SO
L
V
D
 e
li
g
ib
le
 p
at
ie
n
ts
A
CE
-in
hi
bi
to
r 
us
e: 
99
4 
( 6
6%
)
A
CE
-in
hi
bi
to
r 
us
e: 
82
9 
(8
3%
)
AC
E-
in
hi
bi
to
r 
us
e: 
12
05
 (5
7%
)
M
ER
IT
-H
F 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
 4
0-
80
 y
rs
N
o
n=
26
60
Ye
s
n=
80
41
Co
nt
ra
-in
di
ca
tio
ns
 (1
2)
*
Ye
s
n=
58
01
N
o
n=
22
40
LV
E
F 
>
0.
40
n=
35
4 
(3
%
)‡
LV
E
F 
�
0.
40
n
=
50
7
(5
%
)‡
LV
E
F 
un
kn
ow
n
n=
54
7 
(5
%
)‡
M
E
R
IT
-H
F
 e
lig
ib
le
 
p
at
ie
n
ts
�-
bl
oc
ke
r u
se
: 
16
9 
(4
8%
)
�-
bl
oc
ke
r u
se
: 
27
2 
(5
4%
)
�-
bl
oc
ke
r u
se
: 
19
8 
(3
6%
)
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
83
2
Ye
s n
=
14
08
LV
E
F 
in
clu
sio
n
RA
LE
S 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
N
o 
ag
e 
lim
its
N
o
n=
0
Ye
s
n=
10
,7
01
LV
EF
 in
clu
sio
n
LV
E
F 
>0
.3
5
n=
92
3 
(9
%
)‡
LV
E
F 
�
0.
35
n
=
78
2
(7
%
)‡
LV
E
F 
un
kn
ow
n
n=
14
77
 (1
4%
)‡
R
A
L
E
S 
el
ig
ib
le
 p
at
ie
n
ts
sp
iro
no
lac
to
ne
us
e: 
19
8 
(2
2%
)
sp
iro
no
lac
to
ne
us
e: 
33
4 
(4
3%
)
sp
iro
no
lac
to
ne
us
e: 
30
4 
(2
1%
)
Co
nt
ra
-in
di
ca
tio
ns
 (7
)*
Ye
s
n=
42
68
N
o
n=
64
33
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
32
51
Ye
s n
=3
18
2
*)
 n
um
be
r o
f c
on
tra
-in
di
ca
tio
ns
, u
se
d 
in
 th
e a
na
lys
is
‡ ) 
pe
rc
en
ta
ge
 is
 b
as
ed
 o
n 
to
ta
l s
ur
ve
y 
po
pu
lat
io
n
SO
LV
D
 e
nr
ol
lm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
�
80
 y
rs
N
o
n=
24
89
Ye
s
n=
82
12
Co
nt
ra
-in
di
ca
tio
ns
 (5
)*
Ye
s
n=
35
94
N
o
n=
46
18
LV
E
F 
in
clu
sio
n
LV
E
F 
>
0.
35
n=
15
14
 (1
4%
)‡
LV
E
F 
�
0.
35
n
=
10
05
(9
%
)‡
LV
E
F 
un
kn
ow
n
n=
20
99
 (2
0%
)‡
SO
L
V
D
 e
li
g
ib
le
 p
at
ie
n
ts
A
CE
-in
hi
bi
to
r 
us
e: 
99
4 
( 6
6%
)
A
CE
-in
hi
bi
to
r 
us
e: 
82
9 
(8
3%
)
AC
E-
in
hi
bi
to
r 
us
e: 
12
05
 (5
7%
)
M
ER
IT
-H
F 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
 4
0-
80
 y
rs
N
o
n=
26
60
Ye
s
n=
80
41
Co
nt
ra
-in
di
ca
tio
ns
 (1
2)
*
Ye
s
n=
58
01
N
o
n=
22
40
LV
E
F 
>
0.
40
n=
35
4 
(3
%
)‡
LV
E
F 
�
0.
40
n
=
50
7
(5
%
)‡
LV
E
F 
un
kn
ow
n
n=
54
7 
(5
%
)‡
M
E
R
IT
-H
F
 e
lig
ib
le
 
p
at
ie
n
ts
�-
bl
oc
ke
r u
se
: 
16
9 
(4
8%
)
�-
bl
oc
ke
r u
se
: 
27
2 
(5
4%
)
�-
bl
oc
ke
r u
se
: 
19
8 
(3
6%
)
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
83
2
Ye
s n
=
14
08
LV
E
F 
in
clu
sio
n
RA
LE
S 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
N
o 
ag
e 
lim
its
N
o
n=
0
Ye
s
n=
10
,7
01
LV
EF
 in
clu
sio
n
LV
E
F 
>0
.3
5
n=
92
3 
(9
%
)‡
LV
E
F 
�
0.
35
n
=
78
2
(7
%
)‡
LV
E
F 
un
kn
ow
n
n=
14
77
 (1
4%
)‡
R
A
L
E
S 
el
ig
ib
le
 p
at
ie
n
ts
sp
iro
no
lac
to
ne
us
e: 
19
8 
(2
2%
)
sp
iro
no
lac
to
ne
us
e: 
33
4 
(4
3%
)
sp
iro
no
lac
to
ne
us
e: 
30
4 
(2
1%
)
Co
nt
ra
-in
di
ca
tio
ns
 (7
)*
Ye
s
n=
42
68
N
o
n=
64
33
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
32
51
Ye
s n
=3
18
2
SO
LV
D
 e
nr
ol
lm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
�
80
 y
rs
N
o
n=
24
89
Ye
s
n=
82
12
Co
nt
ra
-in
di
ca
tio
ns
 (5
)*
Ye
s
n=
35
94
N
o
n=
46
18
LV
E
F 
in
clu
sio
n
LV
E
F 
>
0.
35
n=
15
14
 (1
4%
)‡
LV
E
F 
�
0.
35
n
=
10
05
(9
%
)‡
LV
E
F 
un
kn
ow
n
n=
20
99
 (2
0%
)‡
SO
L
V
D
 e
li
g
ib
le
 p
at
ie
n
ts
A
CE
-in
hi
bi
to
r 
us
e: 
99
4 
( 6
6%
)
A
CE
-in
hi
bi
to
r 
us
e: 
82
9 
(8
3%
)
AC
E-
in
hi
bi
to
r 
us
e: 
12
05
 (5
7%
)
M
ER
IT
-H
F 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
A
ge
 4
0-
80
 y
rs
N
o
n=
26
60
Ye
s
n=
80
41
Co
nt
ra
-in
di
ca
tio
ns
 (1
2)
*
Ye
s
n=
58
01
N
o
n=
22
40
LV
E
F 
>
0.
40
n=
35
4 
(3
%
)‡
LV
E
F 
�
0.
40
n
=
50
7
(5
%
)‡
LV
E
F 
un
kn
ow
n
n=
54
7 
(5
%
)‡
M
E
R
IT
-H
F
 e
lig
ib
le
 
p
at
ie
n
ts
�-
bl
oc
ke
r u
se
: 
16
9 
(4
8%
)
�-
bl
oc
ke
r u
se
: 
27
2 
(5
4%
)
�-
bl
oc
ke
r u
se
: 
19
8 
(3
6%
)
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
83
2
Ye
s n
=
14
08
LV
E
F 
in
clu
sio
n
RA
LE
S 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
N
o 
ag
e 
lim
its
N
o
n=
0
Ye
s
n=
10
,7
01
LV
EF
 in
clu
sio
n
LV
E
F 
>0
.3
5
n=
92
3 
(9
%
)‡
LV
E
F 
�
0.
35
n
=
78
2
(7
%
)‡
LV
E
F 
un
kn
ow
n
n=
14
77
 (1
4%
)‡
R
A
L
E
S 
el
ig
ib
le
 p
at
ie
n
ts
RA
LE
S 
en
ro
llm
en
t c
rit
er
ia
Su
rv
ey
 p
op
ul
at
io
n
n=
10
,7
01
N
o 
ag
e 
lim
its
N
o
n=
0
Ye
s
n=
10
,7
01
LV
EF
 in
clu
sio
n
LV
E
F 
>0
.3
5
n=
92
3 
(9
%
)‡
LV
E
F 
�
0.
35
n
=
78
2
(7
%
)‡
LV
E
F 
un
kn
ow
n
n=
14
77
 (1
4%
)‡
R
A
L
E
S 
el
ig
ib
le
 p
at
ie
n
ts
sp
iro
no
lac
to
ne
us
e: 
19
8 
(2
2%
)
sp
iro
no
lac
to
ne
us
e: 
33
4 
(4
3%
)
sp
iro
no
lac
to
ne
us
e: 
30
4 
(2
1%
)
Co
nt
ra
-in
di
ca
tio
ns
 (7
)*
Ye
s
n=
42
68
N
o
n=
64
33
AC
E-
i a
nd
 
di
ur
et
ics N
o 
n=
32
51
Ye
s n
=3
18
2
F
ig
u
re
 1
. F
lo
wd
iag
ra
m
, i
llu
str
at
in
g 
th
e 
pr
op
or
tio
n 
of
 tr
ial
-e
lig
ib
le 
pa
tie
nt
s.
Chapter 4 
 54 
  
DISCUSSION 
The present study clearly revealed that the patients enrolled in RCTs are highly selected. Only 
a small proportion of patients enrolled in the Euro Heart Survey on Heart Failure would have 
fulfilled the entry criteria of at least one of the selected landmark trials. In this subgroup of 
trial-eligible patients, barely one half were prescribed a β-blocker and the doses of ACE-
inhibitors and β-blockers used were lower than those proven to be effective in large controlled 
clinical trials. Therefore, lack of similarity between patients with heart failure in clinical 
practice compared to those in clinical trials does not adequately explain under-utilization of 
therapy.  
 It is in keeping with earlier reports, that a minority of heart failure patients in clinical 
practice would have qualified for participation in landmark RCTs. 21-27 It should be noted, 
however, that the absence of a quantitative measurement of the left ventricular function and 
the failure to prescribe ACE-inhibitors excluded many patients from being considered trial-
Table 2. Baseline characteristics of patients enrolled in the Euro Heart Survey on Heart Failure 
  
Total 
 
Trial-eligible 
(pooled) 
 
Trial-ineligible
(pooled) 
 
Other survey 
 patients†  
 
P-value 
      
N 10701 1346* 6595 2760  
     
Age (median [25th–75th]) 73 [64-80] 67 [57-74] 74 [64-82] 74 [66-79] <0.001 
Gender (women) (%) 5020 (47) 342 (25) 3207 (49) 1471 (53) <0.001 
Co-morbidity: (%)      
    Hypertension   5679 (53) 636 (47) 3534 (54) 1509 (55) <0.001 
    Diabetes Mellitus 2907 (27) 355 (26) 1723 (26) 829 (30) <0.001 
    Ischemic heart disease  6419 (60) 841 (63) 4246 (64) 1332 (48) <0.001 
Acute coronary syndrome* 2883 (27) 166 (12) 2505 (38) 212 (8) <0.001 
    Valvular heart disease* 768 (7) 41 (3) 677 (10) 50 (2) <0.001 
    Renal insufficiency±* 1163 (11) 82 (6) 974 (15) 107 (4) <0.001 
    Pulmonary disease 2876 (27) 245 (18) 1701 (26) 930 (34) <0.001 
Severe pulmonary disease* 1743 (16) 188 (14) 971 (15) 584 (21) <0.001 
    Prior / current Stroke 939 (9) 83 (6) 541 (8) 315 (11) <0.001 
    Chronic atrial fibrillation 2482 (23) 284 (21) 1520 (23) 678 (25) 0.04 
    Cancer* 1058 (10) 0 (0) 1058 (16) 0 -- 
      
LVEF known (%) 5311 (50) 1346 (100) 3965 (60) 0 -- 
        LVEF (median [25th–75th])Ŧ  41 [30-55] 29 [22-33] 48 [40-60] - <0.001 
      
Pharmacological treatment (%):      
    ACE-inhibitors 6610 (62) 1158 (86) 3595 (55) 1857 (67) <0.001 
    β-blockers 3744 (37) 650 (48) 2584 (39) 710 (26) <0.001 
    Cardiac glycosides 3825 (36) 622 (46) 2147 (33) 1056 (38) <0.001 
    Diuretics  9297 (87) 1241 (92) 5521 (84) 2535 (92) <0.001 
    Aldosterone antagonists 2197 (21) 522 (39) 1135 (17) 540 (20) <0.001 
      
*) major exclusion criteria of the selected trials, as shown in table 1 
†) patients without major exclusion criteria, but without known LVEF  
±) creatinine ≥ 177 umol/L or ≥ 2.0mg/dl 
   Ŧ) only in patients with known LVEF 
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eligible. As only few patients fulfilled all clinical trial criteria, we also tried to identify the 
maximum potential numbers of patients who should receive an ACE-inhibitor and β-blocker 
(i.e. those with evidence of LVEF, without contra-indications like renal failure or asthma). 
Treatment of these patients compared to trial-eligible patients revealed only minor differences 
with respect to ACE-inhibitors and β-blockers. Aldosterone antagonists, however, were given 
more frequently in trial-eligible patients. 
 
 This analysis shows that the under-representation of women in heart failure trials23,24 is 
partly explained by the use of a low LVEF as an inclusion criterion and the higher prevalence 
of preserved LVEF amongst women. In order to increase the proportion of women in heart 
failure trials it would be necessary to introduce bias in favour of recruiting women or relax the 
LVEF entry criterion. This analysis also reveals that the exclusion of patients with preserved 
left ventricular function (PLVF) and those with renal dysfunction is an important reason for 
the average of patients in trials being about a decade younger than the epidemiological 
Table 3.   Patient characteristics and pharmacological treatment of trial-eligible patients enrolled in the EHS-
Heart Failure 
 
 SOLVD 
eligible 
 
MERIT-HF 
eligible 
RALES 
eligible 
Pooled RCTs*   
trials
      
N 1005 507 782 8223 1,2,3
      
Age  (median [25th–75th]) 65 [55-72] 67 [57-73] 68 [58-75] 63 1,2,3
Female gender (%) 224 (22) 141 (28) 179 (23) 1848 (22) 1,2,3
Non-excluding co-morbidity: (%)      
  Hypertension  447 (45) 254 (50) 382 (49) 2835 (43) 2,3 
  Diabetes mellitus  262 (26) 140 (28) 207 (27) 1647 (25) 2,3 
  Chronic atrial fibrillation 212 (21) 104 (21) 166 (21) 689 (14) 2,3 
  Prior myocardial infarction  463 (46) 229 (45) 409 (52) 3611 (55) 2,3 
  Prior coronary intervention  216 (22) 106 (21) 139 (18) -- -- 
      
Pharmacological treatment: (%)      
  ACE inhibitors                  treated  829 (83) 472 (93) 782 (100) 6714 (91) 1,3 
     ≥ 50% of target dose 605 (60) 337 (67) 564 (72) -- -- 
                 ≥ target dose 408 (41) 231 (46) 375 (48) -- -- 
       
  β-blockers                  treated 489 (49) 272 (54) 357 (46) 371 (9) 1,2 
     ≥ 50% of target dose 172 (17) 102 (20) 129 (17) -- -- 
                 ≥ target dose 54 (5) 29 (6) 44 (6) -- -- 
       
  Cardiac glycosides       treated 484 (48) 260 (51) 373 (48) 5479 (67) 1,2,3
  Diuretics       treated 900 (90) 507 (100) 782 (100) 7463 (91) 1,2,3
  Aldosterone antagonists       treated 418 (42) 213 (42) 334 (43) -- -- 
*) Data based on results as presented in the main articles of the three RCTs (1=SOLVD, 2=MERIT-HF, 
3=RALES)  
Note: for ACE-inhibitors the daily target doses were defined as 75mg for captopril, 20mg for enalapril, 5mg for 
ramipril, 5mg for lisinopril and 4mg for perindopril. For β-blockers these doses were 150mg for metoprolol, 
50mg for atenolol, 50mg for carvedilol, and 10mg for bisoprolol.13 
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population.21-23  Indeed in CHARM-preserved,29 which recruited only patients with PLVF, the 
proportion of women was substantially higher and the patients somewhat older than in other 
RCTs of heart failure.   
 
 
 The limited generalisability of the results of RCTs is widely recognised. Trials with 
more varied enrolment criteria are required to provide information on the complete scope of a 
disease and its treatment in order to extend generalisability. This has happened with ACE-
inhibitors over the last 15 years. Trials in post-infarction patients with LVSD and in patients 
with vascular disease without heart failure suggest that the benefits of ACE-inhibitors may be 
generalisible, although no trials have shown morbidity or mortality benefit in patients with 
PLVF as yet. ACE-inhibitors have a well-recognized side-effect profile and are well tolerated.30 
Similarly, trials of β-blocker have shown benefit in patients with heart failure and LVSD, and 
in patients who have had a myocardial infarction. The SENIORS31 and a smaller study of 
propranolol32 suggest that β-blockers are effective even in elderly patients, regardless of the 
left ventricular ejection fraction. A recent analysis of patients in this survey revealed that 
patients treated with ACE-inhibitors or beta-blockers, irrespective of the LVEF, had a better 
survival than those who did not.33  
 Treatment with aldosterone antagonists is based on only two clinical trials, RALES 
and EPHESUS,9,10 and more RCTs are desirable in order to increase generalisability. 
Achieving the equipoise between the ethics of withholding a treatment that has shown striking 
reductions in mortality versus the desire to demonstrate generalisability may be difficult but 
important to demonstrate safety and efficacy in wider clinical practice.34,35 
 Although adherence to guidelines is encouraged by national and international societies, 
not all patients will or should be treated as advocated in the guidelines. Guidelines only 
Table 4. 12 week mortality of hospital survivors in relation to target doses
 
Subpopulation 
 
Treatment 
 
Target dose 
 
N 
 
Follow-up mortality 
 
P-value 
       
SOLVD eligible ACE-inhibitors ≥ 50% 600 24 (4.0)   0.002
  < 50% 379 33 (8.7)  
      
MERIT HF eligible β-blockers ≥ 50% 102 3 (2.9)  0.04
  < 50% 399 35 (8.8)  
      
      
 ACE-inhibitors ≥ 50% 2367 102 (4.3)  <0.001
  < 50% 3671 317 (8.6)  
Trial-ineligible (pooled)      
      
 β-blockers ≥ 50% 1224 47 (3.8)  <0.001
  < 50% 4814 372 (7.7)  
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provide the general principle of how a patient should be treated; they do not address every 
individual patient’s clinical problem. Management of individual patients is more complex than 
simply following the guidelines, as contra-indications, individual reactions to the medication 
side-effects, co-morbidity, and subsequent multiple co-medications as well as the treatment 
goals for the individual patient can effect management decisions.27,36 However, this survey 
suggests that there is a shortfall in effective therapy, even when patients in clinical practice 
fulfil the criteria of landmark clinical trials of heart failure treatment.  
 These observations raise the question why a sizable proportion of patients were not 
treated according to evidence-based guidelines. Identified barriers in following clinical 
guidelines, like lack of awareness, lack of agreement with the guidelines, difficult to use (not 
concise enough), no motivation to change current practice, as well as economic pressure to 
limit the costs, etc. might partly explain the limited adherence to guidelines in clinical 
practice.29,30,37 These barriers imply that more effort is needed in order to improve guideline 
adherence. It is acknowledged that initiation and up-titration of these drugs require careful 
repeated assessment in order to monitor individual responses. Especially in the case of β-
blockers, treatment can provoke initial worsening. Concerns that initiation of a β-blocker too 
early during hospitalization could destabilize the patient38 should also be taken into account 
when trying to explain why physicians were unable to initiate evidence-based therapy. 
Regarding up-titration of ACE-inhibitors and β-blockers, it should be noted that this requires 
an effective heart failure follow-up program, as it is to be expected that the majority of 
patients are not hospitalised during this phase. Conversely, some have advocated that fixed 
target doses may not be optimal for individual patients.18 In addition to this, doctors may be 
satisfied with a symptomatic improvement already with smaller doses of drugs and not push 
for higher targets to avoid adverse events. Thus, smaller than recommended doses can and 
should not generally be regarded as suboptimal therapy. In our survey, however, the 
underlying reason for choosing dosage cannot be reliable analysed. The clinical trial evidence 
indicating that target doses of ACE inhibitors and beta-blockers are more effective than lower 
doses is sparse. Randomised controlled trials do suggest that higher doses of ACE inhibitors 
may be more effective.39-41 There is less evidence that the dose of beta-blocker is important.42,43 
However, a beneficial effect in patients who were treated with at least 50% of the doses used 
in RCTs, as compared to patients who received less, was observed in this survey. It should be 
noted, however, that most of the evidence for benefit is based on titration to target doses 
recommended by landmark trials.   
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Limitations 
As most hospitals volunteered, it is possible that the observed pharmacological treatment was 
even better than in every day clinical practice because they were energetic in implementing 
existing evidence. In selecting trial-eligible patients, we focussed on the most important entry 
criteria for the trials but did not include every detail. Finally, it is possible that some of the 
under-utilization of β-blockers reflects the fact that the patients had recently been 
hospitalized. At the time of the survey it was generally recommended to stabilize patients first, 
before initiating β-blockers.  
 
Conclusions.   
Only a minority of patients with heart failure would be eligible for participation in the majority 
of randomised controlled trials of heart failure. This reflects the general exclusion of patients 
with PLVF and to a lesser extent, renal dysfunction. Amongst patients who fulfilled the key 
enrolment criteria of selected landmark trials, ACE-inhibitors, β-blockers and aldosterone 
antagonists were under-utilized. This survey, however, gave no clues for the reason of under-
utilization. 
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ABSTRACT 
 
Aims: Due to a lack of clinical trials, scientific evidence regarding the management of patients 
with chronic heart failure and preserved left ventricular function (PLVF) is scarce. The 
EuroHeart Failure Survey provided information on the characteristics, treatment and 
outcomes of patients with PLVF as compared to patients with a LVSD. 
 
Methods and results: We performed a secondary analysis using data from the EuroHeart 
Failure Survey, including only patients with a measurement of LV function (n=6806). We 
selected two groups, patients with LVSD (54%) and patients with a PLVF (46%). Patients 
with a PLVF were on average 4 years older and more often women  (55% vs. 29%, 
respectively, p <0.001) as compared to LVSD patients, and more likely to have hypertension 
(59% vs. 50%, p <0.001) and atrial fibrillation (25% vs. 23%, p=0.01). PLVF patients received 
less cardiovascular medication as compared to PLVF patients, with the exception of calcium 
antagonists. Multivariate analysis revealed that LVSD was an independent predictor for 
mortality, while no differences in treatment effect on mortality between the two groups was 
observed. A sensitivity analysis, using different thresholds to separate patients with and 
without LVSD revealed comparable findings.   
 
Conclusions: In the Euro Heart Failure Survey, a high percentage of heart failure patients 
had PLVF. Although major clinical differences were seen between the groups, morbidity and 
mortality was high in both groups.  
 
Chapter 5 
 
 67
INTRODUCTION 
Chronic heart failure is a major health problem and is associated with high morbidity and 
mortality.1,2 Advances in therapy over the last two decades have proved highly effective in 
reducing morbidity and mortality rates. As a result, nowadays several effective treatment 
strategies are available, including β-blockers and ACE-inhibitors, which have contributed to 
improved outcome in the real world.3,4 However, most clinical investigations in chronic heart 
failure focussed on patients with left ventricular systolic dysfunction (LVSD). Consequently, 
scientific evidence regarding the management of patients with preserved left ventricular 
function (PLVF) is scarce. 
To support physicians in everyday clinical decision-making, the European Society of 
Cardiology (ESC) published guidelines for the investigation and treatment of heart failure 
patients.5,6 Since guidelines are intended to be evidence-based treatment recommendations for 
patients with PLVF remain mainly speculative.5 Still, it should be realised that these patients 
constitute a sizeable group: it is estimated that 30% to 50% of all heart failure patients do not 
have LVSD.7 The EuroHeart Failure Survey was designed to evaluate to what extent treatment 
guidelines are implemented in clinical practice. A total of 10.701 suspected or confirmed heart 
failure patients were enrolled, of whom 3148 had PLVF. The survey provided a wealth of 
information on patient characteristics, diagnosis and treatment.8,9 We aimed to describe to 
what extent the presence or absence of LVSD influenced patient profile, management and 
outcome.  
 
METHODS 
The EuroHeart Failure Survey was the second in a series of surveys that were conducted 
under the umbrella of the Euro Heart Survey Program, aiming to investigate the 
implementation of treatment guidelines in clinical practice. The design details of the Heart 
Failure Survey, which was undertaken during March 2000 and May 2001, were published 
previously.9,10 In short, all consecutive discharges and deaths on the departments of 
cardiology, cardiovascular surgery, general internal medicine and geriatrics were screened over 
a 6-week period. The design of EuroHeart Failure survey included 115 hospitals from 24 ESC 
member countries on a voluntary basis, including general hospitals and university centers. 
 Patients who fulfilled at least one of the following criteria were enrolled:  
(1) a clinical diagnosis of heart failure during the admission;  
(2) a diagnosis of heart failure recorded at any time in the last three years; 
(3) administration of a loop diuretic for any reason other than renal failure during 24h 
of death or discharge; 
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(4) pharmacological treatment for heart failure or ventricular dysfunction within 24h 
of death or discharge.  
In all 10.701 enrolled patients, data were collected on co-morbid conditions including 
hypertension, diabetes, chronic atrial fibrillation and renal insufficiency. A clinical follow-up 
was performed, and vital status (death or alive) was determined at 12 weeks after discharge. 
We also collected data on re-admission(s). Surviving patients were then invited for an 
interview. During this visit, the NYHA classification was determined, and the quality-of-life 
was measured with among other things a single question “how would you rate your quality-of-
life”, using a 7 point rating scale (0=poor, 7=excellent). 
This analysis included patients who had undergone a quantitative or qualitative 
assessment of the left ventricular function (n=6806, 64% of the entire cohort). Of these 
patients, in 80% (n=5451) left ventricular ejection fraction (LVEF) was reported. Patients with 
a LVEF ≥40%, as well as patients with a normal or mildly depressed systolic left ventricular 
function, as assessed by echocardiography were classified as PLVF. Patients with a LVEF 
<40%, patients with a moderate or severe left ventricular systolic dysfunction, and those with 
left ventricular dilatation, as assessed by echocardiography were classified as LVSD.  
 
Statistical analysis 
Continuous variables are described as mean values and corresponding standard deviations, or 
as median values and corresponding 25th and 75th percentiles. Dichotomous variables are 
reported as absolute numbers and percentages. To evaluate differences characteristics, in 
treatment and outcome between patients with and without LVSD, chi-square tests, student’s t-
tests or Mann-Whitney tests were applied as appropriate.  
Multivariable logistic regression analysis was applied to study the relation between 
LVF and all-cause mortality during the 12-week follow-up period. LVSD, age, gender, 
hypertension, diabetes, ischemic heart disease, renal insufficiency, prior stroke, chronic atrial 
fibrillation and pharmacological treatment were forced into the regression model. We report 
odds ratio’s (OR) and corresponding 95% confidence intervals (CI). To examine the 
differential effect of pharmacological treatment in patients with and without LVSD, 
interaction terms were included in the regression model. All calculations were carried out with 
SPSS 10.1 software package. For all tests a P value of 0.05 or less (2-sided) was considered 
statistically significant.  
We acknowledge the fact that the discussion on how to define preserved left 
ventricular function in patients with heart failure is still ongoing, and that choice may be 
challenged. 11-14 Therefore, we repeated all analyses using different thresholds. We first 
analysed quantitative LVEF <40% versus LVEF ≥40% (excluding patients with only 
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qualitative assessment of the LV function), and secondly LVEF <40% versus LVEF >50% 
(leaving out patients with a LVEF ≥40% and ≤50%). Since the results of these analyses were 
highly consistent, we only report on our original choice. 
 
RESULTS 
Patient characteristics 
The mean age (SD) of the 6806 patients was 69 (±13) years and 41% were female. A 
substantial proportion of patients had ischemic heart disease (64%), a history of hypertension 
(54%), documented diabetes (27%) or chronic atrial fibrillation (24%). The median duration of 
the index hospitalisation was 10 days (interquartile range: 6–16).  
 Patients not in the analysis (n=3895) were older and included more females. Fewer 
patients were known with an ischemic heart disease, while a history of stroke was more 
common in these patients. Furthermore, out of the analyses, most patients (68%) where 
admitted to a general internal medicine ward, as compared to the patients who were in the 
analysis (Table 1). 
Table 1. Differences in characteristics of patients with preserved and depressed left ventricular function
 
  Patients with known left ventricular function  
Patients not in 
the analysis 
  PLVF (n=3148) 
LVSD 
(n=3658) P* (n=3895) 
     
Age (mean, SD) 71 ±12 67 ±13 < 0.001 76 ±11.6
Women (%) 1739 (55) 1065 (29) < 0.001 2216 (57)
Men >70 years (%) 666 (21) 961 (26) < 0.001 1039 (27)
Women > 70 years (%) 1099 (35) 607 (17) < 0.001 1748 (45)
Co-morbidity:    
     Hypertension (%)  1845 (59) 1829 (50) < 0.001 2005 (52)
     Diabetes Mellitus (%) 816 (26) 1016 (28) 0.09 1075 (28)
     Ischemic heart disease (%) 1851 (59) 2508 (69) < 0.001 2060 (53)
     Previous revascularisation (%) 377 (12) 674 (18) < 0.001 291 (8)
     Renal insufficiency (%) 155 (5) 220 (6) 0.05 296 (8)
     Prior Stroke (%) 492 (16) 501 (14) 0.02 814 (21)
     Chronic atrial fibrillation (%) 795 (25) 827 (23) 0.01 860 (22)
    
LVEF (mean, SD) 56 ±9.8 33 ±10.9 <0.001 n.a.
    
Speciality at admission (%):   <0.001 
General internal medicine 1299 (42) 1164 (32)  2659 (68)
Cardiology / cardiovascular surgery 1615 (51) 2288 (63)  769 (20)
 
Other 231 (7) 197 (5)  458 (12)
    
Hopitalisation in days (median,IQR) 10 (6 -16) 10 (6-15) 0.26 9 (5-14)
    
Contribution of HF to index admission (%) 1189 (38) 1904 (52) < 0.001 1141 (29)
LVEF= left ventricular ejection fraction 
* the p-value refers to the statistical difference between PLVF and LVSD 
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The comparison between patients with and without LVSD revealed that almost half of all 
patients (n=3148, 46%) had PLVF. Patients with PLVF were on average 4 years older and 
more often women (55% versus 29%, p<0.001) than patients with LVSD (Table 1). Patients 
with PLVF were also more likely to have a history of hypertension (59% vs. 50%, p<0.001) 
and chronic atrial fibrillation (25% vs. 23%, p=0.01), whereas ischemic heart disease (59% vs. 
69%, p<0.001) was more prevalent in those with LVSD. Patients with PLVF were more likely 
to be hospitalised in general internal medicine than those with LVSD (42% vs. 32%, p <0.001) 
and contribution of heart failure to index admission was less prominent (38 % vs. 52% < 
0.001).  
 
Pharmacological treatment 
Table 2 gives an overview of the pharmacological treatment during hospitalisation in patients 
with or without LVSD.  The vast majority of patients received diuretics (87% versus 85%, 
p=0.01), most often loop diuretics. The use of loop diuretics was the sole enrolment criterion 
in 5% of all patients (2% and 10% in patients with and without LVSD, respectively). Patients 
with LVSD were more likely to receive ACE inhibitors or Angiotensin II receptor blockers 
(ARBs) (82% versus 62% in PLVF, p< 0.001), as well as β-blockers (46% and 39%, p<0.001) 
or cardiac glycosides (41% vs 31%, p < 0.001). Calcium channel blockers were the only class 
of agents that was prescribed significantly more often in patients with PLVF than in patients 
with LVSD (28% versus 16%, p< 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacological treatment (multivariable analysis)  
Patients receiving ACE-inhibitors had lower 12-week death rates than those not receiving 
ACE-inhibitors (OR 0.55, 95% CI 0.43-0.71; Figure 1). Similar results were observed in 
relation to treatment with β-blockers (OR 0.61, 95% CI 0.48-0.77) and statins (OR 0.59, 95% 
Table 2. Differences in pharmacological treatment between patients preserved and 
depressed left ventricular function 
 PLVF 
(n=3148) 
LVSD 
(n=3658) 
P 
    
ACE inhibitors (%) 1839 (58) 2848 (78) < 0.001 
Angiotensin II receptor blockers (%) 140 (4) 218 (6) 0.005 
     -ACE or ARB (%) 1956 (62) 3009 (82) < 0.001 
β-Blockers (%) 1231 (39) 1679 (46) < 0.001 
Calcium channel blockers (%) 867 (28) 583 (16) < 0.001 
Cardiac glycosides (%) 986 (31) 1512 (41) < 0.001 
Diuretics (%) 2679 (85) 3188 (87) 0.01 
     -Loop diuretic (%)* 2431 (91) 2952 (93) 0.01 
     -Thiazide diuretic (%)* 343 (13) 381 (12) 0.32 
i.v. inotropic agents (%) 204 (7) 380 (10) < 0.001 
Nitrates (%) 1451 (46) 1811 (50) 0.005 
Spironolactone (%) 527 (17) 1070 (29) < 0.001 
Statins (%) 668 (21) 937 (26) < 0.001 
* the proportions may add up more than 100% as patients received both diuretics 
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P for 
0.1 1 10 
0.78 
0.44 
0.14 
 interaction 
ACE-inhibitors 
Bèta-blockers
Calcium channel blockers  
Treatment
better worse
Diuretics 
ARB 
0.88 
0.71 
Cardiac glycosides 0.93 
All-cause mortality
i.v. inotropes
0.30 
Nitrates 
Spironolactone 
Statins 
0.16 
0.06 
0.12 
LVSD n=2848
PLVF n=1893
LVSD n=218
PLVF n=140
LVSD n=1679
PLVF n=1231
LVSD n=1512
PLVF n=986 
LVSD n=3188
PLVF n=2679
LVSD n=380
PLVF n=204
LVSD n=1811
PLVF n=1451
LVSD n=1070
PLVF n=527 
LVSD n=937
PLVF n=668
LVSD n=583
PLVF n=867
■  = LVSD 
▲= PLVF
CI 0.43-0.81). In contrast, treatment with IV inotropic agents was associated with worse 
outcome (OR 5.53, 95% CI 4.07-6.95). Patients receiving cardiac glycosides, diuretics and 
nitrates had similar 12-week mortality as those not receiving these agents. Noteworthy, there 
was no statistical evidence of a heterogeneous effect of any agent between patients with and 
without LVSD (P for interaction, all >0.05). 
     
       
  Figure 1.  All cause mortality with respect to pharmacological treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Adjusted for age, gender, hypertension, diabetes, ischemic heart disease, renal failure, prior stroke,  
  chronic atrial fibrillation and pharmacological treatment.  
  LVSD = left ventricular systolic dysfunction 
  PLVF = preserved left ventricular function 
 
Outcome  
The incidence of all-cause mortality during 12-week follow-up although high in both groups 
was higher in patients with LVSD than those without (12% versus 10%, OR 1.35, 95% CI 
1.13-1.62). No significant differences were observed in the need for re-admission (22% versus 
21%), time to first re-admission or number of days that patients were hospitalised during the 
follow-up period (Table 3). NYHA classification at follow-up did not differ between patients 
with and without LVSD (25% and 24% had NYHA III/IV, respectively). More patients with 
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LVSD (29%) viewed their quality of life as “quite poor” to “very poor” as compared to 23% 
in the preserved group (p=0.04). 
 
 
Outcome (multivariate analysis)  
After adjustment for age, gender, co-morbidity and pharmacological treatment, patients with 
LVSD had higher mortality than patients with PLVF (OR 1.4, 95% CI 1.1-1.6, p=0.001). No 
differential effect of the presence or absence of left ventricular systolic function on all-cause 
mortality was observed in subgroups of patients according to clinical characteristics, except for 
diabetes (p=0.03) (Figure 2).  
 
DISCUSSION 
Almost half of heart failure patients enrolled in the EuroHeart Failure Survey with left 
ventricular function determination had preserved left ventricular function. This group of 
patients had different patient characteristics to that of patients with LVSD,  including 
advanced age, a higher proportion of women, history of hypertension and chronic atrial 
fibrillation. We furthermore observed higher mortality in patients with LVSD, but mortality 
was high in both groups.   
Our findings are in agreement with prior reports suggesting that patients with LVSD 
are at increased risk for mortality.15-21 However, there is growing recognition that heart failure 
caused primarily by abnormalities in relaxation / diastole represents a substantial proportion 
of all heart failure patients and is also associated with a high morbidity and mortality. We 
Table 3.   Differences in outcome between patients with preserved and depressed left ventricular 
function 
 PLVF 
(n=3148)
LVSD 
(n=3658) 
P
   
Total mortality (%)‡ 307 (10) 425 (12) 0.01
Re-admission < 12 weeks (%) 676 (22) 759 (21) 0.47
     -time to 1ste re-admission in days (median, IQR) 29 (10-54) 28 (10-53) 0.66
     -hospitalisation time in days during follow-up (median,IQR) 11 (6-22) 11 (5-22) 0.30
 
 
  
12-week follow-up interview†  (n,%) 1124 (36) 1304 (36) 
 
NYHA classification: 
  
0.64
          Class I/II (%)     844 (76) 965 (75) 
          Class III/IV (%)  270 (24) 327 (25) 
Quality-of-life:   0.04
          Very good-quite good (%) 516 (46) 545 (42) 
          Average (%) 340 (30) 380 (29) 
          Quite poor- very poor (%) 257 (23) 369 (29) 
‡ Patients who died during index hospitalization or within the 12 week follow-up period 
† Only patients who attended the 12-week follow-up interview 
  NYHA= New York Heart Association classification 
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showed that 12-week mortality was high in both groups, whereas every fifth patient, regardless 
of LV function, was re-admitted within 12 weeks. In the recently published CHARM-
Preserved trial, 24% of patients in the placebo arm experienced a composite endpoint of 
cardiovascular death or hospital admission for heart failure, while 18.5% of these patients 
were hospitalised for heart failure over 36.6 months of follow-up.22 The cardiovascular 
mortality among these patients were 58% lower than in CHARM patients with low LVEF 
<40%.23,24  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The definition of heart failure with preserved systolic function or diastolic heart failure 
remains a matter of controversy12,25 and a difficult exercise in clinical practice. This probably 
explains why clinical trials have been lacking and guidelines on the management of this subset 
of patients remain mainly speculative.6 So far, only a subset of patients enrolled in the DIG 
trial with EF >45% and the CHARM preserved arm have extensively studied the effect of 
Digoxin and Candesartan, respectively in PLVF patients. Digoxin reduced heart failure 
hospitalisations and the Angiotensin II receptor blockers (ARB) reduced cardiovascular 
hospitalisations in these trials.22,26 Our analysis on the large EuroHeart Failure Survey 
Figure 2. Relation between left ventricular systolic function and mortality in subgroup of patients             
    according to patient characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted for age, gender, hypertension, diabetes, ischemic heart disease, renal failure, prior stroke,  
chronic atrial fibrillation and pharmacological treatment.  
LVSD = left ventricular systolic dysfunction / PLVF = preserved left ventricular function 
0,1 1 10 
0.97 
0.35 
0.03 
P for interaction 
Age 
Hypertension 
Diabetes Mellitus 
Characteristics Category
Renal insufficiency 
Gender
0.07 
0.70 
Ischemic Heart Disease 0.22 
All -cause 
mortality
Prior stroke 0.75 
Men
Women
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Chronic Atrial Fibrillation Yes
No 0.86 
<70
> 70
All OR= 1.35 
LVSD better PLVF better
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population provides additional information on the specific clinical profile of patients with 
PLVF and the way these patients are treated in Europe.  
We included only patients with a known LV function, thus excluding 3895 patients 
(36%) of whom we had no information in this context. However, according to the guidelines, 
echocardiography is encouraged in all heart failure patients.5,6 The high percentage of patients 
who could not be included in this secondary analysis reflects the lack of this diagnostic 
procedure in patients with proven or suspected heart failure.  
As discussed in the main article of the EuroHeart Failure Survey8, adherence to the 
guidelines regarding ACE-inhibitors was observed in a majority of patients with a documented 
ventricular dysfunction, whereas treatment with β-blockers was clearly under-prescribed. As 
mentioned earlier, treatment guidelines lack evidence based recommendations for patients 
with a preserved left ventricular function. It is therefore not possible to compare the treatment 
of these patients with the guidelines. Moreover, since more patients with PLVF were 
hospitalised in general internal medicine as compared to those with LVSD, this clearly could 
affect management.  Although there is currently no evidence available from randomised 
controlled trials on treatment of patients with a preserved LVF with ACE-inhibitors or β-
blockers, a considerable percentage of these patients were treated with the above mentioned 
drugs (58% and 39%, respectively). For ACE-inhibitors, the rate of prescription among this 
hospitalised preserved LVF group compares favourably to the rate reported in CHARM 
Preserved (58% versus 18.6%) whereas the use of β-blockers (39% versus 55.5%) was lower 
than in the clinical trial.22 In CHARM preserved there was a statistically marginal effect of the 
ARB candesartan on the outcome of cardiovascular mortality or heart failure hospitalisations. 
However, the total number of these hospitalisations, both for patients and episodes, was 
significantly reduced in this trial. The use of cardiac glycosides was significantly lower in the 
PLVF group although the rate of atrial fibrillation was slightly greater in the LVSD group. The 
relatively high rate of prescription of calcium channel blockers in the preserved group, one of 
the few drugs that are (according to the guidelines) indicated in this subgroup of patients, 
probably reflects the greater proportion of patients with a history of hypertension.  
This study is the first to compare the effects of pharmacological treatment in patients 
with or without LVSD. We would like to stress however, that one should be very cautious in 
interpreting these observational data. Use of ACE-inhibitors or β-blockers was associated with 
improved survival, reflecting either the effects of treatment or patient selection. Therapy with 
diuretics, cardiac glycosides and nitrates seemed to have no influence on mortality, whereas 
those treated with intravenous inotropic agent had a worse prognosis indicating the poor 
clinical condition of patients who need intravenous support with these drugs. Interestingly, 
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this analysis revealed no interaction between the apparent effects of treatment on mortality 
and the presence or absence of LVSD.  
Our study also observed the sub-optimal use of diagnostic procedures to evaluate LVF 
in daily practice, as 3895 patients were left out of this analysis due to the absence of this 
evaluation. Knowing the cardiac function is of great importance, as the guidelines primarily 
focus on heart failure patients with LVSD.6 Given the limited number of randomised trials 
conducted in PLVF patients, the treatment of these patients is referred to as highly 
speculative.  Several ongoing trials address specifically the interest of beta-blockers (SENIOR), 
ACE-Inhibitors (PEP-CHF) or ARBs (I-Preserve) in the setting of patients with preserved 
systolic function. Taken this into account one could argue that a large majority of the 10,701 
patients in the EuroHeart Failure Survey was not treated evidence-based. This was mainly due 
to the missing evidence of cardiac dysfunction and the absence of evidence-based treatment 
aiming at PLVF patients. In order to provide optimal treatment to all heart failure patients, we 
should be more aware of the under-utilisation in evaluating the LVF.  Furthermore, we would 
like to stress that the observed absence of a heterogeneous effect between patients with or 
without LVSD does not mean that patients with PLVF will derive the same benefit from 
pharmacological treatment as those with LVSD. This observation deserves confirmation in 
randomised trials. Thus the evaluation of LVF remains an area for improvement. 
This study has certain limitations that should be taken into account when interpreting 
the results. It should be noted that surveys like the EuroHeart Failure Survey are prone to 
information and selection bias. Since a limited number of centers were recruited across the 24 
countries, interpretation of the results must be cautious due to a potential center effect. 
However, our findings with respect to the proportion of patients with PLVF and use of 
various treatments were in agreement with the IMPROVEMENT survey, which was 
performed by primary care physicians in the same European countries.27   
Furthermore, we acknowledge the fact that only 64% of our overall population had 
undergone an assessment of the left ventricular function and cannot exclude selection bias, as 
the excluded patients slightly differed from those who were in the analysis. Nevertheless, our 
findings regarding patients with heart failure are in line with other observational studies.15-17,21 
By design, the EuroHeart Failure survey included clusters of University hospitals and general 
hospitals. We cannot therefore extend our observation to the overall heart failure population 
as this selection of centers might impact on patients’ profile and treatment modalities. The 
selection of patients studied here was based on the record of the value of ejection fraction 
whatever the method used. We also used an arbitrary threshold of 40% to separate depressed 
and preserved or mildly reduced systolic function. However, a sensitivity analysis showed 
comparable results whatever the threshold for ejection fraction used. Finally, the impact of the 
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various cardiovascular medications was made in the context of an observational study, not of a 
randomised trial. 
In conclusion, this study showed that a high percentage of hospitalised heart failure 
patients had PLVF. Although major statistical differences exist regarding clinical 
characteristics and treatment, morbidity and mortality was high in both groups. A considerable 
number of patients in the preserved group were treated with drugs (ACE-inhibitors and β-
blockers) that have a documented impact on survival in patients with a depressed LV systolic 
ventricular function. Although there was still under-utilisation of these drugs according to the 
guidelines in the depressed group, far more patients in this group received ACE-inhibitors or 
β-blockers compared to patients with a preserved ventricular function. Finally, only a limited 
number of patients were treated by ARBs in both groups. A comparison of the effect of 
pharmacological treatment, in the context of an observational study did not reveal an 
interaction of the treatment effect on mortality between LVSD and PLVF. 
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ABSTRACT 
 
Objectives: This study evaluated gender differences in clinical characteristics, treatment and 
outcome among patients with heart failure, and to which extent these differences are due to 
age and differences in ventricular function. 
 
Background: Although gender differences are observed among heart failure patients, few 
studies have been adequately powered to investigate these differences.  
Methods: The Euro Heart Survey on Heart Failure screened discharge summaries of 10,653 
patients (47% women) with heart failure over a 6-week period in 115 hospitals from 24 
countries belonging to the European Society of Cardiology (ESC). 
 
Results: Men were younger (68.5 vs. 74.5 years, p<.001), and more often had evidence of 
coronary artery disease (66% vs. 55%, age-adjusted odds ratio (OR) 0.61; 95%CI 0.57-0.67). 
Women were more likely to have hypertension, diabetes, or valvular heart disease. Fewer 
women had an investigation of left ventricular function (58% vs. 72%, age-adjusted OR 0.66; 
95%CI 0.61-0.72), and among those investigated, fewer had moderate or severe left 
ventricular systolic dysfunction (41% vs. 67%, age-adjusted OR 0.36; 95%CI 0.33-0.40). Drugs 
with a documented impact on survival, i.e. ACE-inhibitors and beta-blockers were given less 
often to women, even after adjusting for age and left ventricular function (OR 0.77; 95%CI 
0.68-0.86) OR 0.87; 95%CI 0.78-0.98, respectively). Age-adjusted 12-week mortality was 
similar for men and women (OR 0.98; 95%CI 0.88-1.11). 
 
Conclusions: Fewer women had an assessment of left ventricular function, but, when 
investigated, had better ventricular function. Women were less often treated with evidence-
based drugs, even after taking age and ventricular function into account. Clinicians need to be 
aware of deficiencies in the treatment of women with heart failure and measures should be 
taken to rectify them. 
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INTRODUCTION 
Chronic heart failure is a major cause of morbidity and mortality, and the reason for at least 
20% of all hospital admissions in patients older than 65 years.1,2 Major advances over the last 
two decades in the diagnosis and treatment of heart failure have proven highly effective in 
reducing morbidity and mortality among both men and women. However, survival is still poor 
among both men and women, and the absolute number of women dying of heart failure each 
year still increases.3 Men and women with heart failure have different clinical characteristics, in 
that women are older, and have more hypertension but less evidence of coronary heart disease 
and better ventricular function, compared to men with heart failure.3 Few studies have been 
adequately powered to investigate how much of these known differences between men and 
women are due to gender alone, and how much is due to known other differences such as the 
discrepancies in age, ventricular function, or cause of heart failure. The large number of both 
men and women, enrolled in the Euro Heart Survey on Heart Failure (EHS-HF), the 
extensive data collection of patient characteristics, investigations and treatment provide a 
unique opportunity to analyze gender differences in patients with confirmed or suspected 
heart failure.  
 
METHODS 
We performed a comparison of men and women who were enrolled in the EHS-HF. The 
design details of this observational study, which was undertaken between March 2000 and 
May 2001, were published previously.4,5 Briefly, all consecutive discharges and deaths in the 
departments of cardiology, cardiovascular surgery, general internal medicine, non-vascular 
surgery and geriatrics were screened over a 6-week period. Patients who fulfilled at least one 
of the following criteria were enrolled:  
(1) a clinical diagnosis of heart failure during the admission;  
(2) a diagnosis of heart failure recorded at any time in the last three years; 
(3) administration of a loop diuretic for any reason other than renal failure within 24h 
of death or discharge; 
(4) pharmacological treatment for heart failure or ventricular dysfunction within 24h 
of death or discharge.  
From a total of 46,788 deaths and discharges from 115 hospitals in 24 ESC member countries, 
10,701 patients with suspected or confirmed heart failure were enrolled in the EHS-HF. After 
exclusion of 48 patients with missing data for age and gender, the total study population 
consisted of 10,653 patients. 
 Information on clinical characteristics, diagnosis, co-morbid conditions, investigations, 
treatment, was obtained from medical records. Median (quartiles) follow up was 12 (11-14) 
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weeks. CAD was defined as a history of coronary revascularization procedure or myocardial 
infarction or angina pectoris. Patients were considered to have left ventricular systolic 
dysfunction (LVSD) if they had a left ventricular ejection fraction of < 45%, or moderate or 
severe impairment of left ventricular (LV) systolic function on echocardiography. Patients 
with an ejection fraction of ≥ 45%, as well as patients with a normal or only mildly depressed 
LV systolic function were classified as having preserved LV function.   
 
Statistical analysis 
Continuous variables are described as mean values with their corresponding standard 
deviation (SD), and dichotomous variables are described as counts and percentages. To 
evaluate the differences in clinical characteristics between men and women, chi-square tests 
and Student’s t-tests were applied as appropriate. In addition, univariate and multivariate 
analyses were performed to study the association in clinical variables and outcome between 
men and women. In the multivariate analyses we adjusted for age and a number of clinical 
variables with a p-value of < 0.10 in the univariate analyses. These variables included history of 
hypertension, diabetes, stroke or TIA, respiratory disease, coronary artery disease, 
cardiomyopathy, and atrial fibrillation. Adjustment for LVSD was done in a subgroup of 
patients, in whom the left ventricular function was known (n=6986). We report odds ratios 
(OR) and corresponding 95% confidence intervals (CI). For all tests, a p-value of <0.05 (two-
sided) was considered statistically significant. All calculations were performed using the SPSS 
12.0.1 software package. 
 
RESULTS 
In table 1, the baseline characteristics of the 10,662 patients (47% women) with suspected or 
confirmed heart failure are summarized. Women were significantly older than men (74.5 
versus 68.5 years, p <0.001) with more patients aged >80 years (36% versus 19%, p <0.001). 
A history of hypertension and diabetes was more prevalent among women, whereas men 
more often were smokers and heavy alcohol drinkers. Fifty-five per cent of the women but 
66% of the men had known CAD (p<0.001), and corresponding figures for coronary 
revascularization were 18% and 36% (p<0.001), respectively. Older patients (≥ 70 years) had 
more co-morbid conditions such as stroke (20% versus 12%, p <0.001), renal dysfunction 
(19% versus 14%, p <0.001), or atrial fibrillation (47% versus 35%, p <0.001). 
 Table 2 shows that women less often were admitted to a cardiology ward compared to 
men (35% versus 51%, p <0.001). Left ventricular function was measured less often in 
women (58% versus 72%, p<0.001), and when measured, fewer women had left ventricular 
systolic dysfunction (41% versus 67%, p<0.001). In a subgroup of patients who had an
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echocardiogram, valvular heart disease was seen more often in women (41% versus 34%, p 
<0.001). The most frequently observed valvular heart disease was mitral regurgitation (30% 
and 27% for men and women, respectively (p=0.02)). In addition to these gender differences, 
it is also important to note that younger patients were more likely to be admitted to cardiology 
wards (61% versus 32%, p <0.001), and more often had an assessment of the LV function 
(79% versus 57%, p <0.001).   
 After adjusting for age, most of the observed gender differences remained statistically 
significant (Table 3), however, gender differences with respect to stroke or TIA, atrial 
fibrillation and aortic regurgitation did not persist after adjustment for age. Irrespective of left 
ventricular function, women were more likely to have hypertension but less often a history of 
an ischemic heart disease (Table 4). 
 
 Men and women differed with respect to pharmacological treatment (Table 5). Fewer 
women were treated with drugs with a documented impact on survival (ACE-inhibitors (OR 
0.66; 95%CI 0.61-0.71), beta-blockers (OR 0.73; 95%CI 0.67-0.79), and spironolactone (OR 
0.70; 95%CI 0.64-0.77), whereas they were more often treated with diuretics (OR 1.30; 95%CI 
1.16-1.46) and cardiac glycosides (OR 1.11; 95%CI 1.03-1.20). In addition, women were also  
Table 3. Unadjusted and adjusted ORs for the association in clinical characteristics between men and 
women (total population, n=10,653) 
 Gender differences (reference group is men) 
 Unadjusted OR* 
(95% CI) 
OR* adjusted for age 
(95%CI) 
   
Current smoker 0.32 (0.28-0.36) 0.40 (0.35-0.46) 
Heavy alcohol drinker, ever 0.14 (0.11-0.18) 0.17 (0.14-0.22) 
History of hypertension 1.50 (1.39-1.62) 1.46 (1.35-1.58) 
Diabetes 1.17 (1.07-1.27) 1.15 (1.05-1.26) 
Stroke or TIA 1.15 (1.04-1.27) 0.98 (0.88-1.09) 
History of renal dysfunction 0.77 (0.69-0.85) 0.66 (0.60-0.74) 
Respiratory disease 0.90 (0.83-0.98) 0.83 (0.76-0.90) 
Cumulative evidence for CAD† 0.64 (0.59-0.70) 0.61 (0.57-0.67) 
Dilated cardiomyopathy 0.40 (0.30-0.53) 0.57 (0.43-0.76) 
Atrial fibrillation, ever 1.13 (1.05-1.22) 0.99 (0.92-1.08) 
Ward of admission:   
     Cardiology 0.51 (0.48-0.56) 0.66 (0.61-0.72) 
     General internal medicine  1.75 (1.62-1.89) 1.43 (1.32-1.55) 
     Other ward 1.35 (1.17-1.54) 1.07 (0.93-1.23) 
Assessment of LV function: 0.52 (0.48-0.57) 0.66 (0.61-0.72) 
    LVSD ‡ 0.34 (0.31-0.37) 0.36 (0.33-0.40) 
Echocardiography performed: 0.58 (0.53-0.62) 0.71 (0.65-0.77) 
    Mitral stenosis 3.46 (2.55-4.69) 3.90 (2.86-5.33) 
    Aortic stenosis 1.74 (1.45-2.09) 1.48 (1.23-1.80) 
    Mitral regurgitation 1.13 (1.02-1.26) 1.13 (1.01-1.26) 
    Aortic regurgitation 1.28 (1.06-1.53) 1.19 (0.98-1.43) 
* Women compared to men   
† CAD (coronary artery disease): myocardial infarction, angina, or revascularization 
‡ LVSD= EF<45% or moderate to severe LV systolic dysfunction 
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less likely to be treated with anti-thrombotic drugs (OR 0.67; 95%CI 0.61-0.73). After 
adjusting for age and clinical characteristics including CAD, the observed gender differences, 
remained significant for ACE-inhibitors, beta-blockers and spironolactone. Diuretics and 
cardiac glycosides, however, lost their statistical significance. We repeated the analyses in a 
subgroup of patients who had an assessment of LV function (n=6991). After adjustment for 
age and clinical variables in addition to left ventricular systolic dysfunction, ACE-inhibitors 
and beta-blockers were still less likely to be used in women, whereas diuretics and cardiac 
glycosides were more often prescribed to women than to men. Patients admitted to cardiology 
wards (including cardiovascular surgery), were treated more often with ACE-inhibitors (73%), 
beta-blockers (53%), and spironolactone (26%) compared to patients admitted to general 
internal medicine wards (65%, 29%, and 20% respectively), or patients admitted on non-
vascular surgery or geriatric wards (57%, 27%, and 20% respectively). The observed gender 
differences in treating patients with ACE-inhibitors, beta-blockers and spironolactone 
remained significant, irrespective of admission to cardiology or general internal medicine. In 
patients who were admitted to non-vascular surgery or geriatric wards, however, no gender 
differences in treatment with ACE-inhibitors, beta-blockers and spironolactone was found.  
 No substantial gender differences could be demonstrated with respect to 12-week 
mortality and readmission within 12 weeks (Table 6). Although the percentage of women who 
died during the observation period was slightly higher (14.1% versus 11.9%), gender was not 
an independent predictor of mortality (OR 1.15; 95%CI 0.97-1.35).  
Table 4. Age, hypertension and CAD by gender and LVF among patients with known LV function (n=6986) 
   Men 
(n=4082) 
Women 
(n=2904) 
 OR* adjusted for 
age (95%CI) 
       
Left ventricular systolic dysfunction (n) 2738 1182   
 Mean age, SD 65.8 ±12.5 71.1 ±12.5   
 History of hypertension (%) 1292 (47) 678 (57)  1.39 (1.21-1.60) 
 Myocardial infarction, ever (%) 1529 (56) 574 (49)  0.67 (0.59-0.78) 
 History of angina (%) 1307 (48) 543 (46)  0.86 (0.75-0.99) 
 Revascularization (PCI, CABG) (%) 768 (28) 197 (17)  0.54 (0.45-0.64) 
 Cumulative evidence for CAD†  (%) 1939 (71) 784 (66)  0.69 (0.59-0.80) 
     
Preserved left ventricular function (n) 1344 1722   
 Mean age, SD 68.3 ±12.5 72.7 ±11.7   
 History of hypertension (%) 710 (53) 1075 (62)  1.41 (1.22-1.63) 
 Myocardial infarction, ever (%) 497 (37) 394 (23)  0.49 (0.41-0.57) 
 History of angina (%) 650 (48) 686 (40)  0.69 (0.60-0.80) 
 Revascularization (PCI, CABG) (%) 334 (25) 196 (11)  0.41 (0.34-0.50) 
 Cumulative evidence for CAD† (%) 861 (64) 913 (53)  0.60 (0.52-0.70) 
       
* Women compared to men 
† CAD (coronary artery disease): myocardial infarction, angina, or revascularization 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass grafting
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DISCUSSION 
This study confirms earlier reports that women with heart failure have a different clinical 
profile as compared to men, and more often have a preserved left ventricular function.3,6 
These differences remained significant after adjusting for age. In addition, women were 
admitted less often to cardiology wards, or had an assessment of left ventricular function, and 
were also less often treated with evidence-based drugs. The observed differences were still 
evident after adjusting for age, and other clinical variables. Despite the fact that women had 
better left ventricular systolic function and less often had CAD, outcomes with respect to in-
hospital and total 12-week mortality were similar in men and women.  
 Consistent with previous reports, women were older, more often had hypertension, 
diabetes, cerebrovascular disease, and valvular heart disease, but had a lower prevalence of 
CAD and LVSD.3,6-9  Because women were less likely to undergo assessment of the left 
ventricular function a substantial proportion could not be identified as having depressed or 
preserved left ventricular function. Although this gender difference with respect to lack of 
information on ventricular function confirms results from other studies,10,11 the fact that 
women were less likely than men to undergo qualitative or quantitative assessment of left 
ventricular function causes concern, because this information is critical to confirm heart 
failure, to provide optimal treatment and to estimate prognosis.12 Although our study did not 
identify reasons for the observed diagnostic deficiency, we were able to exclude age as an 
important confounder.  
 As discussed in previous reports, recommended drugs in patients who were enrolled in 
the EHS-HF, were underused.13,14 The current study adds another dimension to this 
observation, namely that men and women were treated differently. Univariate analyses 
revealed that women were less likely to be treated with drugs that have a proven effect on 
reducing mortality (ACE-I, beta-blockers, and spironolactone), but were treated more often 
Table 6. Unadjusted and adjusted ORs for outcome (mortality and re-admission) among women, compared to 
men. 
  Gender differences 
 Men / 
Women 
(%) 
Unadjusted OR 
(95% CI) 
OR adjusted 
for age 
(95%CI) 
Adjusted OR, 
excluding LVSD 
(95%CI) † 
Adjusted OR, 
including LVSD 
(95%CI) † ‡ 
      
12 week mortality 11.9 / 14.1 1.23 (1.10-1.38) 0.98 (0.88-1.11) 1.10 (0.97-1.24) 1.15 (0.97-1.35) 
      
Re-admissions during  
follow up period 
19.9 / 18.7 0.93 (0.84-1.02) 0.93 (0.84-1.02) 0.96 (0.87-1.06) 0.98 (0.86-1.11) 
      
* Women compared to men 
† Adjusted for age, hypertension, diabetes, stroke or TIA, renal failure, respiratory disease, coronary artery disease, 
cardiomyopathy, and atrial fibrillation 
‡ Patients with assessment of LV function only, n=6986 
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with cardiac glycosides and diuretics. Although the observed differences decreased after 
adjusting for age and a number of clinical characteristics, treatment with drugs with a proven 
effect on reducing mortality were still less often prescribed to women compared to men. This 
indicates that older age and a different clinical profile in women does not altogether explain 
the observed gender differences in pharmacological treatment between men and women. 
Even in a selected group of patients, those with known LV function, women were less likely 
to be treated with ACE-I and beta-blockers and more often treated with diuretics and cardiac 
glycosides. It is in this context important to note that guidelines do not discriminate between 
men and women, and treatment with evidence-based drugs is advocated in all patients with 
heart failure and left ventricular dysfunction.12 However, women are known to have more side 
effects when treated with ACE-I15,16, and the use of cardiac glycosides may even be associated 
with an increased mortality among women, but not men, with LVSD.17  
 In our study, no differences were observed in the adjusted analyses regarding in-
hospital and 12-week mortality despite the fact that women were less likely to be diagnosed 
with CAD or LVSD, both markers of increased risk. The lack of a sex difference in mortality 
is consistent with a large Italian registry18, but contrasts with others.19-21 However, our data are 
limited by short-term (12 weeks) follow-up and lack of certainty about the preceding duration 
of heart failure. Studies suggest that LVEF and CAD are stronger predictors of prognosis in 
women, as for every 1% increase of LVEF the decrease in mortality was 4% in women versus 
1% in men, and women with CAD and heart failure have a 2.5-fold increase in the risk of 
mortality as compared to a 1.5-fold increase in men.7 Potentially, fewer investigations in 
women might have led to prognostically important information being missed.   
 The limitations of this study are those inherent to observational studies involving 
voluntarily participating hospitals for a clinical syndrome that does not have a clear, simple 
objective definition. Although we attempted to include a wide spectrum of hospitals in many 
European countries, the results will almost certainly be biased towards better than average 
practices. However, a high proportion of relevant patients at each centre were included 
(approximately 16 patients each week per centre) suggesting that the population was relatively 
unselected and likely to be representative of clinical practice. One of the strengths of the 
survey was that it included a large number of unselected and consecutively enrolled patients 
from multiple hospitals across Europe with both suspected and confirmed diagnosis of heart 
failure. We were able to perform multivariate analyses in which we could adjust for age and a 
number of relevant clinical characteristics. 
 In conclusion, in this large population of patients with confirmed or suspected heart 
failure, who were enrolled in the Euro Heart Survey on Heart Failure, we confirmed that, 
compared to men, women are older and more likely to have preserved left ventricular 
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function, hypertension, diabetes, and valvular heart disease, but less likely to have a diagnosis 
of CAD. Women were also less likely to be admitted to cardiology wards, or have an 
assessment of left ventricular function and, in addition, were treated to a lesser extent with 
guideline recommended drugs compared to men. After adjusting for age and important 
clinical characteristics, the observed differences decreased, but remained statistically significant 
for ACE-I, beta-blockers and spironolactone. Despite better left ventricular function and less 
CAD, women and men had similar age-adjusted 12-week mortality. There is no evidence-
based justification for treating women with heart failure less intensively than men.  Clinicians 
need to be aware of these deficiencies in the treatment of women with heart failure and 
measures should be taken to rectify them. 
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ABSTRACT 
 
Background: It has been recognized that a clinically significant portion of patients with 
coronary artery disease (CAD) continue to experience anginal and other related symptoms that 
are refractory to the combination of medical therapy and revascularization. The Euro Heart 
Survey on Coronary Revascularization (EHS-CR) provided an opportunity to assess 
pharmacological treatment and outcome in patients with proven CAD who were ineligible for 
revascularization. 
 
Methods: We performed a secondary analysis of EHS-CR data. After excluding patients with 
ST-elevation myocardial infarction and those in whom revascularization was not indicated, 
4409 patients remained in the analyses. We selected two groups: (1) patients in whom 
revascularization was the preferred treatment option (n=3777, 86%), and (2) patients who 
were considered ineligible for revascularization (n=632, 14%).  
 
Results: Patient ineligible for revascularization had a worse risk profile, more often had a total 
occlusion (59% vs 37%, p<0.001), were treated more often with ACE-inhibitors (65% vs. 
55%, p<0.001) but less likely with aspirin (83% vs. 88%, p<0.001). Overall, they had higher 
case-fatality at 1-year (7.0% vs. 3.7%, p<0.001). Regarding self-perceived health status, 
measured via the EuroQol 5D (EQ-5D) questionnaire, these same patients reported more 
problems on all dimensions of the EQ-5D. Furthermore, in the revascularization group we 
observed an increase between discharge and 1-year follow up (utility score from 0.85 to 1.00) 
whereas patients ineligible for revascularization did not improve over time (utility score 
remained 0.80)    
 
Conclusion: In this large cohort of European patients with CAD, those considered ineligible 
for revascularization had more co-morbidities and risk factors, and scored worse on self-
perceived health status as compared to revascularized patients in the revascularization group. 
With the exception of ACE-inhibitors and aspirin, there were no major differences regarding 
drug treatment between the two groups. Given these clinically significant observations, there 
appears to be a role for nurse-led, multidisciplinary, rehabilitation teams that target clinically 
vulnerable patients whose symptoms remain refractory to standard medical care.  
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INTRODUCTION 
Angina pectoris, the most common manifestation of underlying coronary artery disease 
(CAD) is a condition that reportedly affects approximately 1.5-2% of the population in 
developed countries at one time.1 Angina pectoris remains a significant cause of disability and 
reduced quality of life.2 Treatment of patients with CAD includes risk factor management, 
drug therapy and revascularization techniques. In addition to drug therapy, mechanical 
revascularizations by means of coronary-artery bypass grafting (CABG) or, more increasingly3 
percutaneous coronary interventions (PCI) can be offered to relieve symptoms and improve 
quality of life and prognosis.4-6 However, in recent years it has been recognized that there is a 
group of patients in whom revascularization is no option.7 If these patients have reversible 
myocardial ischemia which cannot be controlled by a combination of medical therapy and 
revascularization, they are considered to have chronic refractory angina (CRA).7 Yet, 
information on the overall proportion and prevalence of patients with proven CAD who are 
ineligible for revascularization is scarce. It is also observed that treatment guidelines do not 
focus on this clinically significant group of patients.8 Accordingly, the management of these 
patients remains reserved to the preference of the treating clinician, without being directed by 
evidence-based guidelines.  
 As it is to be expected that health-related quality of life and perceived health status are 
inflicted by this chronic condition, it is suggested that patients with angina pectoris who are 
ineligible for revascularization may benefit from dedicated nurse-led multidisciplinary 
management programs.9 In a range of other cardiac conditions, these nurse-led management 
programs have been demonstrated to cost-effectively improve health outcomes.10  
 The Euro Heart Survey on Coronary Revascularization (EHS-CR) was designed to 
evaluate invasive diagnosis, treatment, and 1-year outcome in patients with established CAD 
as seen in clinical practice.11 As this survey also included a sizeable proportion of patients who 
were ineligible for revascularization, we were able to compare these patients with those who 
were eligible for revascularization.  
 
STUDY AIMS 
Based on compelling anecdotal and corroborating scientific evidence that a clinically 
significant portion of patients with CAD experience sub-optimal health outcomes and 
available data from the EHS-CR we examined the following important parameters in a large 
cohort of surveyed European patients with CAD who were either considered eligible or 
ineligible for coronary revascularization: 
1) Pharmacological treatment 
2) Perceived health status at discharge 
3) One year case-fatality 
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It was anticipated that these data would provide supportive evidence for the application of 
nurse-led, multidisciplinary rehabilitation teams to improve health outcomes in clinically 
vulnerable patients with limited treatment options.9 
 
METHODS 
Design and setting 
Data for this study were derived from the database of the EHS-CR. A more detailed 
description of this prospective, observational study were published previously.11 In short, all 
consecutive patients undergoing invasive diagnostic or therapeutic procedures in the 
catheterisation laboratory were screened between November 2001 and March 2002. In total 
130 hospitals from 31 member countries of the European Society of Cardiology (ESC) 
participated, and enrolled a total of 5619 patients. All consenting patients who had at least one 
>50% diameter stenosis in a major epicardial vessel were enrolled. Detailed information on 
medical history, demography, clinical and angiographic status, and treatment was collected and 
sent to a central database.  
 
Study population 
From the 5619 patients enrolled in the EHS-CR, patients were included in the analysis if they 
were admitted with a diagnosis of stable or unstable angina (the latter including non-ST 
elevation acute coronary syndromes), and information on the treatment option 
(revascularization or medical treatment) was available. Patients were excluded if they were 
admitted with ST-elevation myocardial infarction (n=906; 16% of the total cohort), when 
revascularization was not indicated (n=230; 4.1%), and if the reason for treating a patient 
medically was not specified (n=74; 1.3%). The remaining 4409 patients (79% of total) who 
were included in the analysis were then divided in two groups:  
1. Those, who were eligible for revascularization (n=3777; 86%), and  
2. Those, who were ineligible for revascularization (n=632; 14%).  
Patients were identified as eligible for revascularization (group 1) if the treating physician 
indicated that revascularization was the preferred treatment option, and considered ineligible 
for revascularization (group 2) if they fulfilled the following criteria: 
i. The general condition or vessels of the patient were not suitable for PCI or CABG 
(n=430; 68% of group 2), 
ii. Presence of extra cardiac contra-indications for PCI or CABG (n=64; 10%), or 
iii. The treating clinician estimated that the procedural risk was too high (n=138; 22%).  
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Measures 
In addition to collecting clinical variables (e.g. demographics, risk factors, diagnosis at 
admission, etc), all patients were asked to fill in a generic health status questionnaire prior to 
hospital discharge, and at 1-year follow up. The used questionnaire, the EQ-5D12, comprises 
five dimensions, namely: mobility, self-care, usual activities, pain or discomfort and anxiety or 
depression. Each of these dimensions has three levels of severity, corresponding to “No 
problem”, “Moderate problems”, and “Severe problems”. Patients were asked which 
statements best described their health status on the day the questionnaire was filled in. By 
combining one level from each of the five dimensions, a unique EQ-5D health state can be 
identified for individual patients. In addition, a weighted index (utility score) can be computed 
for each of the states based on the values of the general public elicited in the United 
Kingdom.12  
 These utility-scores range from –0.594 to +1, with scores < 0 being regarded as worse 
than death and 1 representing full health, from the perspective of the general population. The 
second part of the EQ-5D consists of a visual analogue scale (VAS) ranging from 0 (worst 
imaginable health state) to 100 (best imaginable health state), which is used for rating the 
overall health.  
 
Statistical analysis 
Statistical analyses were carried out with SPSS statistical software (version 12.01 for Windows), 
using mostly descriptive statistics between subsets of patients defined by treatment option. 
Results are presented as mean and median with corresponding values (standard deviation and 
inter quartiles, respectively), and percentages. To evaluate differences between the two groups, 
Chi-square tests, Student’s t-test, and Kruskal-Wallis tests were applied as appropriate. 
Changes over time were analysed, using Wilcoxon Signed Rank test and McNemar test as 
appropriate. We also performed multivariate analyses to study the association in outcome and 
heart failure between the two groups. In the multivariate analyses we adjusted for left 
ventricular ejection fraction (LVEF) < 40% and a history of heart failure. We report odds 
ratios (OR) and corresponding 95% confidence intervals (CI). A p-value of < 0.05 was 
considered statistically significant (two-sided).  
 
RESULTS 
Table 1 summarises the baseline characteristics of the 4409 patients who were included in the 
current study, comparing patients on the basis of eligibility for revascularization. The overall 
proportion of patients considered ineligible for revascularization was 14% of the study 
population (and 11% of the total EHS-CR cohort). As compared to the revascularization 
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group, patients considered ineligible for revascularization often had a worse risk profile 
(including age, diabetes, and cardio-vascular history), but were less often current smokers 
(17% versus 24%, p <0.001). Nearly half of these patients (47%) had undergone a 
revascularization procedure prior to the current admission, versus 27% in the revascularization 
group (p <0.001). 
 The angiographic results (Table 2) revealed that patients without option for 
revascularization more often had a total occlusion of a coronary artery (59% vs. 37%, p 
<0.001) and more often had a depressed left ventricular ejection fraction (23% vs. 10%, p 
<0.001).  
 Information on pharmacological treatment prior to admission and at discharge is 
presented in Table 3. At discharge a considerable number of patients were on prophylactic 
drugs, irrespective of eligibility status for revascularization. Between these two patient groups, 
those ineligible for revascularization were more often treated with ACE-inhibitors (65% vs. 
55%, p < 0.001) but less likely with aspirin (83% vs. 88%, p <0.001).  When broken down to 
patients with a LVEF < 40%, those who were ineligible for revascularization (23%) were 
treated more often with ACE-inhibitors as compared to patients with a depressed LVEF who 
were eligible for revascularization (84% versus 74%, p =0.03). 
Table 1. Differences in clinical characteristics between patients with and without option for  
revascularization 
 
Eligible for 
revascularisation 
Ineligible for 
revascularisation 
P 
 
 N 3777 632  
Age (mean, SD) 63.1 ±10.7 64.5 ±10.4 .003
Male gender, n (%) 2874 (76) 471 (75) .41
Smoking, n (%):   
 Current  877 (24) 102 (17) <.001
 Past 1360 (37) 267 (43) 
Diabetes mellitus, n (%):   
 type 1 140 (4) 33 (5) .001
 type 2 745 (20) 163 (26) 
Hypercholesterolemia, n (%) 2516 (68) 412 (66) .35
Hypertension, n (%) 2286 (61) 413 (66) .002
Sedentary lifestyle, n (%) 1067 (39) 219 (48) <.001
Congestive heart failure, n (%) 624 (17) 148 (24) <.001
Chronic renal failure, n (%) 143 (4) 39 (6) .005
Peripheral vascular disease, n (%) 450 (12) 105 (17) .001
Cerebro-vascular disease, n (%) 274 (7) 71 (11) <.001
Prior revascularisation, n (%) 1004 (27) 290 (46) <.001
                Prior CABG, n (%) 336 (9) 176 (28) <.001
                Prior PCI, n (%) 795 (21) 176 (28) <.001
Prior myocardial infarction, n (%) 1462 (39) 313 (50) <.001
Diagnosis at admission, n (%):‡   
 Stable angina 2319 (61) 415 (66) .002
 Non-ST elevation ACS/ UA 1403 (37) 187 (30) 
Hospitalisation in days (median, IQR) 5 (3-11) 3 (2-8) <.001
‡ Primary diagnosis missing in 91 patients 
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In-hospital case-fatality rates were 1.4% for patients in both groups (Table 4). At 1-year the 
case-fatality was significantly higher in those ineligible for revascularization as compared to the 
revascularization group (7.0% vs. 3.7%, p <0.001). As a considerable number of patients were 
known to have heart failure, we adjusted for this potential confounder. The clear difference in 
case-fatality observed in the crude analysis (OR 1.92; 95% CI 1.36 – 2.73) disappeared almost 
after adjusting for LVEF < 40% (OR 1.47; 95% CI 1.00 – 2.15) and completely after adjusting 
for LVEF < 40% and a history of heart failure (OR 0.89; 95% CI 0.43 – 1.83). Despite initial 
ineligibility, a total of 24 patients (4%) underwent a revascularization procedure within one 
year. 
 Prior to discharge, patients ineligible for revascularization reported more problems 
(moderate or severe) on all dimensions of the EQ-5D health status questionnaire than the 
revascularization group (Table 5); the latter being less likely to report “no problems” on all 
five dimensions (33% vs. 43%, p <0.001). In addition, the EQ-5D utility score was lower in 
patients who were ineligible for revascularization (0.76 vs. 0.85, p <0.001). 
 
 
 
 
 
 
 
 
Table 2. Angiographic results 
 
Eligible for  
revascularisation 
Ineligible for 
revascularisation 
P 
 
N 3777 632  
Severity of coronary artery disease, n (%):   
 Single-vessel disease 1241 (33) 237 (38) 
 Two-vessel disease 1199 (32) 159 (25) .003
 Three-vessel disease 1325 (35) 232 (37) 
    
 Left main lesions 350 (9) 60 (10) .86
   
 Total occlusion, n (%)‡ 1395 (37) 375 (59) <.001
Left ventricular function known, n (%): 3301 (87) 546 (86) .48
 Ejection fraction >50% 2147 (65) 296 (54) 
 Ejection fraction 40 – 50% 821 (25) 125 (23) <.001
 Ejection fraction <40 333 (10) 125 (23) 
‡ Total occlusion in at least one segment 
Table 3. Pharmacological treatment at admission and discharge (in-hospital death excluded) 
 
Eligible for 
revascularisation 
Ineligible for 
revascularisation 
P 
 
   
Treatment prior to admission, n (%)   
  Aspirin 3180 (85) 520 (84) .21 
 Bèta-blocker  2620 (70) 394 (63) <.001 
 ACE-inhibitor 1820 (49) 354 (57) <.001 
 Calcium channel blockers 1021 (27) 181 (29) .75 
 Statin 1925 (52) 322 (52) .40 
Treatment at discharge, n (%)    
 Aspirin 3283 (88) 514 (83) <.001 
 Bèta-blocker  2756 (74) 453 (73) .51 
 ACE-inhibitor 2030 (55) 404 (65) <.001 
 Calcium channel blockers 1020 (27) 202 (32) .009 
 Statin 2518 (68) 421 (68) .99 
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 Table 6 reveals the difference in perceived health status between discharge and 1-year 
follow up. In the revascularization group we observed an increase over time in the median 
utility score (0.85 to 1.00, p <0.001). Alternatively, the utility score did not improve in patients 
who were ineligible for revascularization (0.80 at discharge, and 0.80 at 1-year follow up, p 
=0.72). It should be noted, however, that information on self-perceived health status was 
available in 82% of patients prior to discharge, while only 63% of all patients completed the 
health-status questionnaire prior to discharge and at 1-year follow up. 
 
DISCUSSION 
This study clearly revealed that a clinically significant proportion of patients, with at least one 
> 50% diameter stenosis in a major coronary artery, visualized during an invasive coronary 
procedure, were ineligible for revascularization. These patients had a worse clinical risk profile, 
were more likely to have a total occlusion of at least one coronary artery, and had worse 
outcomes at 1-year in respect to perceived health status and case-fatality, when compared to 
patients who were eligible for revascularization. With the exception of more ACE-inhibitors 
and less aspirin, no major differences with regards to the treatment with prophylactic drugs 
were observed between the two groups. 
 In addition to pharmacological therapy, revascularization can be offered to reduce 
symptoms and improve prognosis in subsets of patients with CAD. It should be noted, 
however, that there is a subgroup of patients with refractory angina in whom revascularization 
is not a viable option. It is this clinically important subgroup of patients that we identified 
among patients who enrolled via the EHS-CR. Although many of these patients are most 
likely to be diagnosed as chronic refractory angina (CRA), it is important to stress that 
identifying survey patients who were ineligible for revascularization as having CRA is, by 
definition, a crude assumption. However, all patients included in the analyses were admitted 
with a diagnosis of angina, had evidence of coronary insufficiency, had undergone an invasive 
coronary procedure in order to evaluate therapeutic option8, and were considered ineligible for 
revascularization. In addition, it is important to note that we were only able to identify patients 
as having CRA who underwent an invasive diagnostic procedure and had a >50% diameter 
stenosis of at least one coronary artery.  
Table 4. Outcome at discharge and 1-year follow up 
(proportions are given per column) 
Eligible for 
revascularisation 
Ineligible for 
revascularisation 
P 
N 3777 632  
    
In-hospital mortality, n (%) 51 (1.4) 9 (1.4) .88 
Total mortality at 1-year, n (%) 141 (3.7) 44 (7.0) <.001 
Rehospitalization for cardiac reason, n (%) 776 (25) 130 (27) .26 
(repeat) Revascularisation, n (%) 286 (8) 24 (4) .001 
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 The clinical judgement of being ineligible for revascularization at the time of the 
survey does not, of course, necessarily imply that these patients were not eligible for active 
treatment thereafter. Surprisingly, although optimizing medical treatment is advocated in the 
management of these patients7, those, ineligible for revascularization did not receive, with the 
exception of ACE-inhibitors, more evidence based drugs as compared to patients who were 
eligible for revascularization; despite the latter requiring greater level of intervention in this 
regard. It is on this basis that this study showed that there remains substantial room for 
improvement in treatment patterns, as 30% of patients did not receive beta-blockers or 
statins, and more than half was not treated with calcium channel blockers.  
 In addition to optimizing medical treatment, there have been alternative therapeutic 
options developed in this clinical context. These include transcutaneous electric nerve 
stimulation, spinal cord stimulation, left stellate ganglion blockade, thoracic epidural 
anaesthesia, endoscopic thoracic sympathicotomy, transmyocardial laser revascularisation, and, 
more latterly, angiogenesis.7,13 Within our study population, however, no information on these 
novel treatment options was available. We could not, therefore, estimate the proportion of 
CRA patients who could be considered for these therapeutic options. However, the clinical 
applicability and therapeutic impact of this novel arsenal of therapeutic options needs further 
Table 5. Perceived health status prior to discharge (n=3613) 
 
Eligible for 
revascularisation 
Ineligible for 
revascularisation 
P 
   
EQ-5D parameter, n (%) 3109 (82) 504 (80) 
Mobility   <.001
 No problems with walking around 2162 (69) 281 (56) 
 Some problems with walking around 917 (30) 216 (43) 
 Confined to bed 30 (1) 7 (1) 
Self-care   .004
 No problems with self-care 2676 (86) 406 (81) 
 Some problems with washing or dressing 408 (13) 91 (18) 
 Unable to wash or dress 25 (1) 7 (1) 
Usual activities   <.001
 No problems performing usual activities  1959 (63) 258 (51) 
 Some performing usual activities 1037 (33) 222 (44) 
 Unable to perform usual activities 113 (4) 24 (5) 
Pain / discomfort   <.001
 Neither pain nor discomfort 1939 (62) 253 (50) 
 Moderate pain or discomfort 1118 (36) 243 (48) 
 Severe pain or discomfort 52 (2) 8 (2) 
Anxiety / depression   <.001
 Neither anxious nor depressed 2153 (69) 295 (59) 
 Moderate anxious nor depressed 862 (28) 191 (38) 
 Severe anxious nor depressed 94 (3) 18 (4) 
   
No problems on all 5 dimensions 1343 (43) 167 (33) <.001
   
EQ-VAS (median, inter quartile range) 70 (60-80) 65 (50-80) <.001
EQ-utility score (median, inter quartile range) 0.85 (0.69-1.00) 0.76 (0.62-1.00) <.001
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research and none of these options would have formed part of the gold-standard management 
of angina pectoris at the time of the survey.7 
 
 The unfavourable condition of patients considered ineligible for revascularization was 
partly expressed by the higher case-fatality at 1-year. This is to be expected as these patients 
had a worse clinical profile and fewer treatment options as compared to the revascularization 
group. However, the observed difference in case-fatality can be explained by a higher 
prevalence of heart failure in patients who were considered ineligible for revascularization. In 
addition, we also observed that a considerably more patients reported problems on the five 
dimensions of the EQ-5D questionnaire. This is in accordance with earlier reports, indicating 
disability and diminished quality of life, as these patients experience recurrent pain, lack of 
energy, poor sleep decreased physical capacity and increased prevalence of anxiety and 
depression.14,15 In addition, we also observed that the self-perceived health status of these 
patients did not improve over time (even with higher attrition of “sicker” patients) compared 
to patients in the revascularization group who showed a significant improvement between 
discharge and 1-year follow up. 
 Patients not treated with revascularization might consider themselves as being at the 
“end of the line”.9,16 This type of misconception and maladaptive beliefs of angina increase 
anxiety and reduce functional status. 17 Even though their prognosis was poorer than patients 
receiving treatment with revascularization, a 93% 1-year survival is considerably higher than in 
patients with moderate to severe heart failure.18,19  
Table 6. Health status prior to discharge and at 1-year follow up* 
 
EQ-5D prior to 
discharge 
EQ-5D at 1-year 
follow up 
P 
 
   
Eligible for revascularisation (n=2383)  n (%) n (%)  
  Mobility** 676 (28) 576 (24) <.001 
 Self-care** 294 (12) 181 (8) <.001 
 Usual activities** 828 (34) 537 (23) <.001 
 Pain / discomfort** 857 (36) 716 (30) <.001 
 Anxiety / depression** 695 (29) 646 (27) .07 
     
 EQ-5D utility score (median, IQR) 0.85 (0.69-1.00) 1.00 (0.73-1.00) <.001 
    
Ineligible for revascularisation (n=373) n (%) n (%)  
 Mobility** 154 (41) 140 (38) .21 
 Self-care** 70 (19) 46 (12) .007 
 Usual activities** 175 (47) 131 (35) <.001 
 Pain / discomfort** 179 (48) 183 (49) .79 
 Anxiety / depression** 153 (41) 143 (38) .40 
     
 EQ-5D utility score (median, IQR) 0.80 (0.62-1.00) 0.80 (0.66-1.00) .72 
*) only patients included who completed the EQ-5D prior to admission and at 1-year follow up  
**) patients indicating problems (moderate or severe) on the EQ-5D dimension 
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 Providing a cardiac rehabilitation programme to patients with CRA has proven to 
increase the health-related quality of life.7,16 Most important areas of intervention in these 
rehabilitation programmes are: optimizing pharmacological therapy, physical training, life style, 
treatment adherence, psychosocial adaptation, and ongoing education. Given the broad range 
of these interventions, a multidisciplinary approach is recommended. In this context, we 
would like to stress the value of including nurses in these multi-disciplinary programmes as 
nurses are known to have expertise in these areas. Nurse-led multi-disciplinary management 
programs have not only been proven cost-effectively, but also improved the delivery and 
outcome of provided care in various patient populations.10 In a recent study by Moore et al16, 
in all patients who received education as part of a rehabilitation programme, they observed an 
improvement in health-related quality of life. In addition, experienced and dedicated nurses 
are well placed health-care workers that cannot only provide patient-tailored education, but 
also refer patients to other health care providers (e.g. dieticians and psychologists) if needed. 
For example, instruct patients how they can use nitroglycerine as prophylactic drug before 
doing physical activities, the importance of warming-up and cooling down before and after 
exercise, to inform patients about CAD and that their prognosis is not so poor, and to 
emphasize the importance of compliance.      
 In addition to the specific limitations outlined previously, the major limitations are 
commonly inherent to observational studies involving voluntarily participating hospitals in 
Europe, which may lead to a biased patient cohort. The results of this study therefore only 
reflect the treatment of a small percentage of all patients who were admitted with CAD 
throughout Europe. However, because patients were included consecutively at the 
participating hospitals, we assumed that the patients enrolled in the EHS-CR were 
representative for ongoing clinical practice in Europe. It should be noted, however, that we 
cannot exclude that the available expertise in local hospitals was decisive in considering 
patients as being ineligible for revascularization. In contrast, these patients have to cope with a 
palliative instead of a curative treatment, and consequently will have completed the EQ-5D 
with this knowledge. It should be re-emphasised that not all patients, enrolled in this study 
completed the EQ-5D questionnaire, and even less patients completed both the questionnaire 
prior to discharge and the questionnaire at 1-year follow up. Despite these limitations of this 
study, the major strength of this study is the large number of patients included from multiple 
hospitals across Europe. 
 In conclusion, patients with CAD who were considered ineligible for revascularization, 
representing 14% of those participating in the study, typically had more co-morbidities and 
risk factors as compared to patients who were eligible for revascularization. This difference 
was also reflected in the self-perceived health status. With the exception of ACE-inhibitors 
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and aspirin, we observed no major differences regarding drug treatment between the two 
groups. Optimizing management in this clinically significant patient group, via the application 
of  nurse-led multidisciplinary rehabilitation programmes9, using the same principles applied in 
parallel programs in cardiac disease10 has clear potential to improve both perceived health and 
actual (e.g. mortality) health outcomes. Further research is obviously needed to reveal whether 
initiatives to implement nurse-led multidisciplinary teams will fulfil the potential to 
substantially improve outcomes in patients with CRA.  
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ABSTRACT 
 
Objective: Self-perceived health status may be helpful in identifying patients at high-risk for 
adverse outcomes. The Euro Heart Survey on Coronary Revascularization (EHS-CR) 
provided an opportunity to explore whether impaired health-status was a predictor of 1-year 
mortality in patients with CAD undergoing angiographic procedures.  
 
Methods: We used data from the EHS-CR that included 5619 patients from 31 member 
countries of the ESC. Inclusion criteria for the current study were completion of a self-report 
measure of health-status (EQ-5D) at discharge and information on 1-year follow-up, resulting 
in a study population of 3786 patients.  
 
Results: The 1-year mortality was 3.2% (n=120). Survivors reported fewer problems on the 
five dimensions of the EQ-5D as compared to non-survivors. We adjusted for a broad range 
of potential confounders, which reached a p-value of <0.10 in the unadjusted analyses. In the 
adjusted analyses, problems with self-care (OR, 3.45; 95%CI 2.14-5.59) and a low rating (≤ 60) 
on health status (OR, 2.41; 95%CI 1.47-3.94) were the most powerful independent predictors 
of mortality, amongst 22 clinical variables included in the analysis. Furthermore, patients who 
reported no problems on all 5 dimensions had significantly lower 1-year mortality rates (OR, 
0.47; 95%CI 0.28-0.81). 
 
Conclusions  This analysis demonstrates that impaired health-status is associated with a 2-3 
fold increased risk of all-cause mortality in patients with CAD, independent of other 
conventional risk factors. These results highlight the importance of including patients’ 
subjective experience of their own health-status in the evaluation strategy in order to optimize 
risk stratification and management in clinical practice. 
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INTRODUCTION 
Treatment options for patients with coronary artery disease (CAD) have expanded 
considerably over the last two decades. In addition to pharmacological therapy, mechanical 
revascularization by coronary-artery bypass grafting (CABG) and percutaneous coronary 
intervention (PCI) can be offered to relieve ischemic symptoms and improve prognosis in 
some subsets.1-6 In addition, behavioural interventions, which include prevention and 
treatment of lifestyle risk factors and psychological risk factors (e.g. anger or anxiety), are 
known to be beneficial for patients with cardiovascular diseases.7  Choosing the most 
appropriate treatment for the individual patient, however, remains controversial in many 
instances.8  
As the observed differences in outcome between competitive treatment options (e.g. 
CABG and PCI) diminish, 9-11 researchers and clinicians have become increasingly interested 
in measuring patients’ health status. In addition to using health related quality of life (HRQL) 
or health status as an endpoint in clinical trials, health status may prove useful in the clinical 
decision-making process as to which treatment to favour.12,13 It is also important to note that 
health status is an important patient-centered outcome, and subsets of patients are known to 
prefer health status over prolonged survival.14 In addition, measuring health status may 
identify patients at high-risk for adverse outcomes.12,15-18 Identification of these patients is 
important as they may benefit from more invasive management and more intensive follow-
up.17 Yet, health status measures are rarely used in clinical practice.19   
 The aim of this study was to explore whether impaired health status was a predictor of 
1-year all-cause mortality in a cohort of patients with established CAD enrolled in the Euro 
Heart Survey on Coronary Revascularization (EHS-CR). 
 
METHODS 
Patients 
Data for this study were derived from the database of the EHS-CR. Details of this 
prospective, observational study were published previously.20 In short, all consecutive patients 
undergoing invasive diagnostic or therapeutic procedures in the catheterization laboratory 
were screened between November 2001 and March 2002 in 130 hospitals from 31 member 
countries of the European Society of Cardiology (ESC). Consenting patients with a >50% 
diameter stenosis in at least one coronary artery were included and detailed information was 
retrieved from their medical records. The EuroSCORE was calculated from the available 
variables.21 From the 5619 patients enrolled in the EHS-CR, 4515 (80%) patients had 
complete data on all five questions (dimensions) of the EQ-5D questionnaire at baseline. The 
study protocol included a one-year follow-up which was available in 3786 patients (84%).  
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Health status 
In addition to  collecting clinical variables, all patients were asked to fill in the self-report EQ-
5D questionnaire22 at the time of hospital discharge. The EQ-5D is a standardized generic 
instrument for assessing health status, with valid translations available for 29 of the 31 
participating countries in the current study. This validated questionnaire comprises five 
dimensions, namely mobility, self-care, usual activities, pain or discomfort and anxiety or 
depression. Each of these dimensions has three levels of severity, corresponding to “No 
problems”, “Moderate problems”, and “Severe problems”. Patients were asked which 
statement best described their health status on the day the questionnaire was filled in. 
Theoretically, 243 different health states can be generated by this classification. The ratings 
can be analyzed on individual-level using health-state utility scores. These scores range from –
0.594 to +1, with scores < 0 being regarded as worse than death and 1 representing full 
health, from the perspective of the general population.22 The second part of the EQ-5D 
consists of a visual analogue scale (VAS) ranging from 0 (best imaginable health state) to 100 
(worst imaginable health state), which is used for rating the overall health.  
 
Statistical analysis 
Continuous variables are reported as mean or median scores with corresponding values 
(standard deviation and inter-quartiles ranges, respectively). Dichotomous variables are 
presented as numbers and percentages. To evaluate differences between the different groups, 
chi-square tests, student’s t-test, ANOVA or Mann-Whitney tests were applied as appropriate. 
Univariate and multivariate logistic regression analyses were performed to evaluate the relation 
between the five dimensions of the EQ-5D at baseline and all-cause mortality at 1-year. To 
examine the relationship between the dimensions of the EQ-5D, we dichotomized the three 
levels of severity: “No problems” was coded 0, while “Moderate problems” and “Severe 
problems” were coded 1. The VAS was dichotomized by using the lowest 25th percentile 
indicating impaired health. These dichotomized variables were than entered separately in the 
adjusted analyses. Crude and adjusted odds ratios (OR) with their corresponding 95% 
confidence intervals (CI) are reported. We adjusted for a broad range of potential 
confounders, which reached a p-value of < 0.10 in the unadjusted analyses. These variables 
included age, risk factors, co-morbidity, admission diagnosis, and treatment. Goodness-of-fit 
was determined by the Hosmer-Lemeshow test, and discriminatory power was evaluated by 
using c-statistics. For all tests a p value of < 0.05 (two-sided) was considered statistically 
significant. Statistical analyses were performed using SPSS 12.0.1 for Windows. 
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RESULTS 
Table 1 summarizes the baseline characteristics of the 3786 patients who were included in the 
current study, comparing survivors at 1-year follow-up with non-survivors. The all-cause 
mortality at 1-year was 3.2% (120 deaths). Cardiac death was observed in 69% of those with a 
known cause of death (n=97). Survivors were younger (62.8 versus 69.0, p < 0.001), had a 
better risk profile (including age, diabetes, cardio-vascular history and EuroSCORE), and were 
more often offered revascularization (80% versus 63%, p < 0.001) as compared to non-
survivors. No significant differences were observed between the admission diagnosis of 
survivors and non-survivors. 
 
 
 By univariate analysis, conventional variables negatively associated with death were: 
age, diabetes, peripheral vascular disease, previous myocardial infarction, history of heart 
Table 1. Baseline characteristics. 
 Vital status at 1-year follow-up    
 Alive  
(n=3666) 
Dead  
(n=120) 
Univariate predictor for 
mortality (OR, 95%CI) 
P 
     
Male sex (%) 2785 (76) 93 (78) 1.09 (0.70-1.68)  .71
Age (mean, SD) 62.8 ±10.6 69.0 ±9.9 1.06 (1.04-1.08)  <.001
Risk factors (%):     
  Smoking ever 2166 (61) 75 (63) 1.05 (0.72-1.53)  .79
  Diabetes mellitus 850 (23) 43 (36) 1.85 (1.26-2.70)  .002
  Hypertension 2254 (62) 75 (63) 1.04 (0.71-1.51)  .85
  Hyperlipidemia 2417 (67) 78 (66) 0.98 (0.66-1.44)  .90
Cardio-vascular history (%):     
  Peripheral vascular disease 412 (11) 32 (27) 2.87 (1.89-4.35)  <.001
  Cerebral vascular disease 283 (8) 12 (10) 1.33 (0.72-2.44)  .36
  Prior myocardial infarction 1440 (39) 72 (60) 2.31 (1.59-3.35)  <.001
  Congestive heart failure 673 (18) 50 (42) 3.17 (2.19-4.61)  <.001
  Prior percutaneous coronary intervention 764 (21) 19 (16) 0.71 (0.43-1.17)  .18
  Prior coronary artery bypass grafting 368 (10) 24 (20) 2.24 (1.41-3.55)  <.001
Diagnosis at admission (%):     
  Stable angina 1978 (55) 60 (52) 0.85 (0.59-1.23)  .39
  NSTE-ACS  1105 (31) 40 (35) 1.16 (0.79-1.71)  .45
  STEMI 537 (15) 16 (14) 0.90 (0.53-1.53)  .90
Angiographic results (%):     
 Multi vessel disease 2308 (63) 89 (74) 1.68 (1.11-2.54)  .01
 Left main lesions 284 (8) 15 (13) 1.70 (0.98-2.96)  .06
 Ejection fraction <40% 296 (12) 34 (37) 4.25 (2.74-6.60)  <.001
EuroSCORE (mean, SD) 4.2 ±2.8 6.8 ±3.4 1.28 (1.21-1.35)  <.001
Treatment option (%)     
  Percutaneous coronary intervention 2201 (60) 54 (45) 0.55 (0.38-0.79)  .001
  Coronary artery bypass grafting 745 (20) 22 (18) 0.88 (0.55-1.41)  .59
  Medical treatment only 720 (20) 44 (37) 2.37 (1.62-3.46)  <.001
Medical treatment at discharge (%):     
  Anti-platelet agents/ oral anticoagulants 3464 (95) 105 (88) 0.41 (0.23-0.71)  .002
  B-blockers 2796 (76) 86 (72) 0.79 (0.53-1.18)  .25
  Statins 2498 (68) 71 (59) 0.68 (0.47-0.98)  .04
  ACE-inhibitors 2027 (55) 76 (63) 1.40 (0.96-2.04)  .08
      
NSTE-ACS = non ST-elevation acute coronary syndrome; STEMI = ST-elevation myocardial infarction 
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failure, previous CABG, multivessel disease, ejection fraction < 40%, EuroSCORE and 
medical treatment only. PCI, use of antiplatelet agents and use of statins were associated with 
improved outcome. Stable angina was the most frequent indication to perform angiography 
(54%), followed by non-ST myocardial infarction or unstable angina (30%) and ST elevation 
myocardial infarction (15%). On all five EQ-5D dimensions, survivors reported significantly 
fewer problems and had a better overall health (i.e. VAS) than non-survivors. The univariate 
analysis revealed that problems on these dimensions were negatively associated with death 
(Table 2). Identical results were observed in a subgroup of patients with cardiac mortality, 
instead of all-cause mortality. 
 
 
 
 On all five EQ-5D dimensions, survivors reported significantly fewer problems and 
had a better overall health (i.e. VAS) than non-survivors. The univariate analysis revealed that 
problems on these dimensions were negatively associated with death (Table 2). Identical  
 
Table 2. EQ-5D questionnaire and distribution, prior to hospital discharge 
 Vital status at 1-year 
follow up 
 
 Alive Dead 
Univariate 
predictor for 
mortality  P 
 (n=3666) (n=120) (OR, 95% CI)  
     
Mobility    3.00 (2.08-4.33)* <.001
 I have no problems in walking about 2579 (70) 53 (44)   
 I have some problems in walking about 1064 (29) 61 (51)   
 I am confined to bed 23 (1) 6 (5)   
Self-care  4.64 (3.18-6.67)* <.001
 I have no problems with self-care 3191 (87) 71 (59)   
 I have some problems washing or dressing myself 453 (12) 46 (38)   
 I am unable to wash or dress myself 22 (1) 3 (3)   
Usual activities (e.g., work, housework, family activities)  3.65 (1.93-3.85)* <.001
 I have no problems with performing my usual activities 2311 (63) 47 (39)   
 I have some problems with performing my usual activities 1227 (33) 62 (52)   
 I am unable to perform my usual activities 128 (4) 11 (9)   
Pain/discomfort  2.12 (1.47-3.05)* <.001
 I have no pain or discomfort 2295 (63) 53 (44)   
 I have moderate pain or discomfort 1320 (36) 59 (49)   
 I have extreme pain or discomfort 51 (1) 8 (7)   
Anxiety/depression  2.47 (1.71-3.55)* <.001
 I am not anxious or depressed 2505 (68) 56 (47)   
 I am moderately anxious or depressed 1061 (29) 54 (45)   
 I am extremely anxious or depressed 100 (3) 10 (8)   
EQ-VAS:  3.45 (2.29-5.19)** <.001
 Mean, SD 69 ±19 57 ±23   
 Median, inter-quartile range 70 (60-80) 58 (45-80)   
    
EQ-utility score:  2.70 (1.87-3.90)** <.001
 Mean, SD 0.81 ±0.23 0.63 ±0.34   
 Median, inter-quartile range  0.85 (0.69-1.0) 0.71 (0.52-0.85)   
*) patients indicating problems on the EQ-5D dimension 
**) dichotomized (using the lowest 25th percentile indicating impaired health status) 
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results were observed in a subgroup of patients with cardiac mortality, instead of all-cause 
mortality. 
Table 3 shows the adjusted association between the EQ-5D and 1-year mortality. Patients 
who reported problems on perceived health status, and patients who had a relatively low score (≤ 
60) on the EQ-VAS had a higher mortality rate as compared to patients who reported no 
problems. Problems with self-care (OR, 3.45; 95%CI 2.14-5.59) and a health rating ≤ 60 (OR, 
2.41; 95%CI 1.47-3.94) were the most powerful predictors of mortality. Furthermore, patients 
who reported no problems on all 5 dimensions had significantly lower 1-year mortality rates (OR, 
0.47; 95%CI 0.28-0.81), whereas patients who reported problems on all dimensions were in the 
highest risk group (OR, 3.85; 95%CI 2.30-6.44). The EQ-5D improved the model c-statistics 
(from 0.78 up to 0.81). Calibration was good for the adjusted analyses as Hosmer-Lemeshow 
tests showed no significant difference between the observed and predicted probabilities. 
Figure 1 clearly reveals per dimension that patients who reported no problems had a low 
mortality rate (< 3%), whereas patients who had moderate or severe problems had considerably 
higher mortality rates (range: 4–21%).  
 
 
 
 
 
 
 
 
 
 
 
 
Since 33% of all patients enrolled in the EHS-CR were excluded from this analysis, we 
compared the baseline characteristics of these patients with the study population. With the 
exception of a higher in-hospital mortality in those who were excluded (5.1% versus 0.3%), no 
major differences were observed.  
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P ≤ 0.001 for five dimensions between the three levels of severity. 
Figure 1. 
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DISCUSSION 
This study demonstrated that impaired health status, as measured by the EQ-5D prior to 
discharge, is associated with a 2-3 fold increased risk of all-cause mortality in patients with 
established CAD. After adjustment for other prognostic variables, including age, risk factors, 
comorbidity and admission diagnosis, impaired health status remained an independent predictor 
of 1-year mortality.  
 Several studies have reported on the predictive value of HRQL and health status 
questionnaires in relation to adverse clinical outcomes in patients with cardiovascular 
diseases.15,16,18,23 To our knowledge, this study is the first to use the EQ-5D, a brief generic self-
perceived health status questionnaire to predict short-term mortality (i.e. after 1 year), 
independently of established bio-medical risk factors in CAD patients with a relatively low overall 
risk. We identified reduced self-care as the most powerful predictor of mortality. Of note, this 
dimension is strongly related to patients’ abilities to care for themselves and adequately manage 
their condition. As a consequence, targeting and improving self-care behaviour in intervention 
programmes could not only lead to improved HRQL but also may enhance survival in this subset 
of patients.24,25 In addition, a major advantage of the EQ-5D is that it is a brief and valid measure 
of health status that can easily be used in clinical practice.  
 Our findings support the recommendations of Krumholz et al 17 to include health status 
measurements in clinical practice as an “additional” tool to identify patients who are at high risk 
for adverse outcomes. These patients may consequently benefit from a more aggressive 
treatment, including invasive, pharmacological and/ or behavioural interventions or a 
combination hereof. An earlier report on the EHS-CR showed that there is room for 
improvement in the medical treatment of these patients, especially with respect to adjunctive 
pharmacology (GP IIb/IIIa inhibitors, statins and ACE-inhibitors).20 Another important issue for 
advocating the use of health status assessment in clinical practice relates to the issue of 
discrepancy between patient-rated and physician-rated health-status.26 As clinicians frequently 
underestimate patients’ health status as reported by their patients27, it is paramount that patients’ 
evaluation of “how they feel” is taken into account. In addition, health status is an important 
patient-centered outcome, with patients emphasizing health status over prolonged survival. 14 
Hence, entering health status into the equation when discussing treatment options with patients 
may also be considered an ethical obligation.   
 Although this study clearly revealed that the EQ-5D provides prognostic information, 
little is known about the “how and why” impaired health status predicts mortality, independently 
of biomedical risk factors. It should be noted, however, that health status involves a much 
broader range of the impact of disease as experienced by the patient (i.e. symptoms, functional 
limitation, and discrepancy between actual and desired function) compared to the focus of 
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clinicians (i.e. symptoms, signs, and diagnosis).19 Further research is warranted into the 
mechanisms that may be responsible for the relation between health status and mortality, as this 
could guide treatment with- or the development of effective interventions. Emphasis should also 
be placed on the identification of the determinants of impaired health status, which has been 
advocated as a means to close the gap between research and clinical practice.17 Both depression 
and the distressed (Type D) personality have been shown to predict impaired health status 
adjusting for measures of disease severity and other risk factors.28,29 The question is whether these 
psychosocial risk factors are more important determinants of individual differences in clinical 
outcome than health status.   
 This study is the first to use the EQ-5D as a predictor of mortality. Although other 
generic and disease-specific health status questionnaires have been found to predict mortality, 
one of the major advantages of the EQ-5D is its brevity. It comprises only 6 questions, while 
most of the other questionnaires ask a multiplicity of questions (range 19 – 36) and are more 
taxing to patients.12,15,16,23 In addition, it is important to note that in patients with CAD a simple 
questionnaire like the EQ-5D is able to discriminate between patients who have a higher 
mortality risk and those who do not. In contrast, we acknowledge that a lack of familiarity with 
the concept of health status, the perception of many clinicians that health status is a soft 
endpoint in evaluating a treatment19, and the high workload of physicians in clinical practice may 
be identified as barriers for implementing self-perceived health status in every day clinical 
practice. It should be noted, however, that it takes less than 5 minutes to complete the 
questionnaire, and other health-care professionals than physicians can become involved in the 
assessment.      
 The current study has several potential limitations. First, patients who did not complete 
the EQ-5D questionnaire or who had missing follow-up data had to be excluded from analyses. 
However, a comparison between responders and non-responders did not reveal major 
differences. Second, it can not be excluded that ill health conditions, other than cardiovascular 
diseases, could have had an impact on the results, as only “classical” risk factors and co-
morbidities were included in the database. Third, health status was only assessed once, and at that 
time not all patients had undergone a revascularization procedure. Fourth, we used a generic 
rather than a disease-specific instrument to evaluate health status; it is well known that generic 
measures may be less sensitive than disease-specific to tap dimensions pertinent to clinical 
populations. Future research is needed to address issues like the predictive value of a single 
measurement as compared to serial measurements, the effect of changes in health-status over 
time on outcomes, and comparing the results of the EQ-5D with disease-specific instruments. 
Despite these limitations, strengths of this study were the relative large number of patients 
included from multiple hospitals across Europe. We were also able to adjust for a number of 
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classical demographic and cardiovascular risk factors, showing that impaired health status is an 
independent predictor for mortality. Lastly, the enrolled patients are representative of “real life” 
practice, across a wide spectrum of European hospitals. 
 In conclusion, this study demonstrated the strong incremental value of the EQ-5D for 
the prediction of mortality in patients admitted with CAD, independently of other 
demographical, clinical and angiographic risk factors. Our results highlight the importance of 
including patients’ subjective experience of their own health status in order to optimize risk 
stratification in clinical practice. 
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ABSTRACT 
 
Background: Although diabetes is known to be a major contributor to cardiovascular 
diseases, as well as an independent predictor for adverse outcomes in patients with coronary 
artery disease (CAD), information on the prognosis of patients with CAD and newly 
diagnosed diabetes or impaired glucose regulation is scarce. The objective of this study was to 
explore 1-year outcome in relation to different glucometabolic states of patients participating 
in the Euro Heart Survey on diabetes and the heart. 
 
Methods and results: In 4676 out of 4961 patients, information on the relation between 1-
year outcome and glucometabolic state, which was based on OGTT or fasting glucose plasma, 
was available. A normal glucose metabolism was identified in 947 patients, impaired glucose 
regulation (impaired fasting glucose or impaired glucose tolerance)) in 1116 patients, and 
diabetes in 1877 patients of whom 1425 were previously diagnosed and 452 newly diagnosed. 
736 patients could not be classified, as no OGTT or fasting plasma glucose was performed. 
Previously recognized and newly detected diabetes was associated with an increased risk of 1-
year mortality as compared to patients with normal glucose regulation (HR 2.4, 95%CI 1.5-3.8 
and HR 2.0, 95%CI 1.1-3.6, respectively). Impaired glucose regulation, however, could not be 
identified as an independent predictor for 1-year mortality (HR 1.1, 95%CI 0.6-1.9).  
 
Conclusions: This study confirmed that patients with CAD and known diabetes are at high 
risk for mortality and cardiovascular events and demonstrated that patients with newly 
diagnosed diabetes are at intermediate risk for adverse outcomes. Impaired glucose regulation, 
however, could not be identified as an independent predictor for adverse outcomes during the 
1-year follow up period. 
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INTRODUCTION 
Diabetes is a major contributor to cardiovascular diseases, including coronary heart, 
cerebrovascular, and peripheral artery disease, as well as an independent predictor for adverse 
outcomes in patients with coronary artery disease (CAD).1-5 In addition, modestly elevated 
levels of blood glucose below the level defined as diabetes have been identified as an 
independent cardiovascular risk factor6 and the GAMI study (Glucose tolerance in patients 
with Acute Myocardial Infarction) revealed that abnormal glucose tolerance is an important 
risk factor for future cardiovascular events after myocardial infarction.7 This is of major 
concern, as Norhammer et al.8 demonstrated that abnormal glucose regulation is present in 
most patients with CAD, a finding confirmed by the Euro Heart Survey on diabetes and the 
heart.9 Yet, information on the prognosis of patients with CAD and newly diagnosed diabetes 
or impaired glucose regulation, as compared to patients with known diabetes and those who 
have normal glucose regulation is lacking. 
   The Euro Heart Survey on diabetes and the heart was designed to assess the 
prevalence of diabetes and impaired glucose regulation in patients with CAD in clinical 
practice.9 This survey also included a 1-year follow-up providing a unique opportunity to 
explore 1-year outcome in relation to the different glucometabolic states of these patients. 
 
METHODS 
Euro Heart Survey on diabetes and the heart 
Between February 2003 and January 2004, 4961 patients from 110 hospitals in 25 member 
countries of the European Society of Cardiology were recruited to the Euro Heart Survey on 
diabetes and the heart after informed consent. The details of this survey have been described 
elsewhere.9 Briefly, all consecutive patients, admitted or visiting the cardiology outpatient 
clinic, were screened for a diagnosis of CAD. Clinical characteristics, treatment and results of 
tests (e.g. fasting glucose or OGTT) were collected in an electronic database. Patients were 
followed-up with respect to survival, cardiovascular procedures and events, and treatment for 
at least 1-year. 
 
Glucometabolic state 
Investigators were asked to provide measurements of fasting plasma glucose and Oral 
Glucose Tolerance Test (OGTT) in all patients without previously diagnosed diabetes. When 
an OGTT was available fasting plasma glucose obtained at that particular occasion was used 
for patient characterisation. Overall, fasting plasma glucose was measured in 2515 patients, an 
OGTT in 1819 patients, while in 736 patients without known diagnoses of diabetes no fasting 
plasma glucose or OGTT was measured. The results of the OGTT, or fasting plasma glucose 
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only when no OGTT was performed, was used to categorize patients as having “normal 
glucose regulation”, “impaired glucose regulation” (IGR), or “newly diagnosed diabetes” in 
accordance with the World Health Organization (WHO) 1999 definitions.10 Patients with a 
recorded history of diabetes were classified as “known diabetes” and those without FPG or 
OGTT as “not classified” (Table 1). IGR included impaired fasting glucose and impaired 
glucose tolerance. 
 
Statistical analysis 
Descriptive statistics included counts and percentages for categorical variables, and mean 
values with corresponding standard deviations for continuous variables. Differences between 
patients with and without follow-up information were analyzed by chi-square and Student’s t-
test. Kaplan-Meier curves were computed for all cause mortality and the composite endpoint 
of major cardiovascular events, including all cause mortality, myocardial infarction, and stroke. 
The Log rank test was used for comparing the differences in survival and cardiovascular 
events. Multivariable Cox proportional hazard modelling was used to analyse the association 
between glucometabolic state at survey entry and 1-year outcome. We adjusted for variables 
which reached a p-value of < 0.15 in the unadjusted analyses. These variables were age, 
gender, history of myocardial infarction, heart failure, peripheral vascular disease, stroke, 
hyperlipidemia, diagnosis at admission, and treatment with anti-thrombotic agents, lipid 
lowering drugs, and beta-blockers at discharge. Results are reported as Hazard Ratios (HR) 
with associated 95% confidence intervals (CI). The assumption of proportional hazards was 
assessed and satisfied by visual inspection of the log-log survival curves for the categorical 
Table 1. Classification of glucometabolic state 
  Glucose concentration, mmol/l (mg/dl) 
Glucometabolic state  OGTT FGP 
    
Normal glucose regulation   
 Fasting  < 6.1 (110) < 6.1 (110) 
 2hr post-load < 7.8 (140) -- 
Impaired glucose regulation (IGR)   
 Fasting  6.1 – 7.0  (126) 
or 
6.1 – 7.0 (126) 
 2hr post-load 7.8 – 11.0 (140-199) -- 
Newly diagnosed diabetes   
 Fasting  ≥ 7.0 (120) 
or 
≥ 7.0 (120) 
 2hr post-load > 11.0 (199) -- 
    
Known diabetes Previously diagnosed† Previously diagnosed†  
    
Patients “not classified” Unknown Unknown 
    
* FGP was used to classify patients only if no OGTT was available 
† no additional measurements  
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variables and by using the Schoenfeld residuals. For the continuous variable (age), we 
constructed age-groups and used a graphical approach to verify the linearity assumption. All 
analyses were carried out with SPSS statistical software version 12.01. A P-value (two-sided) of 
<0.05 was considered statistically significant.  
 As we used a combination of OGTT measurements and, when not available, fasting 
plasma glucose only, we acknowledge that our glucometabolic classification of patients may be 
challenged. Therefore, we repeated the analyses using only patients who were classified 
according to OGTT and patients who were classified by fasting glucose only. In addition, the 
reference group as used in the multivariable Cox proportional hazard modelling was based on 
patients with normal glucose regulation measured by either fasting plasma glucose only or 
OGTT. As we acknowledge that patients with normal fasting glucose in whom no OGTT 
measurement was performed may have impaired glucose tolerance, we repeated the analysis 
using only patients with OGTT measurement and normal glucose regulation as reference 
group (n=668). Since the results of the additional analyses were highly consistent, we only 
report on our original choice.  
 
 
RESULTS 
A total of 4961 enrolled the Euro Heart Survey on diabetes and the heart, of which follow-up 
information was missing in 285 patients (6%). Therefore, the total study population of the 
present study included 4676 patients. When comparing the clinical characteristics between 
patients who were lost to follow-up and those who were included in our analyses, no major 
differences were observed (mean age 65 versus 67 years, diabetes 30% versus 33%). Only the 
proportion of males differed between these two groups (70% versus 78%, respectively). 
 The median follow-up duration was 374 days (interquartile range: 366-397 days). 
Three-quarter of all patients with a known glucometabolic state (n=3940) appeared to have 
diabetes or an abnormal glucose regulation (Table 2), as diabetes was previously diagnosed in 
1425 patients, newly diagnosed in 452 patients, and an IGR was observed in 1116 patients. 
Only 947 of all patients who could be classified according to their glucometabolic state had a 
normal glucose metabolism. We were unable to classify 736 patients since no information on 
OGTT or FPG was available.  
 Differences in baseline characteristics between patients with different glucometabolic 
states are presented in Table 2. Patients with abnormal glucose regulation were older as 
compared to those with normal glucose regulation. Patients with previously diagnosed 
diabetes more often had a history of cardiovascular events and included more women as 
compared to the other patient groups (36% vs. 26-28%). The lowest prevalence of a 
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cardiovascular history was observed in patients with newly diagnosed diabetes (53% vs. 62-
78%). Conversely, these newly diagnosed diabetics were more likely to be admitted with an 
acute coronary syndrome (58% vs. 24-40%). At the time of discharge or after consultation on 
the outpatients, most patients were prescribed on anti-thrombotic drugs, lipid lowering drugs 
(of which in 97% a statin), beta-blockers and ACE inhibitor or angiotensin receptor blockers 
(Table 2). 
  
 
Outcome 
The worst outcome was observed in patients with known diabetes, as the mortality and 
incidence of myocardial infarction, and stroke were twice as high as in the other patients 
(Table 3). Patients with newly diagnosed diabetes clearly presented as an intermediate group 
with respect to outcome, as the 1-year mortality in these patients (5.5%) was in-between 
patients with known diabetes (7.7%) and patients with normal glucose regulation (2.2%), IGR 
Table 2.  Baseline characteristics in relation to glucometabolic state 
 All Normal IGR† DM 
new 
DM 
known 
Not 
classified 
 n=4676 n=947 n=1116 n=452 n=1425 n=736 
       
Age (mean, ±SD) 65 ±11 63 ±12 64 ±12 66 ±11 67 ±10 66 ±12
Males (%) 1398 (30)  704 (74) 807 (72) 332 (74) 907 (64) 528 (72)
    
Cardiovascular history (%) 3154 (68) 590 (62) 687 (62) 238 (53) 1068 (75) 571 (78)
  Myocardial infarction 2059 (44) 396 (42) 471 (42) 162 (36) 672 (47) 358 (49)
  Revascularization (PCI/CABG) 1699 (36) 319 (34) 363 (33) 115 (25) 510 (36) 392 (53)
  Congestive heart failure 1052(23) 165 (17) 208 (19) 71 (16) 468 (33) 140 (19)
  Peripheral artery disease 715 (15) 123 (13) 140 (13) 42 (9) 335 (24) 75 (10)
  Stroke 264 (6) 36 (4) 60 (5) 23 (5) 116 (8) 29 (4)
Risk factors (%)    
  Hypertension 3080 (66) 562 (59) 725 (65) 274 (61) 1111 (78) 408 (55)
  Hyperlipidemia 3617 (77) 747 (79) 887 (80) 323 (72) 1095 (77) 565 (77)
  Smoking (current) 989 (21) 244 (26) 259 (23) 116 (26) 216 (15) 154 (21)
  Family history of CAD 528 (43) 447 (47) 476 (43) 150 (33) 598 (42) 321 (44)
  Family history of diabetes 1188 (25) 154 (16) 212 (19) 97 (22) 622(44) 103 (14)
  Obesity (BMI ≥ 30) 1205 (26) 189 (20) 290 (26) 123 (27) 488 (34) 115 (16)
Diagnosis (%)    
  Acute coronary syndrome  1693 (36) 323 (34) 442 (40) 264 (58) 491 (35) 173 (24)
  Stable coronary artery disease 2040 (44) 469 (50) 474 (43) 143 (32) 539 (38) 415 (56)
  Heart failure 885 (19) 150 (16) 184 (17) 41 (9) 373 (26) 137 (19)
  Other 58 (1) 5 (1) 16 (1) 4 (1) 22 (2) 11 (2)
Medication at discharge (%)*       
  ASA/anti-thrombotic drug 4509 (96) 920 (97) 1079 (97) 437 (97) 1366 (96) 707 (96)
  Lipid lowering drugs 3740 (80) 758 (80) 921 (83) 359 (79) 1133 (80) 569 (77)
  Beta-blockers 3589 (77) 749 (79) 911 (82) 361 (80) 1040 (73) 528 (72)
  ACE-inhibitors/ARBs 3303 (71) 623 (66) 817 (73) 321 (71) 1161 (82) 381 (52)
    
† IGR= impaired glucose regulation   
* at discharge or after the index outpatient visit 
PCI= percutaneous coronary intervention, CABG= coronary artery bypass grafting, ARB= angiotensin receptor 
b k
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(2.7%) and those who could not be classified (3.7%).The highest incidence of the composite 
of mortality, myocardial infarction or stroke was also observed in patients with known 
diabetes (14.5%), followed by newly diagnosed diabetes (8.4%) and subsequently by the other 
subgroups (5.6-6.8%).  
 The Kaplan-Meier curves presenting time to mortality and the composite of mortality, 
myocardial infarction, or stroke over a 1-year period continuously diverged for patients with 
diabetes and those in the other glucometabolic states (Figure 1). Additionally, the curves also 
diverged for patients with known and newly diagnosed diabetes. Survival curves of patients 
with normal glucose regulation, IGR, or those who could not be classified were identical. 
Overall, log rank statistics showed significant differences in survival and survival free of 
myocardial infarction or stroke among the patient groups (p < 0.001). 
  
 After adjustment for a broad range of clinical and demographic characteristics (namely, 
age, gender, history of myocardial infarction, heart failure, peripheral vascular disease, stroke, 
hyperlipidemia, diagnosis at admission, and treatment with anti-thrombotic agents, lipid 
lowering drugs, and beta-blockers), both known diabetes and newly diagnosed diabetes 
remained associated with an increased risk of 1-year mortality (HR 2.4, 95%CI 1.5-3.8 and HR 
2.0, 95%CI 1.1-3.6, respectively). Patients with known diabetes also had an increased higher 
risk of myocardial infarction and stroke (Table 4). Patients with IGR, however, were not at 
higher risk of adverse outcomes as compared to patients with normal glucose regulation.  
Table 3.  Cumulative cardiovascular events during 1-year follow up in relation to glucometabolic state 
        
 All Normal IGR DM new DM known Not 
classified 
P for trend† 
 (n=4676) (n=947) (n=1116) (n=452) (n=1425) (n=736)  
        
Death (%) 212 (4.5) 21 (2.2) 30 (2.7) 25 (5.5) 109 (7.7) 27 (3.7) <.001 
Myocardial infarction (%) 153 (3.3) 24 (2.5) 28 (2.5) 14 (3.1) 76 (5.3) 11 (1.5) <.001 
Stroke (%) 97 (2.1) 9 (1.0) 19 (1.7) 6 (1.3) 50 (3.5) 13 (1.8) <.001 
Death, MI, or stroke (%) 419 (9.0) 53 (5.6) 71 (6.4) 38 (8.4) 207 (14.5) 50 (6.8) <.001 
Revascularization (%)* 673 (14.4) 131 (13.8) 188 (16.8) 75 (16.6) 191 (13.4) 88 (12.0) .38 
    
IGR= impaired glucose regulation 
† patients who could not be classified (n=736) were excluded from the analysis  
* Percutaneous coronary intervention or coronary artery bypass surgery 
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 In the methods section we acknowledged that our glucometabolic classification of 
patients may be challenged, and therefore performed analyses on the classification of patients 
according OGTT measurements or fasting glucose only. This additional analysis enabled us to 
look into more detail in patients with IGR. In 713 out of these 1116 patients an OGTT was 
performed, of whom 587 patients were known to have impaired glucose tolerance. Although 
we observed a higher prevalence of mortality, myocardial infarction and stroke in patients with 
impaired glucose tolerance (6%) as compared to those with impaired fasting glucose only 
(4%), neither of these glucometabolic states could be identified as an independent predictor 
for adverse outcomes (adjusted HR 1.7, 95%CI 0.7-4.5). 
 
Figure 1. 1-year follow-up outcome in relation to glucometabolic state.   
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Table 4. Relative risk of adverse outcomes at 1-year according to glucometabolic state† 
 Normal IGR† DM new DM known Likelihood 
ratio  
P value
 (n=947) (n=1116) (n=452) (n=1425) test (df=3)  
 Adjusted HR (95%CI)  
   Death  1.0 1.06 (0.61-1.85) 2.02 (1.12-3.63) 2.40 (1.50-3.84) 27.4 <.001 
   Myocardial infarction 1.0 0.88 (0.51-1.51) 1.03 (0.53-2.00) 1.64 (1.03-2.62) 10.4    .02 
   Stroke 1.0 1.71 (0.77-3.78) 1.48 (0.52-4.21) 2.79 (1.36-5.69) 11.4    .01 
   Death, MI, or stroke 1.0 1.02 (0.71-1.46) 1.30 (0.85-1.98) 1.95 (1.44-2.65) 33.5 <.001 
    
IGR= impaired glucose regulation MI= myocardial infarction 
† patients who could not be classified (n=736) were excluded from the analysis  
* adjusted for age, gender, history of myocardial infarction, heart failure, peripheral vascular disease, stroke, 
hyperlipidemia, diagnosis at admission, and treatment with anti-thrombotic drugs, lipid lowering drugs, and beta-
blockers. 
** the Likelihood ratio statistics with and without glucometabolic state
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DISCUSSION 
The main finding of the present study is that the presence of diabetes, known or previously 
unrecognized, is an independent predictor of adverse outcomes in patients with CAD. 
Impaired glucose regulation (IGR; i.e. impaired fasting glucose or impaired glucose tolerance), 
however, could not be identified as an independent predictor for adverse outcomes. 
 As shown previously9, abnormal glucose metabolism (i.e. diabetes or IGR) was 
frequently observed in patients with CAD who enrolled the Euro Heart Survey on diabetes 
and the heart. In only one-quarter of patients we observed a normal glucose regulation, 
whereas almost half of the patients had diabetes. Moreover, we confirmed that previously 
known diabetes was associated with an increased risk for adverse outcomes1-5, and found that 
newly diagnosed diabetes also had a negative influence on prognosis.  
 Patients with newly diagnosed diabetes clearly were more likely to be admitted with an 
acute coronary syndrome, whereas a cardiovascular history was seen less often as compared to 
the other glucometabolic states. This finding may be indicative for the fact that these patients 
are more vulnerable for a cardiovascular disease and acute coronary syndrome was the first 
manifestation of this disease.  
 In accordance with the WHO10 guidelines, the study protocol requested fasting plasma 
glucose and OGTT in all patients without previously diagnosed diabetes. A measurement of 
fasting glucose was performed in three-quarter of all these patients, while OGTT was 
performed in just over one half. Moreover, in 36% of the patients with IGR no OGTT was 
measured in order to exclude the diagnosis of diabetes, which is acknowledged as an 
important risk factor in patients with a cardiovascular disease. In the remaining 64%, the 
OGTT revealed that the majority of these patients had an impaired glucose tolerance. In 
contrast to the DECODE study11,12, we could not identify impaired glucose tolerance as a 
better predictor of mortality than impaired fasting glucose alone. It should be noted, however, 
that due to the relatively small numbers of patients with IGR, diagnosed by means of an 
OGTT, the failure to confirm a worse outcome for patients with impaired glucose tolerance 
may be due to a Type II error. Additionally, the follow-up period in our study was restricted to 
1-year, as compared to the median follow-up of almost 9 years in DECODE.12  
 Besides confirming that patients with previously known diabetes had an increased risk 
of death, myocardial infarction or stroke, we clearly identified patients with previously 
unrecognized diabetes as being at increased risk of major adverse events during the 1-year 
follow-up period. In contrast to the results of the GAMI-follow up trial7, no differences were 
observed in event rates between patients with normal glucose regulation and IGR. It should 
be noted, however, that all participants of the GAMI trial were admitted with an acute 
myocardial infarction and followed for almost 3 years, whereas the present study included a 
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heterogeneous group of patients with CAD, admitted on cardiology wards or visiting the 
cardiology outpatient clinics and followed them for only about 1-year. This period may be a 
too short to observe an increased risk for adverse events in patients with CAD and IGR.  
 Although IGR could not be identified as an independent predictor for adverse 
outcomes, it has been shown that IGR markedly increases the risk of developing diabetes.13,14 
It is even estimated that the annual incidence of evolving diabetes is between 6-12% in 
patients with impaired glucose tolerance.15,16 As diabetes is strongly associated with adverse 
outcomes, interventions aiming at delaying or preventing the onset of diabetes may prove 
beneficial for patients with IGR. Several studies have shown that lifestyle and pharmacological 
interventions are effective in delaying or preventing diabetes in patients with impaired glucose 
tolerance.16-18  
 Lifestyle changes aiming at preventing diabetes may also prove effective in modifying 
other risk factors like obesity, hypertension and dyslipidemia.19 Future research, however, is 
needed to study the effect of these interventions on adverse outcomes in patients with CAD 
and IGR. In addition to promoting lifestyle changes, a more aggressive pharmacological 
treatment of patients with diabetes is advocated, as a number of modifiable factors are known 
to contribute to the unfavourable prognosis of these patients.20,21 These factors include 
hyperglycaemia-induced endothelial cell dysfunction, increased pro-coagulation, impaired 
fibrinolysis, and dysfunctional arterial remodelling. Therefore, and in addition to good 
glycemic control, beta-blockers, anti-thrombotic drugs, statins and ACE-inhibitors should be 
considered in the pharmacological management of patients with established CAD and diabetes 
mellitus.20,22-24 Although many patients were treated with these advised drugs, there is still 
room for improvement.   
 Diabetes and IGR are also known to be associated with an increased risk of stroke.25 
Although we observed a higher incidence of stroke in patients with known diabetes, no 
association between newly detected diabetes and stroke was found in our database. It should 
be noted, however, that the lack of significant association with stroke may be due to a lack of 
power. Similarly, we found no significant association between IGR and stroke.  
 In conclusion, in this large population of patients with CAD we confirmed that 
patients with known diabetes are at high risk for mortality and cardiovascular events and 
demonstrated that patients with newly diagnosed diabetes are at intermediate risk for adverse 
outcomes. Impaired glucose metabolism, however, did not significantly increase 1-year 
mortality or cardiovascular events. It should be noted, however, that the follow up period was 
only 1 year. 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
INTRODUCTION 
Cardiovascular diseases are the main cause of mortality and loss of healthy life years in the 
western world and it is expected that this will remain so in the foreseeable future.1-3 Over the 
last decades, major advances have occurred in diagnostic techniques and powerful 
pharmacological and interventional therapies were introduced.4-7 In order to assist clinicians in 
every day clinical decision-making, evidence-based guidelines are prepared and published for 
appropriate use of diagnostic procedures and selection between patient management options. 
In these guidelines, randomized controlled trials (RCTs) are accorded the highest level of 
evidence. However, since RCTs have strict enrolment criteria, patients who participate in 
these trials often are a selected group that is only partly representative of patients seen in 
routine clinical practice. This limits the applicability of the results of RCTs in clinical practice.8-
12 Furthermore, the application of evidence-based guidelines in clinical practice may be 
hindered by physician related barriers (e.g. lack of agreement with the guidelines or lack of 
awareness) or  economic constrains.13,14 
  The Euro Heart Survey (EHS) programme, initiated by the European Society of 
Cardiology (ESC), and adopted by the Netherlands Heart Foundation (NHF-Health Care 
programme, 2000T101), provides a cross-sectional overview of the management of patients 
with cardiovascular diseases in routine clinical practice. This thesis addresses the results of 
three surveys of the EHS/ NHF-Health Care programme: Heart Failure, Coronary 
Revascularization, and Diabetes and the Heart. The main research questions in this thesis are 
closely related to the aims of the EHS programme, namely to evaluate to which extend every 
day clinical practice corresponds with evidence-based guidelines, to evaluate the 
generalisability of evidence-based guidelines, and to identify patients that are under-
represented in clinical guidelines.   
 
GUIDELINE-BASED MANAGEMENT 
Treatment of patients according to evidence-based guidelines is recommended by national and 
international societies, and have increasingly become a familiar part of clinical practice.15 Most 
guidelines offer concise evidence-based instructions on diagnostic and therapeutic strategies, 
and contain systematically developed statements to assist physicians in clinical decision 
making. Guidelines, therefore, can be regarded as an important tool for improving the quality 
of care.16  
 This thesis revealed that the recommendations of evidence-based guidelines were 
endorsed to a great extend. For example, the majority of patients with heart failure were 
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treated with the advised ACE-inhibitors and the selection procedure of patients with coronary 
artery disease (CAD) for revascularization was in accordance with the guidelines, as patients 
selected for surgery were sicker and had more extensive CAD. However, we also identified 
areas for improvement. Such as, the under-use of beta-blockers in patients with heart failure, 
and the observation that the doses of ACE-inhibitors and beta-blockers as given to these 
patients were lower than proven effective in RCTs. Withholding evidence-based drugs or 
treating patients with lower doses than proven beneficial may result in the loss of event-free 
life years as was visualized in the higher mortality rates in patients who were not treated 
according the guidelines and did not receive at least 50% of the recommended treatment dose. 
Additionally, we observed under-use of GP IIb/IIIa receptor blockers in high-risk patients 
undergoing PCI, as well as under-use of statins and ACE-inhibitors in patients with proven 
CAD. The documentation of investigations also revealed the under-use of diagnostic tools, 
like echocardiography in patients with suspected or proven heart failure, particularly in 
women, and measurements of post-procedural necrosis markers in PCI patients. The observed 
discordance between evidence-based guidelines and clinical practice highlights the importance 
of performing observational studies like the EHS, in order to identify specific areas for 
improvement. Emphasizing these areas for improvement in scientific meetings, medical 
journals and educational programmes may increase the higher awareness of clinicians of the 
need for treating all patients according the guidelines, which ideally leads to a higher standard 
of evidence-based care.17   
 The application of evidence-based guidelines in clinical practice may be hindered by 
economic constrains, lack of motivation to change current practice, lack of agreement with the 
guidelines, lack of awareness, or because the guidelines are not concise enough (difficult to 
use).13,14 Additionally, when evidence is contradictory, controversial or lacking, consensus 
procedures are used to formulate recommendations. These consensus procedures are prone to 
different interpretations, and consequently may result in inconsistencies between comparable 
guidelines.18 Guidelines also can become outdated, as the development of novel techniques or 
new drugs often do not follow the same timetable as scientific working groups who are 
involved in preparing and updating the guidelines. For example, the most recent ACC/AHA 
guidelines for PCI (2001) suggests that thrombolysis-facilitated primary PCI may offer 
additional clinical benefit for patients, while the recently updated ESC guidelines for PCI 
(2005) conclude that there is no evidence for recommending thrombolysis-facilitated primary 
PCI.19,20 Moreover, given the huge amount of published guidelines (over 100 in cardiology 
alone in the last 10 years)21, the available information may become unmanageable for 
clinicians. Another important barrier in following guidelines can be identified in the limited 
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generalisability of evidence-based guidelines, as most trials providing the evidence usually 
enrol highly selected patients.8-12  
 
GENERALISABILITY 
This thesis clearly showed that the generalisability of RCTs is of concern indeed, as many 
patients in clinical practice did not match the characteristics of patients who participated in 
landmark trials. The EHS data indicated that less than 10% within a target population could 
be considered as trial-eligible. Patients in clinical practice were older, more often had co-
morbid conditions, and were more likely to be treated with multi-pharmacy than clinical trial 
participants. As a result, the external validity of individual trials, enrolling highly selective 
patients, is questionable. However, when broader enrolment criteria are used, or a series of 
successive trials using different enrolment criteria it is to be expected that the external validity 
increases. For example, over the last 15-20 years, numerous ACE-inhibitor trials were 
performed, including most important subgroups of patients, resulting in a treatment benefit of 
ACE-inhibitors that is nowadays widely recognized as first-line treatment in all patients with 
left ventricular systolic dysfunction, unless patients are known to have contra-indications or 
side-effect. In contrast, treating heart failure patients with an aldosterone antagonist as is 
recommended in patients with advanced heart failure (NYHA III-IV), on top of ACE-
inhibitors and diuretics, was based on only one RCT22, and recently confirmed by a second 
trial.23 It should be noted that it is not a prerequisite of evidence-based guidelines to perform 
multiple RCTs, however, the results of a single RCTs only can be translated to a group of 
patients with comparable clinical characteristics.     
 While advocating guideline-based management, it is important to note that guidelines 
cannot be applied to all individual patients.21 Treating patients is more complex than simply 
following the guidelines, because co-morbidities, individual reactions to administered 
medication, observed side-effects, interaction with co-medications, as well as different 
treatment goals for individual patients can effect management decisions. At the other hand, if 
patients do fulfil the enrolment criteria of landmark trials that are included in the guidelines, it 
is to be expected that the majority of these patients can and should be treated in accordance 
with these guidelines. Although large groups of patients were treated according to the 
guidelines, this thesis also demonstrated under-utilization of evidence-based drugs (e.g. ACE-
inhibitors) in patients who fulfilled enrolment criteria of RCTs. Under-utilization of evidence-
based drugs in patients with heart failure was even more prominent in women than in men, 
indicating a gender difference in treating patients. Guidelines, however, do not discriminate 
between men and women, although women are often under-represented in RCTs. 
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UNDER-REPRESENTED SUBGROUPS 
This thesis revealed information on subgroups of patients who were under-represented in 
RCTs, such as women with heart failure, heart failure patients with preserved left ventricular 
function, and patients with proven CAD who were considered ineligible for revascularization. 
Recognizing patient groups that are under-exposed in the guidelines is important, as this can 
(re-)direct the work of investigators and encourage funding to support studies that limit the 
identified flaws in the available guidelines.15 Although the results of observational databases 
are prone to selection bias, they may be helpful in providing a broader understanding of the 
effectiveness of a treatment in populations that are underrepresented in clinical trials. Clearly, 
these observations deserve confirmation in randomised trials.  
 A major consequence of being underexposed in RCTs is the lacking evidence of 
treatments that have proven to be beneficial for subgroups of patients. For example, 
treatment recommendations are scarce and highly speculative in heart failure patients with 
preserved ventricular function.24,25 Although most of cardiovascular drugs have only proven 
beneficial in heart failure patients with a depressed ventricular function, we observed similar 
treatment effects, irrespective of depressed or preserved ventricular function. Before 
recommending these drugs in patients with preserved ventricular function, RCTs are needed 
to confirm the observed findings. This clearly indicates that more trials are needed in patients 
with preserved systolic ventricular function to provide sufficient evidence to provide 
evidence-based guidance in treating these heart failure patients.  
 In addition to the observation that evidence-based guidelines are lacking in patients 
with preserved ventricular function, we observed that the majority of these patients are 
women. Women respond differently to a specific treatment than men as was illustrated by the 
gender-specific differences in the treatment effect of platelet glycoprotein IIb/IIIa inhibitors 
in acute coronary syndromes26 and aspirin in primary prevention.26,27 Additionally, the Digitalis 
Investigation Group trial showed that treatment with digoxine was associated with an 
increased risk of all-cause mortality among women, but not men.28 These observations 
indicate that we always should be aware of possible gender differences in the treatment effect 
of cardiovascular drugs and the additional value of meta-analyses in providing a more reliable 
estimate of the treatment effect of subgroups that can be identified as being under-
represented.  
  We identified a large proportion of patients with angina pectoris who were considered 
ineligible for revascularization. These patients reported a worse health status, failed to show an 
improvement over time, and had higher 1-year mortality rates as compared to patients in 
whom revascularization was the preferred treatment option. Although it is to be expected that 
these patients have worse outcomes, mortality rates are not excessively high in this subgroup 
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of patients who may consider themselves at the “end of the line”.29 In addition to optimizing 
pharmacological treatment, it is important to address issues like treatment adherence, physical 
training, life style, psychosocial adaptation, patients-tailored education (for example, how to 
use nitroglycerine as prophylactic drug before doing physical activities), etc. in order to refute 
the misconception and maladaptive beliefs of having no treatment options.29-31 As cardiac 
rehabilitation programmes address most of the above mentioned topics and have proven to 
increase the health-related quality of life in these patients who are left with limited curative 
treatment options, we would like to encourage clinical practice to implement cardiac 
rehabilitation programmes for patients who are left with limited curative treatment options. 
However, further research is needed to reveal whether these rehabilitation programmes can 
fulfil the potential to substantially improve outcomes in these patients.     
 
MORTALITY AND HEALTH STATUS 
Major improvements in the management of patients with cardiovascular diseases have been 
realised in the last decades. The effectiveness of these beneficial treatment strategies is 
demonstrated by reduced mortality rates in RCTs. Regarding mortality and clinical practice we 
also observed an improved survival in patients who were treated according to the guidelines. 
For example, patients with depressed ventricular function, who were treated with ≥ 50% of 
the advised dose of ACE-inhibitors, had a lower mortality as compared to patients who 
received a lower dose or no ACE-inhibitor.  
 In contrast to confirming earlier observations that the presence of known or newly 
diagnosed diabetes was an independent predictor for adverse outcomes in patients with CAD, 
impaired glucose metabolism could not be identified as an independent predictor for 1-year 
mortality or cardiovascular events. It should be noted, however, that we followed these 
patients for not more than about 1-year, a period that may be too short to observe an 
increased risk for adverse events in patients with CAD and impaired glucose metabolism. 
Although impaired glucose metabolism could not be identified as an independent risk factor, 
interventions aiming at delaying or preventing the onset of diabetes in patients with impaired 
glucose metabolism may prove beneficial as the presence of diabetes clearly is associated with 
adverse outcomes.       
 In addition to analysing in-hospital and short-term mortality (3 month and/or 12 
month), a health-related quality-of-life questionnaire was included in a number of surveys of 
the EHS programme. Measuring patients’ health status is becoming an important outcome 
variable in clinical trials, as the observed differences in mortality between competitive 
treatment options diminishes.32-34 This thesis confirmed the additional value of patient-
reported health status in patients with CAD. Impaired health status at baseline was associated 
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with an increased risk of mortality, independent of conventional risk factors. In addition, 
others have identified self-perceived health status as an important patient-centered outcome 
and subsets of patients are known to prefer health status over prolonged survival.35 These 
issues highlight the additional value of including patients’ subjective experience of their own 
health status, by means of a short questionnaire, in order to optimize risk stratification and 
patient management in clinical practice. 
 
LIMITATIONS  
Several limitations should be taken into account when interpreting our results. It should be 
noted that the currently applied methodology in the EHS programme is prone to information 
and selection bias. For instance, hospitals participated voluntarily and participating hospitals 
did not resemble an equal geographical distribution. Additionally, the type of hospitals also did 
not fully represented clinical practice, as high proportions (30-40%) of university hospitals 
participated in the survey programme. As it was to be expected that university hospitals were 
more likely to participate, hospitals have been organised into clusters. A cluster is therefore 
composed of academic and non-academic hospitals, with and without cardiac catheterization 
laboratories and cardiac surgery facilities. Nevertheless, because patient inclusion was 
consecutive and a wide spectrum of hospitals in different countries participated, almost 
certainly the results are biased towards better than average practices. Another important 
limitation was the absence of o-site monitoring and source document verification. However, 
data-quality was checked electronically through queries for missing data.  
 Although we observed that many patients in clinical practice were treated in 
accordance with guidelines, areas for improvement were identified, including the 
incompleteness of the guidelines. Within the current survey programme, however, only limited 
data were available on the decision making process and reasons for not performing or not 
prescribing evidence-based treatment was underexposed. Adding this information to future 
survey programmes would reveal even more important information.  
 We acknowledge that data quality of a survey programme can hardly compete with the 
data quality of RCTs, but this was never intended. The EHS programme was developed to 
collect data on patient management as observed in clinical practice, and not to identify small 
differences between an experimental and control group as is done in RCTs. Another 
important difference between these two research designs is related in the different financial 
structures. Most RCTs are industry sponsored and physicians frequently receive payment for 
enrolling patients onto clinical trials (costs between €5000 and €10,000 per patient), whereas 
physicians involved in the EHS programme did not receive any payment for their effort and 
overall costs were less than €500 per patient.36  
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FINAL COMMENTS AND FUTURE DIRECTIONS 
Observing every day clinical practice, as was done in the EHS programme, has proven to be 
feasible and valuable. The EHS programme provided a cross-sectional overview of current 
practice in Europe and can serve as benchmark for future evaluation when surveys are 
repeated. The value of doing repeated surveys was proven by EuroAspire-II revealing the 
increased use of ACE-inhibitors, beta-blockers, and lipid-lowering drugs in comparable 
patients over time.37 Furthermore, participating hospitals taught us that they would welcome a 
system of benchmarking. Since the end of 2005 the EHS programme indeed supports a 
benchmark system in which participating hospitals get feedback on a regular basis and can 
compare these results with the mean of the other participating hospitals. It would be 
interesting to study the effect on guideline-based patient management and patient outcome 
when hospitals can compare themselves with peers (nationally and internationally).  
 Unfortunately, data as gathered in observational studies or registries throughout 
Europe do not always use identical items and definitions. For this reason the ESC recognized 
the importance of using data standards, throughout all ESC member countries. This resulted 
in the development and launch of the Cardiology Audit and Registration Data Standards 
(CARDS) in 2005. Since the launch of CARDS, these standardized data collection is 
implemented in the EHS programme, a number of national registries, and hospital registration 
systems. 
 Although guidelines are developed to assist clinicians in every day clinical decision-
making, it should be noted that the development of guidelines can hardly compete with the 
speed of the development of pharmacological or interventional therapies. This discrepancy 
may lead to outdated guidelines, and consequently lack of enthusiasm to use treat patients 
accordingly. As discussed previously, the huge amount of existing guidelines may even 
become unmanageable for clinicians. We therefore advocate constructing a valid system of 
continuous updating guidelines and the implementing of such a system.  
 When international and national societies, governments, and information technology 
specialists co-operate in providing up-to-date evidence-based guidelines to clinicians in every 
day clinical practice, a major hurdle is taken in building a Cardiology Information System 
(CIS).38 A CIS integrates all relevant sources of information (e.g. patient care, observational 
data, and the knowledge base), as is visualized in figure 1. This more than 30 years old dream 
of the ESC38, however, is not realized yet. In this respect, we also would like to discuss the use 
of systematic verification of patient management by using a checklist. The positive effect of 
using a disease specific checklist in patients admitted with an acute myocardial infarction has 
been proven in the Guidelines Applied in Practice (GAP) project.39 When initiatives like the 
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Figure 1.  The different sources of information needed for an integrated CIS38 
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GAP project could be integrated in the CIS and implemented in clinical practice, another step 
is taken in improving the application and applicability of evidence-based guidelines. This, 
however, warrants further research on how to build a user-friendly information system that 
not only registers patient-related information, but also provides the treating physician with the 
latest knowledge on evidence-based treatment for the individual patient.  
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The main research questions in this thesis correspond to those of the Netherlands Heart 
Foundation (NHF)-Health Care programme and were closely related to the aims of the Euro 
Heart Survey (EHS) programme, namely to evaluate to which extend every day clinical 
practice corresponds with evidence-based guidelines and to evaluate the generalisability of 
evidence-based treatment.   
 The EHS is initiated by the European Society of Cardiology (ESC) and recognized by 
the Netherlands Heart Foundation, resulting in a combined EHS and Netherlands Heart 
Foundation - Health Care programme. Since the start of the EHS programme in 1999, up to 
the end of 2006, over 80,000 patients have been included.  These surveys provided systematic 
information on various groups of patients with cardiovascular diseases. In this thesis we 
present the results of three surveys, namely Heart Failure, Coronary Revascularization, and 
Diabetes and the Heart.   
 Our observations in the EHS on Coronary Revascularization showed a clear 
preference of percutaneous coronary intervention (PCI) over coronary bypass surgery 
(CABG) and pharmacological treatment after coronary angiography in clinical practice 
(chapter 2). In line with the guidelines, patients selected for CABG had more extensive 
coronary artery disease, and more often co-morbid conditions as compared to patients 
undergoing PCI. However, a sizeable proportion of patients with multivessel disease or left 
main, heart failure or diabetes did not undergo CABG but underwent PCI or were treated 
medically. We identified the under-use of adjunctive pharmacology, including GP IIb/IIIa 
inhibitors at time of intervention, statins and ACE-inhibitors as secondary prevention, as main 
areas for improvement in patient care. Yet, we confirmed that the recommendations of 
guidelines were applied in the majority of patients with proven coronary artery disease who 
underwent an invasive coronary procedure.  
 The comparison of patients with coronary artery disease from clinical practice (EHS 
on Coronary Revascularization) with patients who participated in 14 major randomised 
controlled trials (RCTs) comparing PCI with CABG revealed that almost two-third of patients 
as seen in clinical practice would have been disqualified for trial participation (chapter 3). 
Important differences were observed between trial participants and survey patients.  Patients 
in clinical practice were older, more likely to have co-morbidity and left main stenosis, but less 
often multi-vessel disease as compared to trial participants. Although we observed important 
differences in clinical characteristics, the outcomes with respect to repeat revascularization and 
mortality of patients who underwent PCI or CABG in clinical practice were identical to those 
of the RCTs comparing PCI with CABG. 
 In addition to the observed differences between clinical practice and RCT participants 
in patients with coronary artery disease, we confirmed similar differences in patients with heart 
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failure (chapter 4). In this study we selected three landmark trials in which ACE-inhibitors, 
beta-blockers, and spironolactone proved to be save and effective. After identifying the major 
enrolment criteria, we identified patients who fulfilled the criteria of the SOLVD (ACE-i), 
MERIT-HF (beta-blocker), and RALES (spironolactone) trials. Only a small percentage (5-
9%) of the patients enrolled in the EHS on Heart Failure would have qualified for one of 
these three trials. These trial-eligible patients were more likely to be treated with ACE-
inhibitors, beta-blockers, and spironolactone than patients who did not fulfil the enrolment 
criteria. While the majority of trial-eligible patients who were treated with ACE-inhibitors 
received at least half of the target dose, only 20% of the patients treated with beta-blockers 
received at least half of the target dose.  
 It is important to note that guidelines do not provide recommendations for all 
subgroups of patients with heart failure. In particular, the guidelines for the treatment of 
patients with heart failure primarily focus on those with left ventricular systolic dysfunction 
(LVSD). Yet, almost half of all heart failure patients showed to have a preserved left 
ventricular function (PLVF). Treatment of these patients remains mainly speculative, as 
scientific evidence regarding treatment of heart failure patients with PLVF is scarce. In 
chapter 5, we evaluated patient characteristics and management of this major subgroup of 
heart failure patients. As compared to patients with LVSD, those with PLVF were older and 
more often women. Cardiovascular medication was given less often to patients with PLVF, 
with the exception of calcium antagonists. When comparing the treatment effect of 
cardiovascular drugs on mortality in patients with LVSD and PLVF, we could not identify 
significant differences. It should be noted, however, that this observation does not mean that 
patients with PLVF will derive the same benefit from pharmacological treatment as those with 
LVSD. This deserves confirmation in randomised trials. Although mortality was higher in 
patients with LVSD, it is important to note that mortality was high in both groups. 
 We expressed our concerns about the under-representation of women with heart 
failure in RCTs. In chapter 6 we analyzed gender differences in patients with confirmed or 
suspected heart failure. The results of this study confirmed that women with heart failure have 
a different clinical profile as compared to men, which remained statistically significant after 
adjusting for age. Furthermore, we observed that women were less often admitted on 
cardiology wards, were less likely to undergo an assessment of the left ventricular function, 
and were treated less frequently with drugs as advised in the guidelines. These differences also 
remained significant after adjusting for age. Despite the fact that women had a better clinical 
profile, outcomes with respect to mortality were similar in men and women. 
 In chapter 7 we evaluated the differences in clinical characteristics, management, and 
outcome of another group of patients identified as under-represented in the guidelines, namely 
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those with proven coronary artery disease who were considered ineligible for 
revascularization. Out of 4409 patients with angina pectoris, who enrolled the EHS on 
Coronary Revascularization, we identified 632 patients who were ineligible for 
revascularization. As compared to patients who were eligible for revascularization, we 
observed a worse clinical risk profile and more total occlusions in patients who were ineligible 
for revascularization. These patients had higher mortality rates at 1 year (7% vs. 3.7%), 
reported more problems on the EQ-5D health status questionnaire, and no showed no 
improvement in health status between discharge and 1-year follow-up. In contrast, a 
significant improvement was observed in the health status of patients who underwent 
revascularization between discharge and 1-year follow-up. Given these observations, we 
discussed the additional value of nurse-led multi-disciplinary rehabilitation programmes in 
improving perceived and actual health outcomes. 
 We also discussed the additional value of the EQ-5D in predicting 1-year mortality in 
patients with coronary artery disease undergoing an angiographic procedure (chapter 8). 
Impaired health status at baseline was associated with a 2-3 fold risk of all-cause mortality in 
patients with coronary artery disease, and after adjusting for other prognostic factors remained 
an independent risk factor for 1-year mortality. These findings support initiatives to include 
health status measurements when evaluating patients, in addition to other traditional risk 
factors as a tool to identify patients who are at high risk for adverse outcomes.  In chapter 9, 
we discussed the glucometabolic status in relation to the 1-year mortality in patients with 
coronary artery disease. In addition to confirming that case-fatality is highest in patients who 
were known to have diabetes, we clearly identified patients with previously unrecognized 
diabetes as being an intermediate group for developing major adverse events. Impaired 
glucose metabolism, however, we could not identify as an independent predictor for 1-year 
mortality or cardiovascular events in patients with coronary artery disease.  
 Finally (chapter 10), we concluded that observational studies like the EHS have 
proven to be feasible and valuable. In addition to clarifying whether patients were treated 
according the guidelines, this thesis revealed subgroups of patients that were under-
represented in clinical trials and consequently are left without evidence-based guidelines. 
These observations indicate areas for further research. To further improve quality of care, the 
co-operation of national societies, information specialists and governments in providing up-
to-date evidence-based guidelines to clinicians in every day clinical practice is crucial. The 
“Cardiology Information System” as well as the “Guidelines Applied in Practice project” may 
prove valuable in improving the application and applicability of evidence-based guidelines. 
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De laatste decennia is er grote vooruitgang geboekt bij de behandeling van patiënten met een 
cardiovasculaire aandoening. Om clinici van dienst te zijn bij het nemen van beslissingen over 
de beste behandeling voor hun patiënten, worden door onder andere de European Society of 
Cardiology (ESC) richtlijnen ontwikkeld en verbeterd. In dit proefschrift staat het evalueren 
van bestaande richtlijnen en de mate waarin de resultaten van grote klinische studies 
generaliseerbaar zijn naar de dagelijkse praktijk centraal. Deze evaluatie is één van de 
belangrijkste doelstellingen van het Euro Heart Survey  (EHS) programma. 
 Het EHS programma is een door de ESC geïnitieerd observationeel 
onderzoeksprogramma, waarvan het belang door de Nederlandse Hartstichting wordt 
onderschreven. Dit resulteerde in 2001 tot de lancering van het gezamenlijke EHS/ 
Nederlandse Hartstichting-Zorgprogramma in Nederland. In dit survey programma wordt op 
een systematische wijze een veelheid aan gegevens in kaart gebracht over diagnostiek, 
behandeling en uitkomsten van patiënten met verschillende cardiovasculaire ziektebeelden. 
Sinds de start van het EHS programma in 1999 zijn meer dan 80.000 patiënten (eind 2006)  uit 
meer dan 30 bij de ESC aangesloten landen geïncludeerd. In dit proefschrift worden de 
resultaten gepresenteerd van drie verschillende surveys, namelijk de EHS-Heart Failure, EHS-
Coronary Revasculaization en de EHS-Diabetes and the Heart.  
 De EHS-Coronary Revascularization laat zien dat er in de klinische praktijk een 
duidelijke voorkeur bestaat voor percutane coronaire interventies (PCI) boven coronaire 
bypass operaties (CABG) en medicamenteuze behandeling bij patiënten met een coronaire 
hartziekte (hoofdstuk 2). In overeenstemming met de richtlijnen, hadden bypass patiënten 
een uitgebreidere vorm van coronairsclerose en meer comorbiditeit in vergelijking met PCI 
patiënten. Wel dient te worden opgemerkt dat een aanzienlijk aantal patiënten met 
meervatslijden, een hoofdstamleasie, hartfalen of diabetes niet werden geopereerd maar een 
PCI ondergingen of medicamenteus werden behandeld. Een aantal behandelingsstrategieën 
werden geïdentificeerd die voor verbetering vatbaar zijn, waaronder het toedienen van GP 
IIb/IIIa antagonisten tijdens de PCI en het voorschrijven van statines en ACE-inhibitors als 
onderdeel van secundaire preventie. Ondanks deze punten die voor verbetering vatbaar zijn, 
kan geconcludeerd worden dat de overgrote meerderheid van patiënten met een coronaire 
hartziekte volgens richtlijnen werden behandeld. 
 Een vergelijking tussen patiënten met een coronaire hartziekte uit de dagelijkse praktijk 
en patiënten uit 14 gerandomiseerde studies (PCI versus CABG) maakt duidelijk hoe 
geselecteerd deze laatste groep patiënten is (hoofdstuk 3). Immers tweederde van de patiënten 
uit de dagelijkse praktijk komt niet in aanmerking voor deelname aan deze studies. 
Voornamelijk leeftijd, het voorkomen van co-morbiditeit, aantal zieke coronair arteriën en het 
hebben van een hoofdstamleasie verschilde tussen studiepatiënten en patiënten uit de 
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dagelijkse praktijk. Ondanks deze belangrijke verschillen, laten de uitkomsten (noodzaak voor 
een herhalingsinterventie en mortaliteit) geen grote verschillen zien tussen studiepatiënten en 
patiënten uit de dagelijkse praktijk. 
 Dat verschillen tussen patiënten uit de dagelijkse praktijk en patiënten die deelnemen 
aan gerandomiseerde studies zich niet alleen beperken tot patiënten met een coronaire 
hartziekte, wordt duidelijk in hoofdstuk 4. In dit hoofdstuk zijn drie belangrijke 
gerandomiseerde studies (RCT’s) bij patiënten met hartfalen geselecteerd die het gunstige 
effect van een ACE-inhibitor, betablokker, en spironolactone op mortaliteit hebben 
aangetoond, te weten de SOLVD, de MERIT-HF en RALES. Vervolgens zijn survey 
patiënten geïdentificeerd die voldeden aan de belangrijkste in- en exclusie criteria van deze 
studies. Uiteindelijk bleek minder dan 10% (5-9%) van de survey patiënten in aanmerking te 
komen voor deelname aan één van deze RCT’s. Deze zogenaamde “trial-eligible” patiënten 
werden vaker behandeld met een ACE-inhibitor, beta-blokker en spironolactone dan 
patiënten die niet voldeden aan de studie criteria. De meeste trial-eligible patiënten die 
behandeld werden met een ACE-inhibitor werden met minimaal de helft van de aanbevolen 
dosering behandeld. Van de trial-eligible patiënten die met een beta-blocker behandeld werd 
kreeg slechts een minderheid (20%) minimaal de helft van de aanbevolen dosering.  
 Dat richtlijnen niet van toepassing blijken te zijn op alle patiënten is ook een belangrijk 
gegeven dat we in ogenschouw dienen te nemen. De richtlijnen bij patiënten met hartfalen 
richten zich vooral op patiënten met een linker ventrikel systolische disfunctie (LVSD). In de 
dagelijkse praktijk blijkt echter dat bijna de helft van alle hartfalen patiënten geen LVSD heeft, 
maar dat er sprake is van een behouden systolische ventrikel functie (PLVF). Helaas is er voor 
deze groep patiënten amper sprake van een wetenschappelijk onderbouwde behandeling. In 
hoofdstuk 5 gaan we hier verder op in. Patiënten met een LVSD zijn jonger en vaker man in 
vergelijking met patiënten met een behouden ventrikel functie. Cardiovasculaire medicatie 
werd minder vaak voorgeschreven aan patiënten met PLVF, met uitzondering van calcium 
antagonisten. Overigens konden we bij de meeste cardiovasculaire medicijnen geen verschil in 
effect op mortaliteit aantonen tussen patiënten met een LVSD en PLVF. Wel is het belangrijk 
om hierbij te melden dat op basis van deze observationele studie niet geconcludeerd mag 
worden dat hartfalen patiënten met een behouden systolische ventrikel functie op eenzelfde 
wijze profiteren van deze cardiovasculaire medicatie. Hiervoor is het van groot belang dat de 
resultaten in een gerandomiseerd onderzoek worden bevestigd. Tot slot dient hier te worden 
opgemerkt dat hartfalen patiënten een slechte prognose hebben, ongeacht het hebben van een 
gestoorde of behouden systolische ventrikel functie.  
 In hoofdstuk 6 wordt ingegaan op de ondervertegenwoordiging van vrouwen bij 
gerandomiseerde studies met hartfalen patiënten. Een belangrijke bevinding in dit hoofdstuk 
Samenvatting 
 
 165
betreft de constatering dat vrouwen minder vaak op cardiologische afdelingen werden 
opgenomen, minder vaak een diagnostisch onderzoek naar de ventrikelfunctie werd verricht 
en minder vaak volgens richtlijnen werden behandeld. Al deze verschillen bleven bestaan na 
een correctie voor verschillen in leeftijd. Het feit dat vrouwen een beter klinisch profiel 
hadden dan mannen, werd niet vertaald naar een betere uitkomst. Vrouwen hadden geen 
lagere mortaliteit dan mannen.  
 Een andere ondervertegenwoordigde groep betreft patiënten met een coronaire 
hartziekte die niet (meer) in aanmerking komen voor een coronaire revascularisatie 
(hoofdstuk 7). Veertien procent van de patiënten met angina pectoris die werden 
geïncludeerd in de EHS-Coronary Revascularization konden worden geïdentificeerd als 
inoperabel. In vergelijking met patiënten die een PCI of CABG ondergingen, hadden 
inoperabele patiënten een ongunstiger risicoprofiel (waaronder meer co-morbiditeit) en vaker 
een totale occlusie van minimaal één coronair arterie. Inoperabele patiënten hadden een hoger 
risico op overlijden (na 1 jaar 7% vs. 3.7%), rapporteerden meer problemen op de EQ-5D 
vragenlijst (kwaliteit van leven/ gezondheidsstatus) en lieten hierbij geen verbetering zien 
tussen ontslag en 1 jaar follow-up. Op basis van deze bevindingen wordt in dit hoofdstuk 
nader ingegaan op de aanvullende waarde die het opzetten van een multidisciplinair revalidatie 
programma kan hebben, waarin gespecialiseerde verpleegkundigen een centrale rol vervullen. 
 Het gebruik van vragenlijsten die de kwaliteit van leven/ gezondheidsstatus meten, 
zoals de EQ-5D, wordt ook in hoofdstuk 8 besproken. Patiënten die een invasieve coronaire 
procedure hebben ondergaan in verband met een coronaire hartziekte blijken een 2-3 maal 
grotere kans op overlijden te hebben wanneer ze tijdens opname op deze vragenlijst invullen 
dat er sprake is van een gezondheidsprobleem. Zelfrapportage van gezondheidsproblemen 
blijkt dan ook een onafhankelijke voorspeller te zijn voor mortaliteit. Op grond van deze 
resultaten wordt nader ingegaan op de mogelijkheden en het belang van het meten van de 
gezondheidstoestand in de dagelijkse praktijk om patiënten vroegtijdig te identificeren die een 
hoger risico lopen op overlijden. 
 De laatste survey waaraan in dit proefschrift aandacht wordt geschonken betreft de 
EHS-Diabetes and the Heart (hoofdstuk 9). Het merendeel van de patiënten met een 
coronaire hartziekte die in deze survey werden geïncludeerd blijkt een gestoorde glucose 
huishouding te hebben. De hoogste mortaliteit werd geobserveerd bij patiënten die al langer 
bekend zijn met diabetes, gevolgd door patiënten bij wie de diagnose diabetes tijdens de 
initiële opname werd gesteld. Licht verhoogde glucosespiegels, waarbij de criteria van diabetes 
niet werden gehaald, bleek niet te resulteren in een slechtere prognose. Wel moet hier worden 
opgemerkt dat de duur van de follow-up periode slechts één jaar was, wat mogelijk tekort is 
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om een verschil aan te tonen tussen patiënten met een normale en een licht gestoorde glucose 
huishouding.  
 In het laatste hoofdstuk (hoofdstuk 10) van dit proefschrift, wordt nader ingegaan op 
de bevindingen van de afzonderlijke hoofdstukken. Op basis van de onderzoeksresultaten, 
zoals besproken in deze hoofdstukken, wordt geconcludeerd dat observationele studies zoals 
het EHS programma niet alleen haalbaar zijn, maar ook een waardevolle aanvulling zijn op 
RCT’s. Behalve het evalueren van bestaande richtlijnen in de dagelijkse praktijk, wordt ook 
aandacht geschonken aan de ondervertegenwoordiging in RCT’s van belangrijke subgroepen. 
Een belangrijk gevolg hiervan is het ontbreken van wetenschappelijk gefundeerde richtlijnen 
voor deze patiënten. Het wijzen op deze lacunes kan een stimulans zijn voor het initiëren van 
aanvullend onderzoek met als belangrijkste doel het genereren van kennis om óók deze 
patiënten een op wetenschappelijk onderzoek gebaseerde behandeling te kunnen aanbieden. 
Verder wordt in dit hoofdstuk ingegaan op het belang van een goede samenwerking tussen 
beroepsverenigingen, informatie specialisten en overheden om clinici van actuele en 
betrouwbare informatie te voorzien waarmee ze de aan hun zorg toevertrouwde patiënten zo 
optimaal mogelijk kunnen behandelen. Zowel het “Cardiology Information System” als het 
“Guidelines Applied in Practice project” zijn voorbeelden van projecten die de toepasbaarheid 
en toepassing van richtlijnen in de dagelijkse praktijk kunnen helpen verbeteren. 
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De totstandkoming van een proefschrift is het resultaat van de inspanning van velen. Graag 
wil ik iedereen die hieraan heeft bijgedragen bedanken. In dit dankwoord wil ik graag een 
aantal van deze mensen persoonlijk bedanken.  
 Allereerst wil ik mijn promotor prof.dr. M.L. Simoons bedanken. Beste Maarten, ik 
ervaar het als een voorrecht om bij jou te mogen promoveren. Hartelijk dank voor dit 
vertrouwen. Je hebt me niet alleen de kans gegeven om als verpleegkundige aan een 
promotietraject te beginnen, je hebt met veel betrokkenheid mijn vorderingen gevolgd. Ik 
waardeerde je kritisch commentaar en ideeën voor het doen van (aanvullende) analyses en 
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schrijven aan ons artikel heb ik me niet alleen zeer welkom gevoeld, ik heb deze momenten 
ook als zeer leerzaam ervaren. Hartelijk dank hiervoor. 
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Stellingen behorende bij het proefschrift: 
 
“Evaluating the Application and Applicability of Treatment Guidelines in Daily Clinical Practice.  
Closing the loop with the Euro Heart Survey programme” 
 
 
1. De mogelijkheid tot medicamenteuze beïnvloeding van cardiovasculaire ziektebeelden 
wordt niet ten volle benut  
2. Protocollair ziek zijn is geen garantie voor een protocollaire behandeling  
3. Een gelijke behandeling van mannen en vrouwen met een cardiovasculaire ziekte is geen 
vanzelfsprekendheid 
4. Kwaliteit van leven is een factor om rekening mee te houden  
5. Observationele studies zijn een waardevolle aanvulling op gerandomiseerde klinische 
trials 
 
6. Om selectiebias te reduceren worden patiënten geselecteerd 
7. Gespecialiseerde verpleegkundigen zijn uitstekend toegerust om de coördinatie van zorg 
rondom een patiënt te verbeteren. 
8. De behoefte van mensen aan zekerheid en de vrijheid om keuzes te maken vraagt om 
conflicten 
9. Richtlijnen worden ontwikkeld om clinici te assisteren bij het maken van keuzes, nu nog 
een goede richtlijn om de juiste richtlijn te kunnen kiezen 
10. Journalisten zijn vooral geïnteresseerd in de kwaliteit van zorg als deze tekort schiet 
 
11. Het gunstige effect van een parachute op overleving bij het springen uit een vliegtuig is 
nooit aangetoond met behulp van gerandomiseerde studies 
